"Rank","NCT Number","Title","Acronym","Status","Study Results","Conditions","Interventions","Outcome Measures","Sponsor/Collaborators","Gender","Age","Phases","Enrollment","Funded Bys","Study Type","Study Designs","Other IDs","Start Date","Primary Completion Date","Completion Date","First Posted","Results First Posted","Last Update Posted","Locations","Study Documents","URL"
1,"NCT03532737","Concomitant Immune Check Point Inhibitor With Radiochemotherapy in Head And Neck Cancer",,"Recruiting","No Results Available","Locally Advanced Head and Neck Cancer","Drug: Pembrolizumab","Dose Limiting Toxicity (DLT)|Response Rate|Locoregional control rates|Progression free survival|Overall survival","Kuwait Cancer Control Center","All","16 Years and older   (Child, Adult, Older Adult)","Phase 2","50","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HNIT 01","October 7, 2018","September 30, 2021","October 31, 2022","May 22, 2018",,"October 17, 2018","Kuwait Cancer Control Center, Kuwait, Kuwait",,"https://ClinicalTrials.gov/show/NCT03532737"
2,"NCT04196465","Phase II Study of Neoadjuvant Immune Checkpoint Inhibitor in Patients With Resectable Gastrointestinal Cancers","NeoChance","Recruiting","No Results Available","Subjects With Resectable and Localized Gastric Cancer|Subjects With Resectable Esophageal Cancer or Liver Cancer|Subjects With Resectable Liver Cancer","Drug: IMC-001","Major pathologic response rate|The safety and feasibility|R0 resection rate|Clinical tumor response rate|Clnical disease control rate|Progression-free survival|Relapse-free survival|Overall survival|The rates and patterns of cancer progression/relapse|Patterns of cancer progression/relapse","Asan Medical Center","All","19 Years and older   (Adult, Older Adult)","Phase 2","48","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2019-0988","September 9, 2019","September 9, 2026","September 26, 2026","December 12, 2019",,"December 12, 2019","Asan Medical Center, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT04196465"
3,"NCT04104893","A Study of CHeckpoint Inhibitors in Men With prOgressive Metastatic Castrate Resistant Prostate Cancer Characterized by a Mismatch Repair Deficiency or Biallelic CDK12 Inactivation","CHOMP","Recruiting","No Results Available","Metastatic Castration Resistant Prostate Cancer","Drug: Pembrolizumab","PSA Decline|Objective Response Rate|Time to Progression of Disease|Overall Survival|Maximum PSA Response|Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]","VA Office of Research and Development|Merck Sharp & Dohme Corp.","Male","18 Years and older   (Adult, Older Adult)","Phase 2","30","U.S. Fed|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CSDR-003-18F","February 20, 2020","March 31, 2023","March 31, 2023","September 26, 2019",,"March 16, 2020","VA Greater Los Angeles Healthcare System, West Los Angeles, CA, West Los Angeles, California, United States|Jesse Brown VA Medical Center, Chicago, IL, Chicago, Illinois, United States|VA Ann Arbor Healthcare System, Ann Arbor, MI, Ann Arbor, Michigan, United States|James J. Peters VA Medical Center, Bronx, NY, Bronx, New York, United States|Manhattan Campus of the VA NY Harbor Healthcare System, New York, NY, New York, New York, United States|VA Puget Sound Health Care System Seattle Division, Seattle, WA, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT04104893"
4,"NCT03755739","Trans-Artery/Intra-Tumor Infusion of Checkpoint Inhibitors for Immunotherapy of Advanced Solid Tumors",,"Recruiting","No Results Available","Hepatocarcinoma|Lung Cancer|Melanoma|Renal Cancer|Head and Neck Cancer|Pancreas Cancer|Ovarian Cancer|Colo-rectal Cancer|Cervical Cancer|Breast Cancer","Drug: Checkpoint inhibitor (CPI) such as Pembrolizumab","Overall survival|Complete response (CR) rate before or at Month 6|Progression-free survival|Duration of remission (DOR)|Disease control rate|Cause of death (COD) when appropriate","Second Affiliated Hospital of Guangzhou Medical University","All","18 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","200","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Local Checkpoint Inhibitors","November 1, 2018","November 1, 2033","November 1, 2033","November 28, 2018",,"February 17, 2020","The Second Affiliated Hospital of Guangzhou Medical University, Guanzhou, Guangdong, China",,"https://ClinicalTrials.gov/show/NCT03755739"
5,"NCT03762161","A Phase II Study of Lonsurf (TAS-102) in Metastatic Platinum and Checkpoint Inhibitor-resistant Bladder Cancer",,"Recruiting","No Results Available","Bladder Cancer","Drug: TAS 102","Clinical benefit rate (complete response+ partial response+ stable disease)|Progression-free survival rate (PFS) among participants|Overall response rate (ORR) among participants|Overall survival rate (OS) among participants|Overall change in patient-reported quality of life outcomes|Proportion of participants with Grade 3 or higher Adverse and Serious Adverse Events","Rahul Parikh|Taiho Oncology, Inc.|University of Kansas Medical Center","All","18 Years and older   (Adult, Older Adult)","Phase 2","22","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IIT-2018-TAS-102","January 3, 2019","July 2021","January 2024","December 3, 2018",,"February 1, 2019","University of Kansas Cancer Center - Clinical Research Center, Fairway, Kansas, United States|University of Kansas Cancer Center, Westwood Campus, Kansas City, Kansas, United States",,"https://ClinicalTrials.gov/show/NCT03762161"
6,"NCT03287674","TIL Therapy in Combination With Checkpoint Inhibitors for Metastatic Ovarian Cancer",,"Active, not recruiting","No Results Available","Metastatic Ovarian Cancer","Drug: Cyclophosphamide|Drug: Fludarabine|Biological: TIL infusion|Drug: Interleukin-2|Drug: Ipilimumab|Drug: Nivolumab","Number and type of reported adverse events|Treatment related immune responses|Objective response rate|Overall Survival|Progression free survival","Inge Marie Svane|Herlev Hospital","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 1|Phase 2","6","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GY1721","October 9, 2017","October 2022","October 2023","September 19, 2017",,"February 12, 2020","Center for Cancer Immune Therapy Dept. of Hematology/oncology, Copenhagen, Denmark",,"https://ClinicalTrials.gov/show/NCT03287674"
7,"NCT03544723","Safety and Efficacy of Ad-p53 Combined With Checkpoint Inhibitor in Head and Neck Cancer",,"Recruiting","No Results Available","Solid Tumor|Lymphoma","Drug: Ad-P53","Progression-Free Survival (PFS) of patients using RECIST 1.1|Safety assessment with the collection and assessment of adverse events per the CTCAE|Preliminary assessment of Duration of Response (DoR), progression free survival (PFS) by RECIST 1.1 in injected lesions only","MultiVir, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 2","40","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Ad-p53-002","October 1, 2018","October 1, 2021","May 1, 2022","June 4, 2018",,"June 2, 2020","Robert H. Lurie Comprehensive Cancer Center   Northwestern University, Chicago, Illinois, United States|Rush University Cancer Center, Chicago, Illinois, United States|Morristown Medical Center, Morristown, New Jersey, United States|MD Anderson Cancer Center, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT03544723"
8,"NCT04062708","CHIO3 Trial: CHemotherapy Combined With Immune Checkpoint Inhibitor for Operable Stage IIIA/B Non-Small Cell Lung Cancer",,"Not yet recruiting","No Results Available","Stage IIIA Non-small Cell Lung Cancer|Stage IIIB Non-small Cell Lung Cancer","Drug: Durvalumab|Procedure: Surgery|Radiation: Radiotherapy","N2 nodal clearance (N2NC)|Number of participants with treatment-related adverse events as assessed by CTCAE v4.0|Radiographic response rate|Rate of major pathologic response and pathologic complete response|Evaluate event free survival (EFS)|Overall survival rate|Rate of complete resection.|Post-operative complications","Alliance Foundation Trials, LLC.|AstraZeneca","All","18 Years and older   (Adult, Older Adult)","Phase 2","55","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AFT-46","September 2019","July 2021","September 2024","August 20, 2019",,"August 20, 2019","Mayo Clinic, Phoenix, Arizona, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|St. Joseph Mercy Hospital, Ypsilanti, Michigan, United States|Mayo Clinic Rochester, Rochester, Minnesota, United States|Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|Stephenson Cancer Center, Oklahoma City, Oklahoma, United States|University of Virginia Health System, Charlottesville, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT04062708"
9,"NCT04009681","A Study Evaluating Safety and Therapeutic Activity of THOR-707 in Adult Subjects With Advanced or Metastatic Solid Tumors","THOR-707-101","Recruiting","No Results Available","Solid Tumor, Unspecified, Adult","Drug: THOR-707|Drug: Checkpoint inhibitor","Rate of Dose-Limiting Toxicities (DLTs)|Maximum Tolerated Dose (MTD)|Recommended Phase 2 Dose|Objective Response Rate (ORR) according to RECIST version 1.1|Duration of Response (DOR) according to RECIST version 1.1|Progression-Free Survival (PFS) according to RECIST version 1.1|Overall Survival according to RECIST version 1.1|Time to Response (TTR) according to RECIST version 1.1|Disease Control Rate (DCR) according to RECIST version 1.1|Immunophenotyping of peripheral blood at various timepoints|Immunophenotyping of tumor samples at various timepoints|Assess presence of antibodies to THOR-707 at various timepoints|Assess plasma concentration of THOR-707 at various timepoints","Synthorx, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","300","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","THOR-707-101","June 20, 2019","June 2022","June 2022","July 5, 2019",,"March 17, 2020","Synthorx Investigational Site, Denver, Colorado, United States|Synthorx Investigational Site, Sarasota, Florida, United States|Synthorx Investigational Site, Nashville, Tennessee, United States|Synthorx Investigational Site, Houston, Texas, United States|Synthorx Investigational Site, San Antonio, Texas, United States|Synthorx Investigational Site, Melbourne, Australia|Synthorx Investigational Site, Perth, Australia|Synthorx Investigational Site, Singapore, Singapore",,"https://ClinicalTrials.gov/show/NCT04009681"
10,"NCT03228667","QUILT-3.055: A Study of ALT-803 in Combination With PD-1/PD-L1 Checkpoint Inhibitor in Patients With Advanced Cancer",,"Recruiting","No Results Available","Non-Small Cell Lung Cancer|Small Cell Lung Cancer|Urothelial Carcinoma|Head and Neck Squamous Cell Carcinoma|Merkel Cell Carcinoma|Melanoma|Renal Cell Carcinoma|Gastric Cancer|Cervical Cancer|Hepatocellular Carcinoma|Microsatellite Instability|Mismatch Repair Deficiency|Colorectal Cancer","Drug: ALT-803 + Pembrolizumab|Drug: ALT-803 + Nivolumab|Drug: ALT-803 + Atezolizumab|Drug: ALT-803 + Avelumab","Objective Response Rate|Disease-specific Survival|Overall Survival|Time to Response|Duration of Response|Incidence of Adverse Events|Quality of Life (QOL)|Progression-free Survival","Altor BioScience","All","18 Years and older   (Adult, Older Adult)","Phase 2","611","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CA-ALT-803-02-17","December 11, 2018","June 2020","August 2020","July 25, 2017",,"February 28, 2020","Alaska Clinical Research Center, Anchorage, Alaska, United States|Genesis Cancer Center, Hot Springs, Arkansas, United States|Chan Soon-Shiong Institute for Medicine, El Segundo, California, United States|Glendale Adventist Medical Center, Glendale, California, United States|Desert Hematology Oncology Medical Group, Inc., Rancho Mirage, California, United States|Memorial Healcare System, Hollywood, Florida, United States|Miami Cancer Institute (Baptist Health South Florida), Miami, Florida, United States|University of Miami, Miami, Florida, United States|Horizon Oncology Associates, Lafayette, Indiana, United States|Baptist Health - Lexington, Lexington, Kentucky, United States|Baptist Health- Louisville, Louisville, Kentucky, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Henry Ford Hospital, Detroit, Michigan, United States|University of Minnesota - Masonic Cancer Center, Minneapolis, Minnesota, United States|Mercy Research Joplin, Joplin, Missouri, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Mercy Clinic Cancer & Hematology - Chub O'Reilly Cancer Center, Springfield, Missouri, United States|St. Vincent Frontier Cancer Center (SCL), Billings, Montana, United States|Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|University of Rochester, Rochester, New York, United States|Cleveland Clinic - Main Site, Cleveland, Ohio, United States|Mercy Clinic Oklahoma City, Oklahoma City, Oklahoma, United States|Providence Portland Medical Center, Portland, Oregon, United States|Medical University of South Carolina, Charleston, South Carolina, United States|St. Francis Cancer Center/Bon Secours St. Francis Health System, Greenville, South Carolina, United States|Spartanburg Medical Center, Spartanburg, South Carolina, United States|Sanford Clinical Research, Sioux Falls, South Dakota, United States|University of Tennessee Medical Center, Knoxville, Tennessee, United States|Oncology Consultants of Houston, Houston, Texas, United States|Bon Secours Richmond, Richmond, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT03228667"
11,"NCT03453164","Checkpoint Inhibitor and Radiotherapy for Recurrent Gastric Cancer (CIRCUIT)",,"Recruiting","No Results Available","Gastric Cancer","Radiation: Radiotherapy + Nivolumab","Disease control rate|Median survival time|Incidence of treatment-emergent adverse events|Local control rate|Expression of PD-L1 and MHC class I on tumor cells, number of CD8 positive lymphocytes in tumor microenvironment|Peak plasma cytokine concentration|Peak regulatory T-cell population|Peak antigen-specific cytotoxic T lymphocyte population","Fukushima Medical University|Kanagawa Cancer Center","All","20 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","40","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","RK29040","March 28, 2018","August 31, 2020","February 28, 2021","March 5, 2018",,"January 18, 2020","Fukushima Medical University Hospital, Fukushima, Japan","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/64/NCT03453164/SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03453164"
12,"NCT03612791","Trial Assessing the Inhibitor of Programmed Cell Death Ligand 1 (PD-L1) Immune Checkpoint Atezolizumab","ATEZOLACC","Recruiting","No Results Available","Locally Advanced Cervical Cancer","Drug: Atezolizumab|Radiation: Radiotherapy|Drug: Cisplatin","Progression Free Survival (PFS)","Gustave Roussy, Cancer Campus, Grand Paris","Female","18 Years to 70 Years   (Adult, Older Adult)","Phase 2","190","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2017-003622-33|2017/2608","July 2, 2018","July 2020","July 2022","August 2, 2018",,"August 2, 2018","Gustave Roussy, Villejuif, Val De Marne, France",,"https://ClinicalTrials.gov/show/NCT03612791"
13,"NCT03511391","CHEckpoint Inhibition in Combination With an Immunoboost of External Body Radiotherapy in Solid Tumors","CHEERS","Recruiting","No Results Available","Urothelial Carcinoma|Melanoma|Renal Cell Carcinoma|Non-small Cell Lung Cancer|Head and Neck Cancer","Drug: Pembrolizumab or Nivolumab|Radiation: SBRT","Progression-free survival|Overall survival|Tumor response as per RECIST|Tumor response as per iRECIST|Incidence of Treatment-Related Adverse Events [safety and tolerability]","University Hospital, Ghent|GZA Ziekenhuizen Campus Sint-Augustinus|AZ Sint-Lucas Brugge","All","18 Years and older   (Adult, Older Adult)","Phase 2","97","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","EC2017/1678","March 9, 2018","February 14, 2022","August 14, 2022","April 27, 2018",,"May 8, 2018","AZ Sint-Lucas, Brugge, West-Vlaanderen, Belgium|GasthuisZusters Antwerpen, Antwerp, Belgium|University Hospital Ghent, Ghent, Belgium",,"https://ClinicalTrials.gov/show/NCT03511391"
14,"NCT04214418","Study of Combination Therapy With the MEK Inhibitor, Cobimetinib, Immune Checkpoint Blockade, Atezolizumab, and the AUTOphagy Inhibitor, Hydroxychloroquine in KRAS-mutated Advanced Malignancies","MEKiAUTO","Not yet recruiting","No Results Available","Gastrointestinal Cancer","Drug: Cobimetinib|Drug: Hydroxychloroquine|Drug: Atezolizumab","Phase 1: Estimated maximum tolerated dose (MTD)|Phase 1: Incidence of Treatment-Emergent Adverse Events with drug combination (Safety and Tolerability)","Columbia University|Genentech, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","175","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AAAS4165|ML41472","March 2020","September 2022","September 2023","January 2, 2020",,"March 2, 2020","Columbia University Irving Medical Center, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT04214418"
15,"NCT02467361","A Study of BBI608 Administered in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced Cancers",,"Active, not recruiting","No Results Available","Cancer","Drug: BBI608|Drug: Ipilimumab|Drug: Nivolumab|Drug: Pembrolizumab","Determination of the safety and tolerability of BBI608 administered in combination with selected immunotherapeutic agent by assessing dose-limiting toxicities (DLTs)|Determination of the Recommended Phase 2 Dose (RP2D) by assessing dose-limiting toxicities (DLTs)|Assessment of the preliminary anti-tumor activity by performing tumor assessments every 8 weeks (Phase 2 portion)|Pharmacokinetic profile of BBI608 administered in combination with the selected immunotherapeutic agent as assessed by maximum plasma concentration and area under the curve|Pharmacodynamic activity of BBI608 administered in combination with the selected immunotherapeutic agent as assessed by biomarker analysis","Boston Biomedical, Inc","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","104","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","BBI608-201CIT","August 2015","June 2020","July 2020","June 10, 2015",,"January 21, 2020","University of Colorado Cancer Center, Denver, Colorado, United States|Emory University Winship Cancer Institute, Atlanta, Georgia, United States|University of Chicago Medicine Comprehensive Cancer Center, Chicago, Illinois, United States|Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Weill Cornell Medical College, New York, New York, United States|Institute for Translational Oncology Research, Greenville, South Carolina, United States|MD Anderson Cancer Center, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT02467361"
16,"NCT03311334","A Study of DSP-7888 Dosing Emulsion in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced Solid Tumors",,"Recruiting","No Results Available","Neoplasms|Melanoma|Non Small Cell Lung Cancer (NSCLC)|Head and Neck Squamous Cell Carcinoma (HNSCC)|Renal Cell Carcinoma (RCC)|Urothelial Neoplasm|Hepatocellular Carcinoma (HCC)|Microsatellite Instability-high or Mismatch Repair Deficient (MSI-H/dMMR)|Colorectal Cancer|Gastroesophageal Junction Adenocarcinoma|Gastric Cancer|Cervical Cancer|Primary Peritoneal Cancer|Platinum-resistant Ovarian Cancer (PROC)|Serous Epithelial Ovarian Cancer|Fallopian Tube Cancer","Drug: DSP-7888 Dosing Emulsion|Drug: Nivolumab|Drug: Pembrolizumab","Phase Ib: Determination of the safety and tolerability of DSP-7888 Dosing Emulsion given intradermally with a checkpoint inhibitor (Nivolumab or Pembrolizumab) in adult patients with advanced solid tumors by assessing dose-limiting toxicities (DLTs).|Phase Ib: Determination of the Recommended Phase 2 Dose (RP2D) by assessing dose-limiting toxicities (DLTs).|Phase II: Evaluation of the preliminary antitumor activity of DSP-7888 Dosing Emulsion administered with pembrolizumab in terms of Objective Response Rate (ORR) in patients with platinum-resistant ovarian cancer (PROC).|Phase Ib: Objective response rate (ORR)|Phase Ib: Disease control rate (DCR)|Phase Ib: Duration of response (DOR)|Phase Ib: Progression-free survival (PFS)|Phase Ib: 6-month PFS|Phase Ib: Overall survival (OS)|Phase II: DOR|Phase II: DCR|Phase II: PFS|Phase II: 6 month PFS|Phase II: OS|Phase II: Immune objective response rate (iORR)|Phase II: Immune disease control rate (iDCR)|Phase II: Immune progression-free survival (iPFS)|Phase II: Evaluation of the safety and tolerability of DSP-7888 Dosing Emulsion administered with pembrolizumab.","Boston Biomedical, Inc","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","84","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","BBI-DSP7888-102CI","December 14, 2017","November 2021","May 2022","October 17, 2017",,"January 22, 2020","Decatur Memorial Hospital, Decatur, Illinois, United States|Horizon Oncology Research, Lafayette, Indiana, United States|St Vincent Frontier Cancer Center, Billings, Montana, United States|UC Health, LLC, Cincinnati, Ohio, United States|The University of Texas MD Anderson Cancer Center, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT03311334"
17,"NCT03173950","Immune Checkpoint Inhibitor Nivolumab in People With Select Rare CNS Cancers",,"Recruiting","No Results Available","Medulloblastoma|Ependymoma|Pineal RegionTumors|Choroid Plexus Tumors|Atypical/Malignant Meningioma","Drug: Nivolumab","objective response|progression free survival rate","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","18 Years and older   (Adult, Older Adult)","Phase 2","180","NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","170102|17-C-0102","July 13, 2017","December 31, 2022","December 1, 2024","June 2, 2017",,"April 20, 2020","National Institutes of Health Clinical Center, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT03173950"
18,"NCT03775850","A Study of EDP1503 in Patients With Colorectal Cancer, Breast Cancer, and Checkpoint Inhibitor Relapsed Tumors",,"Recruiting","No Results Available","Colorectal Cancer Metastatic|Triple Negative Breast Cancer|Non Small Cell Lung Cancer|Bladder Cancer|GastroEsophageal Cancer|Renal Cell Carcinoma|MSI-H","Biological: EDP1503|Biological: Pembrolizumab","Safety and tolerability of EDP1503 alone and in combination with pembrolizumab as assessed per CTCAE v5.0|Safety and tolerability of EDP1503 alone and in combination with pembrolizumab|Evidence of anti-tumor activity of EDP1503 based on ORR|Progression Free Survival|Overall Survival","Evelo Biosciences, Inc.|SCRI Development Innovations, LLC|Merck Sharp & Dohme Corp.","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","120","Industry|Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","EDP1503-101","December 19, 2018","December 19, 2020","December 19, 2020","December 14, 2018",,"May 27, 2020","Highlands Oncology Group, Rogers, Arkansas, United States|Florida Cancer Specialists, Sarasota, Florida, United States|Stephenson Cancer Center, Oklahoma City, Oklahoma, United States|Tennessee Oncology, PLLC, Chattanooga, Tennessee, United States|Tennessee Oncology, Nashville, Tennessee, United States|Centre de Recherche du CHUM, Montréal, Quebec, Canada|Jewish General Hospital, Montréal, Quebec, Canada|CHU de Québec - Université Laval, Québec, Canada",,"https://ClinicalTrials.gov/show/NCT03775850"
19,"NCT03693014","A Study of Several Radiation Doses for Patients With Progression on Immunotherapy/Checkpoint Inhibitors",,"Recruiting","No Results Available","Metastatic Cancer|Melanoma Cancer|Lung Cancer|Bladder Cancer|Renal Cancer|Head/Neck Cancers","Radiation: Stereotactic Body Radiotherapy|Biological: Ipilimumab, Nivolumab, Pembrolizumab or Atezolizumab","evaluate overall response rate (ORR)","Memorial Sloan Kettering Cancer Center","All","18 Years and older   (Adult, Older Adult)","Phase 2","60","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","18-359","October 1, 2018","October 2021","October 2021","October 2, 2018",,"March 24, 2020","Memorial Sloan Kettering Basking Ridge, Basking Ridge, New Jersey, United States|Memoral Sloan Kettering Monmouth, Middletown, New Jersey, United States|Memorial Sloan Kettering Bergen, Montvale, New Jersey, United States|Memorial Sloan Kettering Commack, Commack, New York, United States|Memoral Sloan Kettering Westchester, Harrison, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Memorial Sloan Kettering Rockville Centre, Rockville Centre, New York, United States|Memorial Sloan Kettering Nassau, Uniondale, New York, United States",,"https://ClinicalTrials.gov/show/NCT03693014"
20,"NCT04327986","Immune Checkpoint Inhibitor M7824 and the Immunocytokine M9241 in Combination With Stereotactic Body Radiation Therapy (SBRT) in Adults With Advanced Pancreas Cancer",,"Not yet recruiting","No Results Available","Histologically or Cytologically Confirmed Pancreatic Cancer|Unresectable or Borderline Resectable Pancreatic Cancer|Pancreatic Neoplasms|Pancreatic Cancer|Metastatic Pancreatic Cancer","Drug: M7824|Drug: M9241|Radiation: SBRT","To determine a preliminary estimate of efficacy as best overall response (BOR) according to RECIST 1.1 of M7824 and M9241 in combination with SBRT as neoadjuvant/perioperative treatment in subjects with locally advanced pancreas cancer|To determine the safety and tolerability and the recommended phase 2 dose (RP2D) of M7824 and M9241 in combination with SBRT as neoadjuvant / perioperative treatment in subjects with pancreas cancer|To determine the PK of M7824 in combination with M9241|To assess overall survival (OS) in patients after completion of RT in combination with M9241 and M7824|To asses progression-free survival (PFS) for all participants|To asses progression-free survival (PFS) for participants who did not undergo surgical resection|To determine fraction of patients with LAPC who are able to undergo surgical resection after M7824 and M9241 in combination with SBRT treatment|For patients who underwent surgical resection after M7824 and M9241 in combination with SBRT treatment to determine time-to-recurrence of the disease|For patients who underwent surgical resection after M7824 and M9241 in combination with SBRT treatment to determine complete pathological response rate(s)","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","52","NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","200074|20-C-0074","June 5, 2020","December 31, 2025","December 31, 2025","March 31, 2020",,"June 2, 2020","National Institutes of Health Clinical Center, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT04327986"
21,"NCT03735290","A Study to Evaluate the Safety and Effectiveness of ILIxadencel Administered Into Tumors in Combination With Checkpoint Inhibitor (CPI) in Patients With ADvanced Cancer","ILIAD","Recruiting","No Results Available","Carcinoma, Squamous Cell of Head and Neck|Carcinoma, Non-Small-Cell Lung|Gastric Adenocarcinoma|Gastroesophageal Junction Adenocarcinoma|Non-small Cell Lung Cancer|Human Papilloma Virus","Biological: ilixadencel|Drug: Pembrolizumab","Frequency of adverse events (AEs) (Phase 1b)|Severity of adverse events (SAEs) (Phase 1b)|Number of Dose Limiting Toxicities (DLTs) (Phase 1b)|Number of subjects with clinically significant laboratory test abnormalities (Phase 1b)|Number of subjects with vital sign abnormalities (Phase 1b)|Antitumor Objective Response Rate (ORR) (Phase 2)|Antitumor Objective Response Rate (ORR) RECIST 1.1 (Phase 1b and Phase 2)|Antitumor Objective Response Rate (ORR) iRECIST (Phase 1b and Phase 2)|Clinical Benefit Rate (Phase 1b and Phase 2)|Number of circulating CD8 t-cell responses to tumor-specific or tumor-associated antigens (Phase 1b and Phase 2)|Duration of response (Phase 1b and Phase 2)|Time to Progression (TTP) (Phase 1b and Phase 2)|Progression-free Survival (PFS) (Phase 1b and Phase 2)|Overall Survival (OS) (Phase 1b and Phase 2)|Frequency of adverse events (AEs) (Phase 2)|Severity of adverse events (AEs) (Phase 2)|Number of Dose Limiting Toxicities (DLTs) (Phase 2)|Number of subjects with clinically significant laboratory test abnormalities (Phase 2)|Number of subjects with vital sign abnormalities (Phase 2)","Immunicum AB|PPD","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","150","Industry","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IM-202","January 14, 2019","December 2022","July 2023","November 8, 2018",,"December 20, 2019","Site 1010, Coral Gables, Florida, United States|Site 1006, Iowa City, Iowa, United States|Site 1011, Louisville, Kentucky, United States|Site 1001, Detroit, Michigan, United States|Site 1004, Chapel Hill, North Carolina, United States|Site 1009, Cleveland, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT03735290"
22,"NCT02903914","Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors",,"Recruiting","No Results Available","Metastatic Cancer|Solid Tumors|Colorectal Cancer (CRC)|Gastric Cancer|Head and Neck Cancer|Lung Cancer|Renal Cell Carcinoma (RCC)|Bladder Cancer|UC (Urothelial Cancer)|Mesothelioma","Drug: INCB001158|Drug: Pembrolizumab","Safety and Tolerability of INCB001158 as a single agent and in combination with Pembrolizumab: Incidence of Adverse Events|Recommended Phase 2 Dose (RP2D) of INCB001158|RP2D of INCB001158 with Pembrolizumab|Plasma pharmacokinetic (PK) profile of INCB001158 alone and in combination with Pembrolizumab|Anti-tumor Activity of INCB001158 as Monotherapy and in Combination with Pembrolizumab for patients with advanced/metastatic solid tumors","Incyte Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","424","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","INCB 01158-101","September 14, 2016","August 28, 2020","August 28, 2020","September 16, 2016",,"February 27, 2020","University of South Alabama, Mobile, Alabama, United States|Honor Health/Pinnacle Oncology Hematology, Scottsdale, Arizona, United States|University of Arizona, Tucson, Arizona, United States|Georgetown, Washington, District of Columbia, United States|Johns Hopkins, Baltimore, Maryland, United States|BIDMC, Boston, Massachusetts, United States|DFCI, Boston, Massachusetts, United States|Henry Ford, Detroit, Michigan, United States|Sarah Cannon Research Institute at Tennessee Oncology, Nashville, Tennessee, United States|Vanderbilt, Nashville, Tennessee, United States|MD Anderson, Houston, Texas, United States|MD Anderson, Houston, Texas, United States|START, San Antonio, Texas, United States|Ospedale San Raffaele, Milan, Italy|Oncologica Azienda Ospedaliera Universitaria Senese, Siena, Italy|NKI, Amsterdam, Netherlands|Radboudumc, Nijmegen, Netherlands|Hospital Universitari Vall d'Hebron, Barcelona, Spain|Institut Catala d'Oncologia, Barcelona, Spain|START Madrid-HM CIOCC, Madrid, Spain",,"https://ClinicalTrials.gov/show/NCT02903914"
23,"NCT03506997","Trial of Pembrolizumab in Metastatic Castration Resistant Prostate Cancer","PERSEUS1","Recruiting","No Results Available","Castration-resistant Prostate Cancer","Drug: Pembrolizumab","To evaluate tumour response|Radiological progression-free survival (rPFS)|Time to radiological progression|Progression free survival|Time to PSA progression|Duration of PSA response|Overall survival|Safety and tolerability defined by CTC-AE, V 4.0 criteria.","Institute of Cancer Research, United Kingdom|Merck Sharp & Dohme Corp.","Male","18 Years and older   (Adult, Older Adult)","Phase 2","100","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ICR-CTSU/2016/10060|2017-000931-15","November 27, 2018","September 1, 2023","September 1, 2025","April 24, 2018",,"December 24, 2018","The Royal Marsden Hospital, Sutton, Surrey, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03506997"
24,"NCT03313804","Priming Immunotherapy in Advanced Disease With Radiation",,"Recruiting","No Results Available","Non-small Cell Lung Cancer|Squamous Cell Carcinoma of the Head and Neck","Drug: Immune checkpoint inhibitor|Radiation: Radiation Therapy","The primary study endpoint is 6-month progression-free survival.|Percentage of (programmed death) PD-1+ CD4+ T (helper) cells and PD-1+ CD8+ T (cytotoxic) cells prior to treatment versus with concurrent treatment.|Percentage of CD8+ T-cells that are gamma-interferon positive during treatment.|Percentage PD-L1+ CD4+ and PD-L1+ CD8+ T-cell expression differences during treatment","John L. Villano, MD, PhD|University of Kentucky","All","18 Years and older   (Adult, Older Adult)","Phase 2","57","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MCC-17-MULTI-20-PMC","October 26, 2017","September 30, 2020","June 30, 2028","October 18, 2017",,"August 6, 2019","University of Kentucky Markey Cancer Center, Lexington, Kentucky, United States",,"https://ClinicalTrials.gov/show/NCT03313804"
25,"NCT03257722","Pembrolizumab + Idelalisib for Lung Cancer Study","PIL","Recruiting","No Results Available","Non Small Cell Lung Cancer|Metastasis|Recurrence","Drug: Pembrolizumab|Drug: Idelalisib","Number of Participants With Dose-Limiting Toxicity (DLT) Events as Assessed by CTCAE v4.03|Dose-Finding Assessment for optimum dose of idelalisib in combination with pembrolizumab|Overall Response Rates (ORR) to combination therapy","Zhonglin Hao|Merck Sharp & Dohme Corp.|Gilead Sciences|Augusta University","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","40","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GCC-16053","September 26, 2017","August 2020","August 2021","August 22, 2017",,"September 29, 2017","Georgia Cancer Center at Augusta University, Augusta, Georgia, United States",,"https://ClinicalTrials.gov/show/NCT03257722"
26,"NCT04315701","A PD-1 Checkpoint Inhibitor (Cemiplimab) for High-Risk Localized, Locally Recurrent, or Regionally Advanced Skin Cancer",,"Not yet recruiting","No Results Available","Recurrent Skin Squamous Cell Carcinoma|Resectable Skin Squamous Cell Carcinoma|Stage I Skin Cancer|Stage II Skin Cancer|Stage III Skin Cancer","Biological: Cemiplimab|Procedure: Resection","Confirmed pathologic partial response|Pathologic complete response rate|Objective response rate|Progression-free survival|Incidence of toxicities","University of Southern California|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Phase 2","34","Other|NIH","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","14SK-19-1|NCI-2020-01247|P30CA014089","April 1, 2020","April 1, 2022","October 31, 2022","March 19, 2020",,"March 19, 2020","Los Angeles County-USC Medical Center, Los Angeles, California, United States|USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States|Hoag Memorial Hospital, Newport Beach, California, United States",,"https://ClinicalTrials.gov/show/NCT04315701"
27,"NCT04407247","Infliximab or Vedolizumab in Treating Immune Checkpoint Inhibitor-Related Colitis in Patients With Genitourinary Cancer or Melanoma",,"Not yet recruiting","No Results Available","Colitis|Lung Non-Small Cell Carcinoma|Malignant Genitourinary System Neoplasm|Malignant Solid Neoplasm|Melanoma","Biological: Infliximab|Biological: Vedolizumab","Clinical remission/response rate of immune-mediated colitis (IMC)|Treatment-related adverse events|Clinical remission/response rate of IMC|Complete weaning of corticosteroid|Recurrent immune-related diarrhea/colitis","M.D. Anderson Cancer Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","100","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2019-0276|NCI-2019-04986|P30CA016672","June 30, 2020","December 31, 2021","December 31, 2021","May 29, 2020",,"May 29, 2020","M D Anderson Cancer Center, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT04407247"
28,"NCT02981303","Study of Imprime PGG and Pembrolizumab in Advanced Melanoma and Triple Negative Breast Cancer",,"Active, not recruiting","No Results Available","Advanced Melanoma|Triple-Negative Breast Cancer","Biological: Imprime PGG|Drug: Pembrolizumab","Overall Response Rate (ORR) to Imprime PGG + pembrolizumab using RECIST v1.1 criteria|Time to response (TTR) using RECIST v1.1 criteria|Complete response rate (CRR) using RECIST v1.1 criteria|Duration of overall response (DoR) using RECIST v1.1 criteria|Progression-Free Survival (PFS) and PFS rate at 6 months and 1 year using RECIST v1.1 criteria|Overall survival (OS) and OS rate at 1 year using RECIST v1.1 criteria|Pharmacokinetic (PK) data of Imprime PGG in combination with Pembrolizumab","Biothera|Merck Sharp & Dohme Corp.","All","18 Years and older   (Adult, Older Adult)","Phase 2","64","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","BT-CL-PGG-MEL/BCA-1621/MK3475","December 2016","April 2019","November 2021","December 5, 2016",,"February 27, 2019","Arizona Center for Cancer Care, Avondale, Arizona, United States|John Wayne Cancer Institute, Santa Monica, California, United States|University of Colorado Cancer Center, Aurora, Colorado, United States|Sarah Cannon Research Institute, Denver, Colorado, United States|University Cancer and Blood Center, Athens, Georgia, United States|Piedmont Cancer Institute, Atlanta, Georgia, United States|Stony Brook University Cancer Center, Stony Brook, New York, United States|Thomas Jefferson University Sidney Kimmel Cancer Center, Philadelphia, Pennsylvania, United States|Sarah Cannon Research Institute, Nashville, Tennessee, United States|Millennium Oncology, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT02981303"
29,"NCT03259867","Combination of TATE and PD-1 Inhibitor in Liver Cancer","TATE-PD1","Active, not recruiting","No Results Available","Hepatocellular Carcinoma|Colorectal Neoplasms|Gastric Cancer|Lung Cancer","Drug: Opdivo Injectable Product or Keytruda Injectable Product|Combination Product: Trans-arterial tirapazamine embolization","Response rate|Overall Response rate|Duration of Response|Progression Free Survival|Overall survival","Teclison Ltd.","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 2","80","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","LT-004","July 1, 2017","October 30, 2020","December 1, 2021","August 24, 2017",,"September 11, 2019","University of California, Irvine, Orange, California, United States",,"https://ClinicalTrials.gov/show/NCT03259867"
30,"NCT03878979","Preoperative Immune Checkpoint Inhibitor for Patients With Primary Untreated or Recurrent/Metastatic SCCHN",,"Recruiting","No Results Available","Head and Neck Squamous Cell Carcinoma|Head and Neck Cancer|Head and Neck Cancer Metastatic","Drug: Nivolumab 480mg and surgical resection","Safety as measured by number of participants with drug-related adverse events|Feasibility as measured by number of participants with successful completion of preoperative treatment and no extended treatment-related delays|Major pathologic response rate|Progression free survival (PFS)|Radiographic response rate","Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|Bristol-Myers Squibb","All","18 Years and older   (Adult, Older Adult)","Phase 2","24","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","J1923|IRB00207577|CA209-9H7","July 8, 2019","July 2021","July 2024","March 18, 2019",,"February 7, 2020","Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT03878979"
31,"NCT03219333","A Study of Enfortumab Vedotin for Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer","EV-201","Active, not recruiting","No Results Available","Carcinoma, Transitional Cell|Urinary Bladder Neoplasms|Urologic Neoplasms|Renal Pelvis Neoplasms|Urothelial Cancer|Ureteral Neoplasms|Urethral Neoplasms","Drug: Enfortumab vedotin","Objective response rate (ORR) by an independent review facility (IRF)|Duration of response (DOR) by an IRF|Disease control rate at 16 weeks (DCR16) by an IRF|Progression free survival (PFS) by an IRF|ORR by investigator assessment|DOR by investigator assessment|DCR16 by investigator assessment|Progression free survival (PFS) by investigator assessment|Overall survival (OS)|Incidence of adverse events (AEs)|Incidence of laboratory abnormalities|Pharmacokinetics (PK) parameter for enfortumab vedotin: Maximum concentration (Cmax)|PK parameter for enfortumab vedotin: Trough concentration (Ctrough)|PK parameter for monomethyl auristatin E (MMAE): Cmax|PK parameter for MMAE: Ctrough|PK parameter for Total Antibody (TAb): Cmax|PK parameter for Total Antibody (TAb): Ctrough|Incidence of antitherapeutic antibodies (ATA) to enfortumab vedotin","Astellas Pharma Global Development, Inc.|Seattle Genetics, Inc.|Astellas Pharma Inc","All","18 Years and older   (Adult, Older Adult)","Phase 2","219","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SGN22E-001","October 8, 2017","November 2020","May 2025","July 17, 2017",,"May 15, 2020","Alaska Urological Institute, Anchorage, Alaska, United States|Arizona Oncology Associates, PC - HAL, Phoenix, Arizona, United States|Mayo Clinic Arizona, Scottsdale, Arizona, United States|Arizona Oncology Associates, PC - HOPE, Tucson, Arizona, United States|University of California Davis, Davis, California, United States|Keck Medical Center / University of Southern California, Los Angeles, California, United States|Keck Medical Center / Newport Beach, Newport Beach, California, United States|Kaiser Permanente Oakland, Oakland, California, United States|Chao Family Comprehensive Cancer Center University of California Irvine, Orange, California, United States|University of California Irvine - Newport, Orange, California, United States|Kaiser Permanente Roseville, Roseville, California, United States|Kaiser Permanente Sacramento, Sacramento, California, United States|Kaiser Permanente San Francisco, San Francisco, California, United States|Kaiser Permanente San Jose, San Jose, California, United States|Kaiser Permanente San Leandro, San Leandro, California, United States|Kaiser Permanente Santa Clara, Santa Clara, California, United States|Kaiser Permanente South San Francisco, South San Francisco, California, United States|Kaiser Permanente Medical Center Northern California, Vallejo, California, United States|Kaiser Permanente Walnut Creek, Walnut Creek, California, United States|Rocky Mountain Cancer Centers - Aurora, Aurora, Colorado, United States|Yale Cancer Center, New Haven, Connecticut, United States|Ocala Oncology Center, Ocala, Florida, United States|H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States|Augusta University, Augusta, Georgia, United States|University of Chicago, Chicago, Illinois, United States|Norton Cancer Institute, Louisville, Kentucky, United States|Johns Hopkins Medical Center, Baltimore, Maryland, United States|Maryland Oncology Hematology, P.A., Silver Spring, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Karmanos Cancer Institute / Wayne State University, Detroit, Michigan, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States|New York Oncology Hematology, P.C., Albany, New York, United States|New York University (NYU) Cancer Institute, New York, New York, United States|Columbia University Medical Center, New York, New York, United States|Mount Sinai Medical Center, New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|James P. Wilmot Cancer Center / University of Rochester Medical Center, Rochester, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|Cleveland Clinic, The, Cleveland, Ohio, United States|James Cancer Hospital / Ohio State University, Columbus, Ohio, United States|Northwest Cancer Specialists, P.C., Tualatin, Oregon, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States|Hillman Cancer Center / University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States|Greenville Health System Cancer Institute, Greenville, South Carolina, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|Texas Oncology - Austin Central, Austin, Texas, United States|Texas Oncology - Baylor Sammons Cancer Center, Dallas, Texas, United States|Houston Methodist Cancer Center, Houston, Texas, United States|University of Virginia, Charlottesville, Virginia, United States|Virginia Cancer Specialists, PC, Fairfax, Virginia, United States|Virginia Oncology Associates, Norfolk, Virginia, United States|Seattle Cancer Care Alliance / University of Washington, Seattle, Washington, United States|Site FR33001, Villejuif-Cedex-France, France|Site DE49004, Muenster, Germany|Site DE49001, Tübingen, Germany|Site IT39001, Milano, Italy|Site IT39003, Terni, Italy|Site JP81001, Hirosaki, Aomori, Japan|Site JP81004, Tsukuba, Ibaraki, Japan|Site JP81002, Morioka, Iwate, Japan|Site JP81008, Osakasayama, Osaka, Japan|Site JP81006, Shinjuku-ku, Tokyo, Japan|Site JP81009, Ube, Yamaguchi, Japan|Site JP81005, Chiba, Japan|Site JP81011, Fukuoka, Japan|Site JP81012, Fukuoka, Japan|Site JP81003, Nigata, Japan|Site JP81007, Osaka, Japan|Site JP81010, Tokushima, Japan|Site KR82005, Daejeon, Korea, Republic of|Site KR82003, Seongnam-si, Korea, Republic of|Site KR82001, Seoul, Korea, Republic of|Site KR82002, Seoul, Korea, Republic of|Site KR82004, Seoul, Korea, Republic of|Site NL31001, Amsterdam, Netherlands|Site ES34002, Barcelona, Spain|Site ES34003, Santander, Spain|Site ES34004, Sevilla, Spain",,"https://ClinicalTrials.gov/show/NCT03219333"
32,"NCT02989714","Phase Ib/II Trial of Interleukin-2 and PD-1 Checkpoint Inhibitor, Nivolumab In Metastatic Clear Cell Renal Cell Cancer",,"Active, not recruiting","Has Results","Renal Cell Carcinoma","Drug: Interleukin-2|Drug: Nivolumab","The Number of Patients With Grade 3 and Grade 4 Adverse Events of Interest|The Number of Patients That Respond to Treatment|The Number of Patients With Grade 3-5 Adverse Events of Interest|The Number of Patients Alive at 24 Months|Time to Progression","University of Michigan Rogel Cancer Center","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","13","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","UMCC 2016.103|HUM00120502","March 16, 2017","February 25, 2019","October 2020","December 12, 2016","March 9, 2020","March 9, 2020","University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States|University of Minnesota, Minneapolis, Minnesota, United States|University Hospitals Seidman Cancer Center, Cleveland, Ohio, United States|Ohio State University, Columbus, Ohio, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/14/NCT02989714/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02989714"
33,"NCT04188119","A Proof of Concept Window Trial of the IMmunological Effects of AveLumab and Aspirin in Triple-Negative Breast Cancer","IMpALA","Not yet recruiting","No Results Available","Breast Cancer","Drug: Avelumab|Drug: Aspirin|Drug: Lansoprazole","1. Mean combined gene expression of COX-2 tumour-promoting genes|Post treatment tumour infiltrating lymphocytes (TIL)|Mean combined gene expression of the cancer-inhibitory elements of the COX-2 inflammatory signature|The post treatment COX-2 inflammatory signature|Safety and tolerability assessed by grade 3-4 AEs and SAEs","The Christie NHS Foundation Trust|University of Manchester","Female","18 Years and older   (Adult, Older Adult)","Phase 2","42","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","CFT / sp123|2018-004121-80|017NovCC107","March 2, 2020","August 30, 2021","August 30, 2021","December 5, 2019",,"January 18, 2020",,,"https://ClinicalTrials.gov/show/NCT04188119"
34,"NCT02678741","Multi-center Phase I/IIa Trial of an Autologous Tumor Lysate (TL) + Yeast Cell Wall Particles (YCWP) + Dendritic Cells (DC) Vaccine in Addition to Standard of Care Checkpoint Inhibitor of Choice in Metastatic Melanoma Patients With Measurable Disease.",,"Active, not recruiting","No Results Available","Metastatic Melanoma","Drug: TLPLDC Vaccine","Graded Standard Local and Systemic Toxicities (using CTCAE graded toxicity scale) months|Tumor Response to Treatment Using Response Evaluation Criteria in Solid Tumors (RECIST) criteria","Cancer Insight, LLC|Elios Therapeutics, LLC","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","45","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20152397","February 2016","December 2020","December 2020","February 10, 2016",,"March 26, 2020","University of Alabama Birmingham Comprehensive Cancer Center, Birmingham, Alabama, United States|John Wayne Cancer Institute/Providence Saint John's Health Center, Santa Monica, California, United States|Mount Sinai Comprehensive Cancer Center, Miami Beach, Florida, United States|Northside Hospital, Atlanta, Georgia, United States|University of Cincinnati Cancer Institute, Cincinnati, Ohio, United States|Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States|Providence Regional Medical Center, Everett, Washington, United States",,"https://ClinicalTrials.gov/show/NCT02678741"
35,"NCT04278092","Paclitaxel Plus Cetuximab After First-line Checkpoint Inhibitor Failure",,"Recruiting","No Results Available","Head and Neck Squamous Cell Carcinoma","Drug: Paclitaxel|Drug: Cetuximab","Overall response rate|Median Overall Survival|Median Progression Free Survival|Median Duration of response|Health-related quality-of-life scores per patient measured according to the European Organisation for Research and Treatment of Cancer (EORTC) quality of life questionnaire (QLQ) C-30 scoring manual|Health-related quality-of-life scores per patient measured according to the European Organisation for Research and Treatment of Cancer (EORTC) quality of life questionnaire (QLQ) H&N35 scoring manual|Number of participants with adverse events","Medical University of Vienna","All","18 Years and older   (Adult, Older Adult)","Phase 2","50","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PACE ACE","February 10, 2020","December 2021","December 2022","February 20, 2020",,"March 4, 2020","Medical University of Vienna, Vienna, Austria",,"https://ClinicalTrials.gov/show/NCT04278092"
36,"NCT02979977","Dual Inhibition of EGFR With Afatinib and Cetuximab in the Treatment of Advanced Squamous Cell Cancers of the Head and Neck",,"Recruiting","No Results Available","Squamous Cell Cancers of the Head and Neck","Drug: cetuximab|Drug: afatinib","Tumor shrinkage|Progression-free survival in weeks|Overall survival in months|Duration of response in weeks|Toxicity assessed with National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE) version 4.0","Yale University|National Comprehensive Cancer Network|Boehringer Ingelheim","All","18 Years and older   (Adult, Older Adult)","Phase 2","50","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1608018260","March 24, 2017","December 2020","January 2021","December 2, 2016",,"January 14, 2020","Yale Cancer Center, New Haven, Connecticut, United States",,"https://ClinicalTrials.gov/show/NCT02979977"
37,"NCT04230759","Radiochemotherapy +/- Durvalumab for Locally-advanced Anal Carcinoma. A Multicenter, Randomized, Phase II Trial of the German Anal Cancer Study Group","RADIANCE","Recruiting","No Results Available","Anal Cancer|Anal Carcinoma|Anal Cancer Stage III|Anal Cancer Stage II","Drug: Chemotherapy|Radiation: Radiation|Drug: Durvalumab","Disease-free survival (DFS)|Major adverse events|cCR|Overall survival|Colostomy-free survival|Cumulative incidence of locoregional recurrence|Cumulative incidence of distant recurrence|Quality of life questionnaires","Goethe University","All","18 Years and older   (Adult, Older Adult)","Phase 2","178","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","RADIANCE|2018-003005-25|70113615|ESR-17-13077","January 15, 2020","March 31, 2023","June 30, 2026","January 18, 2020",,"January 23, 2020","Radioonkologie und Strahlentherapie, Berlin, Germany|Institut für Radioonkologie und Strahlentherapie, Darmstadt, Germany|Klinik und Poliklinik für Strahlentherapie und Radioonkologie, Dresden, Germany|Klinik und Poliklinik für Strahlentherapie, Essen, Germany|University Hospital Goethe University Frankfurt, Frankfurt, Germany|Klinik für Strahlenheilkunde, Universitätsklinikum Freiburg, Freiburg, Germany|Medizinische Hochschule Hannover, Hannover, Germany|RadioOnkologie und Strahlentherapie, Universitätsklinikum Heidelberg, Heidelberg, Germany|UKSH Campus Kiel, Kiel, Germany|Universitätsklinikum Leipzig, Leipzig, Germany|Universitätsklinikum Magdeburg, Magdeburg, Germany|Universitätsmedizin Mainz, Mainz, Germany|Uniklinikum Marburg, Marburg, Germany|Kliniken Maria Hilf GmbH Mönchengladbach, Mönchengladbach, Germany|LMU Klinikum der Universität München, München, Germany|Technische Universität München, München, Germany|Universitätsklinikum Regensburg, Regensburg, Germany|Universitätsklinikum Rostock, Rostock, Germany|Universitätsklinik Tübingen, Tübingen, Germany|Universitätsklinikum Würzburg, Würzburg, Germany|UniversitätsSpital Zürich, Zürich, Switzerland",,"https://ClinicalTrials.gov/show/NCT04230759"
38,"NCT04020185","Safety and Efficacy Study of IMSA101 in Refractory Malignancies",,"Recruiting","No Results Available","Solid Tumor, Adult","Drug: IMSA101|Drug: Immune checkpoint inhibitor (ICI)|Drug: Immuno-oncology (IO) therapy","Maximum Tolerated Dose|Pharmacokinetic Sampling (Ph I)|Anti-tumor Effects","ImmuneSensor Therapeutics Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","115","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IMSA101-101","September 23, 2019","February 16, 2023","February 16, 2023","July 15, 2019",,"January 22, 2020","Honor Health, Scottsdale, Arizona, United States|Northwestern University, Chicago, Illinois, United States|UT Southwestern, Dallas, Texas, United States|MD Anderson Cancer Center, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT04020185"
39,"NCT03734692","Systemic Immune Checkpoint Blockade and Intraperitoneal Chemo-Immunotherapy in Recurrent Ovarian Cancer",,"Recruiting","No Results Available","Ovarian Cancer Recurrent","Drug: Rintatolimod|Drug: Pembrolizumab|Drug: Cisplatin","Objective Response Rate (ORR)|Progression-Free Survival (PFS)|Change in number of CD8+ cells|Change in number of CD3+ cells","Robert Edwards|AIM ImmunoTech Inc.|Merck Sharp & Dohme Corp.|University of Pittsburgh","Female","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","45","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HCC 18-087","January 28, 2019","February 20, 2021","November 20, 2023","November 8, 2018",,"December 3, 2019","Magee-Womens Hospital of UPMC, Pittsburgh, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT03734692"
40,"NCT04350463","A Safety and Efficacy Study of CC-90011 in Combination With Nivolumab in Subjects With Advanced Cancers",,"Not yet recruiting","No Results Available","Neoplasms","Drug: CC-90011|Drug: Nivolumab","Overall response rate|Adverse Events (AEs)|Duration of response|Progression-free survival|Overall Survival","Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 2","135","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CC-90011-ST-002|U1111-1248-8352|2019-004194-95","May 4, 2020","October 22, 2022","July 13, 2024","April 17, 2020",,"April 29, 2020","Augusta University - Georgia Cancer Center, Augusta, Georgia, United States|Joliet Oncology-Hematology Associates, Ltd., Joliet, Illinois, United States|Investigative Clinical Research of Indiana, LLC, Indianapolis, Indiana, United States|Memorial Sloan-Kettering Cancer Center - David H. Koch Center for Cancer Care, New York, New York, United States|Novant Health Presbyterian Medical Center, Charlotte, North Carolina, United States|Piedmont Hematology Oncology Associates, Winston-Salem, North Carolina, United States|Gabrail Cancer Center Research, Canton, Ohio, United States|University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States|University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States|Brooke Army Medical Center Francis Street Medical Center, Fort Sam Houston, Texas, United States|Millennium Oncology, Houston, Texas, United States|Virginia Cancer Specialists, PC, Fairfax, Virginia, United States|CHU de Grenoble Alpes Hopital Nord, Grenoble cedex 9, France|Hospital Le Timone, Marseille Cedex 5, France|Hospital Pontchaillou, Rennes, France|CHU Nantes Hopital Nord Laennec, Saint-Herblain, France|Gustave Roussy, Villejuif CEDEX, France|DRK-Kliniken Berlin Mitte, Berlin, Germany|Lungenklinik Hemer, Hemer, Germany|Lungenfachklinik Immenhausen Pneumologische Lehrklinik der Universitaet Goettingen, Immenhausen, Germany|Klinik Loewenstein gGmbH, Loewenstein, Germany|Centro di Riferimento Oncologico, Aviano, Italy|Azienda Ospedaliera Istituti Ospitalieri di Cremona, Cremona, Italy|Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy|Policlinico Universitario Campus Biomedico Di Roma, Roma, Italy|Azienda Ospedaliera Universitaria Integrata di Verona, Verona, Italy|Hospital Universitari Germans Trias i Pujol Can Ruti, Badalona (Barcelona), Spain|Hospital Quiron Barcelona, Barcelona, Spain|Hospital Universitari Vall d'Hebron, Barcelona, Spain|Clinica Universidad de Navarra, Madrid, Spain|Hospital Universitario Fundacion Jimenez Diaz, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Clinica Universidad de Navarra, Pamplona, Spain|Hospital Universitari i Politecnic La Fe de Valencia, Valencia, Spain|Clatterbridge Centre for Oncology NHS Trust, Bebington, Wirral, United Kingdom|The Royal Marsden Hospital, London, United Kingdom|The Christie NHS Foundation Trust, Manchester, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04350463"
41,"NCT02805660","Phase 1/2 Study of Mocetinostat and Durvalumab in Patients With Advanced Solid Tumors and NSCLC",,"Active, not recruiting","No Results Available","Advanced Cancer","Drug: mocetinostat|Drug: durvalumab","Incidence of dose limiting toxicities|Number of patients experiencing tumor size reduction|Number of patients experiencing Adverse Events|Blood plasma MGCD0103 concentration|Blood plasma MEDI4736 concentration","Mirati Therapeutics Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","119","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","0103-020","May 2016","April 2019","July 2020","June 20, 2016",,"June 11, 2019","Southern Cancer Center, PC, Mobile, Alabama, United States|David Geffen School of Medicine at UCLA, Los Angeles, California, United States|Woodlands Medical Specialists - Pensacola, Pensacola, Florida, United States|Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois, United States|NorthShore University Health System, Evanston, Illinois, United States|Unniversity of Minnesota Masonic Cancer Center, Minneapolis, Minnesota, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Montefiore Medical Center, Bronx, New York, United States|Sarah Cannon Research Institute, Nashville, Tennessee, United States|Mary Crowley Cancer Research Centers, Dallas, Texas, United States|Texas Oncology - Denton South, Denton, Texas, United States|Texas Oncology-Plano West, Plano, Texas, United States|Virginia Cancer Specialists, Fairfax, Virginia, United States|Shenandoah Oncology - Winchester, Winchester, Virginia, United States|Seattle Cancer Care Alliance, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT02805660"
42,"NCT04180215","A Phase I/II Study of TheraT® Vector(s) Expressing Human Papillomavirus 16 Positive (HPV 16+) Specific Antigens in Patients With HPV 16+ Confirmed Cancers",,"Recruiting","No Results Available","HPV-Related Squamous Cell Carcinoma","Drug: HB-201 intravenous administration|Drug: HB-201 intratumoral administration on first cycle, followed by HB-201 intravenous administration on subsequent cycles","Recommended Phase 2 Dose (RP2D) for IV administration|Recommended Phase 2 Dose (RP2D) for IT administration|Number of patients receiving IV HB-201 experiencing treatment-emergent adverse events.|Number of patients receiving IT HB-201 experiencing treatment-emergent adverse events|Number of patients receiving IV HB-201 with tumor response throughout the study using RECIST v1.1 and/or iRECIST|Number of patients receiving IT HB-201 with tumor response throughout the study using RECIST v1.1 and/or iRECIST|Characterization of preliminary immunogenic properties of IV administration by intracellular staining and ELISpot assay.|Characterization of preliminary immunogenic properties of IT administration","Hookipa Biotech","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","100","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","H-200-001|2019-000907-34","December 11, 2019","January 2022","June 2022","November 27, 2019",,"May 7, 2020","Banner MD Anderson Cancer Center, Gilbert, Arizona, United States|USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States|Sylvester Comprehensive Cancer Center, Miami, Florida, United States|University of Kansas Medical Center, Fairway, Kansas, United States|Henry Ford Hospital, Detroit, Michigan, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Montefiore-Einstein Center for Cancer Care, Bronx, New York, United States|Icahn School of Medicine at Mount Sinai, New York, New York, United States|University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States|Providence Portland Medical Center, Portland, Oregon, United States|Greenville Hospital System University Medical Center (ITOR), Greenville, South Carolina, United States",,"https://ClinicalTrials.gov/show/NCT04180215"
43,"NCT02664181","Rational EpigenetiC Immunotherapy for SEcond Line Therapy in Patients With NSCLC: PRECISE Trial","PRECISE","Completed","No Results Available","Lung Cancer|Non-small Cell Lung Cancer","Drug: Nivolumab|Drug: oral decitabine|Drug: Tetrahydrouridine","Objective response by Response Evaluation Criteria in Solid Tumors (RECIST1.1)|Progression-free survival|Overall survival","Case Comprehensive Cancer Center","All","18 Years and older   (Adult, Older Adult)","Phase 2","13","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CASE3516","June 6, 2017","July 2, 2019","July 2, 2019","January 26, 2016",,"July 10, 2019","Center for Cancer Research, Bethesda, Maryland, United States|Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT02664181"
44,"NCT04394624","SAR408701 in Combination With Ramucirumab in Pre-treated Patients With Non Squamous Non-small Cell Lung Cancer (NSQ NSCLC)","CARMEN-LC04","Not yet recruiting","No Results Available","Non-small Cell Lung Cancer Metastatic","Drug: SAR408701|Drug: ramucirumab","Part 1: Incidence of study drug-related dose-limiting toxicity (DLT) at Cycle 1 and Cycle 2|Part 2: Objective response rate|Incidence of treatment emergent adverse events (TEAEs) and serious adverse events (SAEs)|Duration of response (DOR)|Progression-free survival (PFS)|PK - Cmax of SAR408701|PK - AUC0-14d of SAR408701|PK - Ctrough of SAR408701|Ctrough of ramucirumab|Incidence of anti-therapeutic antibodies (ATAs) against SAR408701","Sanofi","All","18 Years and older   (Adult, Older Adult)","Phase 2","36","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ACT16525|2019-003914-15|U1111-1244-1585","June 5, 2020","October 14, 2021","February 2022","May 19, 2020",,"May 19, 2020",,,"https://ClinicalTrials.gov/show/NCT04394624"
45,"NCT04029181","ImmunoPET With an Anti-CD8 Imaging Agent",,"Recruiting","No Results Available","Metastatic Cancer|Unresectable Malignant Neoplasm","Other: Anti-CD8 PET imaging agent","Incidence of adverse events related to tracer administration as assessed by CTCAE v4.0|Appropriate dosing of anti-CD8 imaging agent and PET imaging time points|Pharmacokinetics (PK) of anti-CD8 imaging agent|Immunogenic potential of the anti-CD8 imaging agent by measuring incidence of anti-drug antibodies|Heterogeneity of tumor uptake of the anti-CD8 imaging agent|Correlation of normal organ uptake of the anti-CD8 imaging agent to (serious) adverse events (possibly) related to immune checkpoint inhibitor treatment|Correlation of tumor uptake of the anti-CD8 imaging agent and immune cell CD8 expression|Correlation of anti-CD8 imaging agent normal tissue kinetics with blood kinetics|Dosimetry","University Medical Center Groningen","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","40","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","201700848","February 14, 2019","February 2021","February 2021","July 23, 2019",,"July 23, 2019","University Medical Center Groningen, Groningen, Netherlands",,"https://ClinicalTrials.gov/show/NCT04029181"
46,"NCT04195373","A Safety Study of TMV-018 in Patients With Tumors of the Gastrointestinal Tract",,"Not yet recruiting","No Results Available","Gastrointestinal Cancer","Biological: TMV-018 + 5-FC|Biological: TMV-018 + anti-PD-1|Biological: TMV-018 + 5-FC + anti-PD-1","Frequency of Adverse Events|Determine MTD and dose for phase II|Viral replication|Viral distribution|Efficacy of therapy assessed by RECIST 1.1|Efficacy of therapy assessed by changes in tumor marker level","Themis Bioscience GmbH|Assign Data Management and Biostatistics GmbH|SSS International Clinical Research GmbH","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","39","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TMV-018-101","April 2020","December 2022","December 2024","December 11, 2019",,"December 11, 2019","University Hospital Bonn, Bonn, Germany|University Hospital Tübingen, Tübingen, Germany",,"https://ClinicalTrials.gov/show/NCT04195373"
47,"NCT03041311","Carboplatin, Etoposide, and Atezolizumab With or Without Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Extensive Stage Small Cell Lung Cancer (SCLC)",,"Active, not recruiting","No Results Available","Small Cell Lung Cancer","Drug: Trilaciclib|Drug: Placebo|Drug: Carboplatin|Drug: Etoposide|Drug: Atezolizumab","Evaluate the potential of trilaciclib to reduce chemotherapy-induced myelosuppression|Overall survival (OS)|PFS based on RECIST v1.1|Number of patients with objective response (CR or PR) based on RECIST v1.1|Treatment related adverse events (AE) based on NCI CTCAE v4.0|Abnormal Laboratory Events|Incidence of of immune-related adverse events (irAEs)","G1 Therapeutics, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 2","105","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","G1T28-05|2017-000358-20","April 7, 2017","July 28, 2018","May 2020","February 2, 2017",,"July 26, 2019","Beverly Hills Cancer Center, Beverly Hills, California, United States|St. Jude Heritage Healthcare, Fullerton, California, United States|Loma Linda University, Loma Linda, California, United States|UCLA Medical Center - Santa Monica Hematology And Oncology, Santa Monica, California, United States|Redwood Regional Medical Group (RRMG) - Fountain Grove, Santa Rosa, California, United States|Singing River Health System, Whittier, California, United States|Piedmont Cancer Institute, Atlanta, Georgia, United States|Northside Hospital - Georgia Cancer Specialists, Atlanta, Georgia, United States|Joliet Oncology-Hematology Associates, Joliet, Illinois, United States|Horizon Oncology Center, Lafayette, Indiana, United States|Kentucky One Health, Louisville, Kentucky, United States|Ochsner Clinic Foundation, New Orleans, Louisiana, United States|St. Louis Cancer Care, LLP, North County, Bridgeton, Missouri, United States|The Alvin J. Siteman Cancer Center - Center for Advanced Med, Saint Louis, Missouri, United States|Summit Medical Group, P.A., Morristown, New Jersey, United States|Northern Westchester Hospital, Mount Kisco, New York, United States|Trinity Health - Trinity CancerCare Center, Minot, North Dakota, United States|Oklahoma University - Peggy and Charles Stephenson Cancer Center, Oklahoma City, Oklahoma, United States|Gibbs Cancer Center, Spartanburg, South Carolina, United States|Millennium Oncology, Houston, Texas, United States|Virginia Cancer Specialists, Arlington, Virginia, United States|Blue Ridge Cancer Care, Blacksburg, Virginia, United States|Fort Belvoir Community Hospital, Fort Belvoir, Virginia, United States|Complex Oncology Center - Burgas, Burgas, Bulgaria|Multiprofile Hospital for Active Treatment ""Serdika"", Sofia, Sofia, Bulgaria|Multiprofile Hospital for Active Treatment ""Serdika"", Sofia, Bulgaria|East Tallinn Central Hospital Ltd., Clinic of Internal Medicine, Center for Oncology, Tallinn, Estonia|CHU Caen De La Côte De Nacre, Caen, France|Centre Oscar Lambret, Lille, France|Daugavpils Regional Hospital, Department of Oncology, Daugavpils, Latvia|Pauls Stradiņš Clinical University Hospital, Oncology Clinic, Riga, Latvia|Hospital Universitario Son Espases, Palma, Islas Baleares, Spain|Hospital Teresa Herrera, A Coruña, La Coruña, Spain|Hospital Universitario Puerta de Hierro Majadahonda, Majadahonda, Madrid, Spain|Hospital Clínico, San Carlos, Madrid, Spain|H.U. Quirón Dexeus, Hospital Universitario, Barcelona, Spain|Hospital Clinic de Barcelona- Servicio de Oncología Médica, Barcelona, Spain|Hospital Universitario Ramón y Cajal, Madrid, Spain|Hospital 12 de Octubre, Madrid, Spain|H. Donostia, Hospital Donostia- Servicio de Oncología, San Sebastián, Spain|Hospital Universitario Ntra. Sra. de Valme, Sevilla, Spain|Hospital Arnau de Vilanova, Valencia, Spain|Chernivtsi Regional Clinical Oncology Center, Chernivtsi, Ukraine|Dnipropetrovsk City Multispecialty Clinical Hospital #4, Dnipro, Ukraine|Lviv State Regional Treatment and Diagnostics Oncology Center, Lviv, Ukraine",,"https://ClinicalTrials.gov/show/NCT03041311"
48,"NCT03601455","Radiation Therapy and Durvalumab With or Without Tremelimumab in Treating Participants With Unresectable, Locally Advanced, or Metastatic Bladder Cancer",,"Recruiting","No Results Available","Bladder Urothelial Carcinoma|Stage IV Bladder Cancer AJCC v8|Stage IVA Bladder Cancer AJCC v8|Stage IVB Bladder Cancer AJCC v8","Biological: Durvalumab|Radiation: External Beam Radiation Therapy|Biological: Tremelimumab","Incidence of adverse events assessed by Common Terminology Criteria for Adverse Events (CTCAE) version (v.) 4.03 criteria (Safety lead-in cohort)|Progression- free survival (PFS) assessed by Response Evaluation Criteria in Solid Tumors (RECIST) v 1.1 (Expansion cohort)|Local control at the primary irradiate site determined by RECIST v 1.1|Pathologic complete rate (CR) of primary irradiated tumor|Overall response rate (ORR) defined as the number (%) of patients with at least 1 visit response of CR or partial response (PR) determined by RECIST v 1.1|Abscopal response (in patients with metastatic disease) determined by RECIST v 1.1 with response (PR and CR) sites away from the primary irradiated tumor|Duration of response|Disease-specific survival|Overall survival|Incidence of adverse events assessed by National Cancer Institute CTCAE v4.0","Jonsson Comprehensive Cancer Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Phase 2","74","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","17-001894|NCI-2018-01415|P30CA016042","October 26, 2018","November 1, 2021","November 1, 2022","July 26, 2018",,"January 28, 2020","UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States",,"https://ClinicalTrials.gov/show/NCT03601455"
49,"NCT02873975","A Study of LY2606368 (Prexasertib) in Patients With Solid Tumors With Replicative Stress or Homologous Repair Deficiency",,"Active, not recruiting","No Results Available","Advanced Cancers","Drug: LY2606368","Progression-Free Rate|Objective Response Rate|Toxicity|Overall Survival Rate","Dana-Farber Cancer Institute","All","18 Years and older   (Adult, Older Adult)","Phase 2","50","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","16-281","October 12, 2016","April 2020","April 2022","August 22, 2016",,"December 11, 2019","Dana Farber Cancer Institute, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT02873975"
50,"NCT03325816","Nivolumab and 177Lu-DOTA0-Tyr3-Octreotate for Patients With Extensive-Stage Small Cell Lung Cancer",,"Active, not recruiting","No Results Available","Small Cell Lung Cancer|Small Cell Lung Cancer Extensive Stage","Drug: Nivolumab|Radiation: 177Lu-DOTA0-Tyr3-Octreotate","Phase I - Recommended phase II dose (RP2D) of 177Lu-DOTA0-Tyr3-Octreotate|Phase II - Progression Free Survival|Safety profile of 177Lu-DOTA0-Tyr3-Octreotate in combination with nivolumab|Phase II - Overall survival|Phase II - Disease Control Rate|Phase II - Objective Response Rate|Phase II - Metabolic Response","Georgetown University|Bristol-Myers Squibb|Advanced Accelerator Applications","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","9","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2017-1081","November 20, 2017","March 28, 2019","December 2020","October 30, 2017",,"February 19, 2020","Georgetown Lombardi Comprehensive Cancer Center, Washington, District of Columbia, United States|John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT03325816"
51,"NCT03939962","PD-1 Inhibitor Combined With FOLFOX Neoadjuvant Therapy for Resectable Gastric and Gastroesophageal Junctional Adenocarcinoma",,"Not yet recruiting","No Results Available","Gastric Cancer","Drug: SHR1210 combined with FOLFOX","R0 resection rate|pathological complete response (pCR) rate|Progression-free Survival (PFS)|Overall survival(OS)","Henan Cancer Hospital","All","18 Years to 73 Years   (Adult, Older Adult)","Phase 2","60","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HNGC-004","June 2019","June 1, 2021","June 2021","May 7, 2019",,"May 8, 2019",,,"https://ClinicalTrials.gov/show/NCT03939962"
52,"NCT03572478","Rucaparib and Nivolumab in Patients With Prostate or Endometrial Cancer",,"Active, not recruiting","No Results Available","Prostate Cancer|Endometrial Cancer","Drug: Rucaparib|Drug: Nivolumab","Dose limiting toxicities (DLT) rate of the combination of rucaparib and nivolumab (phase 1)|Frequency of patients with T cell inflammation in the tumor compared between treatment arms (phase 2)|Time to disease progression in prostate cancer patients (phase 2)|Time to disease progression in endometrial cancer patients (phase 2)|Response rate in prostate cancer patients (phase 2)|Response rate in endometrial cancer patients (phase 2)|Changes in number of T cells in tumor samples compared between treatment arms (phase 2)|Correlation of change in T cells in tumor samples and PTEN mutation status (phase 2)","University of Chicago|Bristol-Myers Squibb|Clovis Oncology, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","12","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB18-0154","August 14, 2018","February 29, 2020","December 2021","June 28, 2018",,"May 22, 2020","University of Chicago Medical Center, Chicago, Illinois, United States",,"https://ClinicalTrials.gov/show/NCT03572478"
53,"NCT03526887","Re-challenge Pembrolizumab Study as a Second or Further Line in Patients With Advanced NSCLC","Replay","Recruiting","No Results Available","Lung Cancer","Drug: Pembrolizumab","Efficacy of Pembrolizumab re-challenge measured by Overall Response Rate per RECIST v1.1|Efficacy of Pembrolizumab re-challenge measured by Progression Free Survival per RECIST v1.1.","Spanish Lung Cancer Group","All","18 Years and older   (Adult, Older Adult)","Phase 2","110","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GECP 17/02_REPLAY","July 15, 2018","July 15, 2022","July 15, 2023","May 16, 2018",,"November 22, 2019","Hospital General Universitario de Elche, Elche, Alicante, Spain|H. Germans Trias i Pujol, Badalona, Barcelona, Spain|Hospital Parc Taulí, Sabadell, Barcelona, Spain|Consorci Sanitari de Terrassa, Terrassa, Barcelona, Spain|Complejo Hospitalario de la Coruña, La Coruña, Coruña, Spain|Clínica Universidad de Navarra, Pamplona, Navarra, Spain|Hospital de Basurto, Bilbao, Vizcaya, Spain|Hospital de Santa Creu i Sant Pau, Barcelona, Spain|H.U.Vall D´Hebrón, Barcelona, Spain|Hospital Dr. Josep Trueta, Girona, Spain|Complejo Hospitalario de Jaén, Jaén, Spain|Complejo Asistencial Universitario de León, León, Spain|Fundación Jiménez Díaz, Madrid, Spain|H. 12 de Octubre, Madrid, Spain|Puerta de Hierro, Madrid, Spain|H. Son Llàtzer, Palma de Mallorca, Spain|Hospital General Universitario de Valencia, Valencia, Spain|Hospital La Fe, Valencia, Spain|Hospital Miguel Servet, Zaragoza, Spain",,"https://ClinicalTrials.gov/show/NCT03526887"
54,"NCT04239443","Clinical Study of PD-1 Monoclonal Antibody SHR-1210 and Apatinib in Advanced NSCLC, Soft Tissue Sarcoma, and Uterine Cancer",,"Recruiting","No Results Available","Advanced Non Small Cell Lung Cancer|Uterine Cancer|Soft Tissue Sarcoma","Drug: PD-1 inhibitor|Drug: Apatinib","Objective remission rate (ORR)|Progression free survival (PFS)|Overall survival (OS)|The number of Circulating Tumor Cell (CTC)|Analysis of PD-L1 expression on Circulating Tumor Cell (CTC) and tumor tissue|Duration of response(DOR)|Disease control rate(DCR)","Hunan Cancer Hospital|Jiangsu HengRui Medicine Co., Ltd.","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 2","120","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HNCHIIT001","January 30, 2019","March 31, 2022","March 31, 2022","January 27, 2020",,"January 27, 2020","Hunan cancer Hospital, Changsha, Hunan, China",,"https://ClinicalTrials.gov/show/NCT04239443"
55,"NCT03996473","Study to Test the Safety and How Radium-223 Dichloride an Alpha Particle-emitting Radioactive Agent Works in Combination With Pembrolizumab an Immune Checkpoint Inhibitor in Patients With Stage IV Non-small Cell Lung Cancer With Bone Metastases",,"Recruiting","No Results Available","Carcinoma, Non-Small-Cell Lung","Drug: Radium-223 dichloride (Xofigo, BAY 88-8223)|Drug: Pembrolizumab","Number of participants with adverse events (AEs) in Phase 1|Number of participants with dose limiting toxicities (DLTs) in Phase 1|Objective response rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 in Phase 2|ORR per RECIST v1.1 in Phase 1|ORR per iRECIST in Phase 1|Duration of response (DOR) per RECIST v1.1 in Phase 1|DOR per iRECIST in Phase 1|Disease control rate (DCR) per RECIST v1.1 in Phase 1|DCR per iRECIST in Phase 1|ORR per iRECIST in Phase 2|DOR per RECIST v1.1 in Phase 2|DOR per iRECIST in Phase 2|DCR per RECIST v1.1 in Phase 2|DCR per iRECIST in Phase 2|Progression free survival (PFS) per RECIST v1.1 in Phase 2|PFS per iRECIST in Phase 2|Overall survival (OS) in Phase 2|Number of participants with AE in Phase 2","Bayer|Merck Sharp & Dohme Corp.","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","164","Industry","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","19781|2018-003704-39","March 10, 2020","April 30, 2023","July 30, 2023","June 24, 2019",,"June 3, 2020","Highlands Oncology Group, PA, Fayetteville, Arkansas, United States|Ccare San Marcos Cancer Center & Urology, San Marcos, California, United States|Cancer Treatment Centers of America, Atlanta, Newnan, Georgia, United States|Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States|Regional Cancer Care Associates, LLC, Somerset, New Jersey, United States|Stony Brook University Medical Center, Stony Brook, New York, United States|Levine Cancer Institute, Charlotte, North Carolina, United States|Oncology/Hematology Care (OHC) Clinical Trials, LLC, Cincinnati, Ohio, United States|CTCA Southwestern, Tulsa, Oklahoma, United States|St. Luke's University Health Network System, Bethlehem, Pennsylvania, United States|UPMC Shadyside, Pittsburgh, Pennsylvania, United States|Carilion Clinic, Roanoke, Virginia, United States|UZ Brussel, Bruxelles - Brussel, Belgium|UZ Gent, Gent, Belgium|CHU de Liège, Liege, Belgium|CHU UCL Namur, Namur, Belgium|Universitätsklinikum der Johann Wolfgang Goethe Universität, Frankfurt, Hessen, Germany|Medizinische Einrichtungen der Universität Bonn, Bonn, Nordrhein-Westfalen, Germany|Klinikum der Stadt Köln gGmbH - Krankenhaus Merheim, Köln, Nordrhein-Westfalen, Germany|Krankenhaus Grosshansdorf, Grosshansdorf, Germany|Edith Wolfson Medical Center, Holon, Israel|Meir Medical Center, Kfar Saba, Israel|Tel-Aviv Sourasky Medical Center, Tel Aviv, Israel|A.O.U. di Parma, Parma, Emilia-Romagna, Italy|IRCCS Istituto Europeo di Oncologia (IEO), Milano, Lombardia, Italy|IRCCS Fondazione Policlinico San Matteo, Pavia, Lombardia, Italy|Nederlands Kanker Instituut, Amsterdam, Netherlands|Centrum Onkologii im. Prof. Franciszka Lukaszczyka, Bydgoszcz, Poland|Wojskowy Instytut Medyczny, Warszawa, Poland|Uniwersytecki Szpital Kliniczny UM we Wroclawiu, Wroclaw, Poland|Institut Català d'Oncologia Badalona, Badalona, Barcelona, Spain|Hospital Universitario Clinica Puerta de Hierro, Majadahonda, Madrid, Spain|Ciutat Sanitària i Universitaria de la Vall d'Hebron, Barcelona, Spain|Hospital Clínic i Provincial de Barcelona, Barcelona, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Royal Marsden NHS Trust (Surrey), Sutton, Surrey, United Kingdom|Freeman Hospital, Newcastle Upon Tyne, Tyne And Wear, United Kingdom|Leeds teaching Hospitals, Leeds, West Yorkshire, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03996473"
56,"NCT03616834","Tomivosertib (eFT-508) in Combination With PD-1/PD-L1 Inhibitor Therapy",,"Active, not recruiting","No Results Available","Solid Tumors","Drug: Tomivosertib (eFT-508)","Proportion of subjects with treatment-emergent AEs (TEAEs) and serious AEs (SAEs)|Overall Response Rate (ORR) as determined by RECIST 1.1|Progression Free Survival (PFS) as determined by RECIST 1.1|ORR as determined by iRECIST|PFS as determined by iRECIST|Overall survival","Effector Therapeutics","All","18 Years and older   (Adult, Older Adult)","Phase 2","39","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","eFT508-0010","July 25, 2018","March 2020","May 2020","August 6, 2018",,"December 5, 2019","University of Arizona - Cancer Center, Tucson, Arizona, United States|Pacific Shores Medical Group, Long Beach, California, United States|Hoag Memorial Hospital Presbyterian, Los Angeles, California, United States|USC Norris Comprehensive Cancer Center, Los Angeles, California, United States|St. Mary's Medical Center, San Francisco, California, United States|St. Joseph Heritage Healthcare, Santa Rosa, California, United States|Columbus Regional Research Institute, Columbus, Georgia, United States|Saint Alphonsus Regional Medical Center, Boise, Idaho, United States|Indiana University Health Melvin & Bren Simon Cancer Center, Indianapolis, Indiana, United States|Anne Arundel Medical Center, Annapolis, Maryland, United States|Karmanos Cancer Institute, Detroit, Michigan, United States|Gabrail Cancer Center, Canton, Ohio, United States|Universty of Toledo Medical Center, Toledo, Ohio, United States|Providence Portland Medical Center, Portland, Oregon, United States|Spartanburg Medical Center, Spartanburg, South Carolina, United States|Avera Cancer Institute, Sioux Falls, South Dakota, United States|Oncology Consultants, Houston, Texas, United States|Virginia Cancer Specialists, PC, Fairfax, Virginia, United States|University of Wisconsin Clinical Science Center, Madison, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT03616834"
57,"NCT04317105","Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Immunotherapy (Nivolumab With or Without Ipilimumab) in Patients With Advanced Solid Cancers That Have Changes in the Following Genes: PIK3CA and PTEN",,"Not yet recruiting","No Results Available","Advanced Malignant Solid Neoplasm|Metastatic Malignant Solid Neoplasm|Unresectable Malignant Solid Neoplasm","Drug: Copanlisib Hydrochloride|Biological: Ipilimumab|Biological: Nivolumab","Incidence of adverse events and serious adverse events|Incidence of dose limiting toxicities (DLTs)|Objective response (OR) rate (complete response [CR] + partial response [PR])|Clinical benefit rate (OR + stable disease [SD] > 6 months)|Progression free survival (PFS)|Overall survival (OS)","National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","102","NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NCI-2020-01917|NCI10221|10221|UM1CA186688","May 6, 2020","December 31, 2022","December 31, 2022","March 23, 2020",,"April 8, 2020",,,"https://ClinicalTrials.gov/show/NCT04317105"
58,"NCT03955198","A Study Evaluating the Efficacy of the Combination of Hypofractionated Stereotactic Radiation Therapy With the Anti-PDL1 Immune Checkpoint Inhibitor Durvalumab in NSCLC Patients With 1 to 4 Brain Metastases","SILK BM","Recruiting","No Results Available","Brain Metastases|NSCLC","Radiation: Radiotherapy|Combination Product: Radiotherapy + durvalumab","Time to intra-cranial progression according to Response Assessment in Neuro-Oncology Brain Metastases (RANO-BM) criteria|Progression-free survival|Safety will be assessed by the toxicity grading of the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE v 5.0)|Quality of life will be evaluated using the EORTC QLQ-C30 (European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire - Core 30)|Quality of life will be evaluated using European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire - Brain Cancer Module","Institut Claudius Regaud","All","18 Years and older   (Adult, Older Adult)","Phase 2","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","18POUM06","March 2020","December 2021","July 2024","May 20, 2019",,"March 3, 2020","Centre Hospitalier Universitaire, Lyon, France|Institut Cancerologie de L'Ouest, Saint-Herblain, France|Institut Universitaire du Cancer Toulouse - Oncopole, Toulouse, France",,"https://ClinicalTrials.gov/show/NCT03955198"
59,"NCT03406858","Pembrolizumab and HER2Bi-Armed Activated T Cells in Treating Patients With Metastatic Castration Resistant Prostate Cancer",,"Recruiting","No Results Available","Castration Levels of Testosterone|Castration-Resistant Prostate Carcinoma|Prostate Carcinoma Metastatic in the Bone|PSA Progression|Stage IV Prostate Adenocarcinoma AJCC v7","Biological: HER2Bi-Armed Activated T Cells|Other: Laboratory Biomarker Analysis|Biological: Pembrolizumab","Progression-free survival","Barbara Ann Karmanos Cancer Institute|National Cancer Institute (NCI)","All","19 Years and older   (Adult, Older Adult)","Phase 2","33","Other|NIH","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2015-135|NCI-2017-02156|P30CA022453","June 7, 2018","December 1, 2019","December 1, 2019","January 23, 2018",,"September 21, 2018","Wayne State University/Karmanos Cancer Institute, Detroit, Michigan, United States",,"https://ClinicalTrials.gov/show/NCT03406858"
60,"NCT02109328","Alisertib in Chemotherapy-pretreated Urothelial Cancer",,"Completed","No Results Available","Bladder Cancer|Transitional Cell Carcinoma","Drug: Alisertib|Drug: Paclitaxel|Drug: Placebo","Response rate|Progression-free survival|To evaluate the safety and tolerability of Alisertib in a population of chemotherapy pretreated patients with UC.","Fondazione IRCCS Istituto Nazionale dei Tumori, Milano","All","18 Years and older   (Adult, Older Adult)","Phase 2","22","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","UC-Aurora_INT01|2014-000557-36","August 28, 2014","July 2, 2015","October 12, 2016","April 9, 2014",,"April 11, 2019","Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Mi, Italy",,"https://ClinicalTrials.gov/show/NCT02109328"
61,"NCT04262466","Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors",,"Recruiting","No Results Available","Select Advanced Solid Tumors","Drug: IMC-F106C|Drug: anti-PD(L)1","Phase 1: Incidence of Dose-limiting toxicity (DLT)s|Phase 1: incidence and severity of adverse events (AE) and serious adverse events (SAE)|Phase 1: changes in laboratory parameters|Phase 1: changes in vital signs|Phase 1: changes in electrocardiogram parameters|Phase 1: dose interruptions, reductions, and discontinuations|Phase 2: Best overall response (BOR)|Phase I: Best Overall Response (BOR)|Progression-free survival (PFS)|Duration of response (DOR)|Overall survival|Pharmacokinetics Area under the plasma concentration-time curve (AUC)|Pharmacokinetics The maximum observed plasma drug concentration (Cmax)|Pharmacokinetics The time to reach maximum plasma concentration (Tmax)|Pharmacokinetics The elimination half-life (t1/2)|Incidence of anti-IMC-F106C antibody formation|Changes in lymphocyte counts over time|Changes in serum cytokines over time","Immunocore Ltd","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","170","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IMC-F106C-101","February 25, 2020","February 2022","February 2024","February 10, 2020",,"April 21, 2020","University of Oklahoma Peggy and Charles Stephenson Cancer Center, Oklahoma City, Oklahoma, United States|Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States|Sarah Cannon Research Institute, Nashville, Tennessee, United States|MD Anderson Cancer Center, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT04262466"
62,"NCT04179110","Study of Pembrolizumab and Ramucirumab in Pts With Progressive TCC After Treatment With an Immune Checkpoint Inhibitor",,"Not yet recruiting","No Results Available","Transitional Cell Carcinoma","Drug: Pembrolizumab and Ramucirumab","Overall response rate (ORR)|Progression free survival (PFS)|Overall survival (OS)","Yale University","All","18 Years and older   (Adult, Older Adult)","Phase 2","28","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2000022801","May 15, 2020","December 15, 2022","June 15, 2023","November 27, 2019",,"March 31, 2020",,,"https://ClinicalTrials.gov/show/NCT04179110"
63,"NCT03092856","Axitinib With or Without Anti-OX40 Antibody PF-04518600 in Treating Patients With Metastatic Kidney Cancer",,"Recruiting","No Results Available","Clear Cell Renal Cell Carcinoma|Metastatic Renal Cell Cancer|Recurrent Renal Cell Carcinoma|Stage IV Renal Cell Cancer","Biological: Anti-OX40 Antibody PF-04518600|Drug: Axitinib|Other: Laboratory Biomarker Analysis|Other: Placebo","Progression‐free survival (PFS)|Incidence of unacceptable toxicity|ORR defined as either complete response or partial response occurring any time during treatment and assessed by RECIST 1.1 and immune-related RECIST (irRECIST) criteria","University of Southern California|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Phase 2","104","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","4K-16-5|NCI-2017-00223|P30CA014089","July 19, 2017","July 19, 2021","July 19, 2022","March 28, 2017",,"February 17, 2020","Los Angeles County-USC Medical Center, Los Angeles, California, United States|USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States|USC Norris Oncology/Hematology-Newport Beach, Newport Beach, California, United States|University of California Davis Comprehensive Cancer Center, Sacramento, California, United States|University of Kansas Cancer Center, Kansas City, Kansas, United States|Weill Cornell Medical College, New York- Presbyterian Hospital, New York, New York, United States|Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States|Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States|University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania, United States|University of Virginia Cancer Center, Charlottesville, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT03092856"
64,"NCT03347838","Nivolumab for the Reversal of Squamous Dysplasia in High Risk Current and Former Smokers",,"Recruiting","No Results Available","Bronchial Dysplasia|Tobacco Smoking|History of Non-Small Cell Lung Cancer|History of Head and Neck Cancer","Drug: Nivolumab","Improvement in endobronchial histology|Incidence of immune-related adverse events (irAEs)|Additional endobronchial histology endpoints using the 2004 WHO classification scale for pre-invasive squamous lesions of the bronchus","University of Colorado, Denver|Bristol-Myers Squibb","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 2","42","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","17-1492.cc","December 6, 2018","July 2021","December 2021","November 20, 2017",,"May 14, 2020","University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States|Denver VA Hospital, Denver, Colorado, United States",,"https://ClinicalTrials.gov/show/NCT03347838"
65,"NCT02797964","A Phase 1/2 Trial of SRA737 in Subjects With Advanced Cancer",,"Completed","No Results Available","Advanced Solid Tumors or Non-Hodgkin's Lymphoma (NHL)","Drug: SRA737","Number of subjects with adverse events as assessed by CTCAE 4.03|Maximum tolerated dose of SRA737|Recommended Phase 2 dose of SRA737|Objective response rate of SRA737","Sierra Oncology, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","112","Industry","Interventional","Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SRA737-01","July 2016","October 28, 2019",,"June 14, 2016",,"December 11, 2019","Royal Marsden Hospital, Sutton, London, United Kingdom|Belfast City Hospital, Belfast, Northern Ireland, United Kingdom|Oxford University Hospitals, Headington, Oxford, United Kingdom|Velindre Cancer Centre - Cardiff, Cardiff, Whitchurch, United Kingdom|The Clatterbridge Cancer Centre, Bebington, Wirral, United Kingdom|Western General Hospital, Edinburgh, United Kingdom|The Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom|The Leeds Teaching Hospitals of St James University Hospital, Leeds, United Kingdom|University Hospitals of Leicester, Leicester, United Kingdom|Guy's and St. Thomas, London, United Kingdom|Sarah Cannon Research Institute, London, United Kingdom|University College London Hospitals, London, United Kingdom|The Christie, Manchester, United Kingdom|Freeman Hospital, Newcastle upon Tyne, United Kingdom|Sheffield Teaching Hospitals, Sheffield, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02797964"
66,"NCT02439450","A Study of Combination Therapies With Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung Cancer",,"Active, not recruiting","No Results Available","Non-small Cell Lung Cancer","Biological: Viagenpumatucel-L|Drug: Nivolumab|Drug: Pembrolizumab|Drug: Pemetrexed","Phase 1b: Frequency of treatment emergent adverse events (TEAEs) as assessed by CTCAE v4.03.|Phase 2, Arm 5: Objective Response Rate (ORR)|Phase 2, Arm 6: Progression Free Survival (PFS)|Objective Response Rate (ORR)|Overall survival (OS)|Progression-Free survival (PFS)|Duration of response (DOR)|Disease control rate (DCR)|Durable Response Rate (DRR)|Frequency of treatment emergent adverse events (TEAEs) as assessed by CTCAE v4.03.","Heat Biologics","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","121","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HS110-102","April 15, 2015","December 2020","December 2021","May 8, 2015",,"April 27, 2020","University of Arizona Cancer Center, Tucson, Arizona, United States|UC San Diego, La Jolla, California, United States|BRRH Lynn Cancer Institute, Boca Raton, Florida, United States|Memorial Cancer Institute, Pembroke Pines, Florida, United States|Horizon Oncology Research, Lafayette, Indiana, United States|Ashland-Bellefonte Cancer Center, Ashland, Kentucky, United States|Baptist Health Louisville, Louisville, Kentucky, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|New York Oncology Hematology, Albany, New York, United States|Winthrop Hospital, Mineola, New York, United States|Oncology Hematology Care, Inc., Cincinnati, Ohio, United States|Cleveland Clinic, Cleveland, Ohio, United States|Providence Portland Medical Center, Portland, Oregon, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|Rhode Island Hospital, Providence, Rhode Island, United States|Virginia Cancer Specialists, Fairfax, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT02439450"
67,"NCT03583086","Phase I/II Eval Safety & Prelim Activity Nivolumab Comb W/Vorolanib Pts W/Refractory Thoracic Tumors",,"Recruiting","No Results Available","Thymic Carcinoma|Non-small Cell Lung Cancer|Refractory Thoracic Tumors|Small-Cell Lung Cancer","Drug: VEGFR/PDGFR Dual Kinase Inhibitor X-82|Biological: Nivolumab","Phase II recommended combination dose per Common Terminology Criteria for Adverse Events (CTCAE) criteria version 4.03|Phase II best response per Response Evaluation Criteria in Solid Tumors (RECIST)|Phase II best response|Progression-free survival|Overall survival|Objective response rate as related to PD-L1 status measured as < 1%, 1-49%, and > 50%.|Disease control rate","Vanderbilt-Ingram Cancer Center|Bristol-Myers Squibb|Xcovery Holdings, INC","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","177","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","VICC THO 1802|CA209-982","July 10, 2018","July 2023","July 2024","July 11, 2018",,"May 18, 2020","Stanford Cancer Institute, Palo Alto, California, United States|Winship Cancer Institute, Emory University, Atlanta, Georgia, United States|University of Chicago Medical Center, Chicago, Illinois, United States|Baptist Clinical Research Institute, Memphis, Tennessee, United States|Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT03583086"
68,"NCT02404441","Phase I/II Study of PDR001 in Patients With Advanced Malignancies",,"Active, not recruiting","No Results Available","Melanoma|NSCLC|Triple Negative Breast Cancer|Anaplastic Thyroid Cancer|Other Solid Tumors","Biological: PDR001","Part l: The exposure (AUC(0-336h)) after first dose of treatment|Part l: Incidence of dose limiting toxicities (DLTs)|Part ll: Overall response Rate (ORR)|Presence and/or concentration of anti-PDR001|Overall Response Rate (ORR) - Phase l only|Progression Free Survival (PFS) - Phase l/ll|Duration of Response (DOR) - Phase l/ll|Disease Control Rate (DCR) - Phase l/ll|Overall Response Rate (ORR) per immune related Response Criteria - Phase ll only|Serum pharmacokinetic (PK) parameter AUCs|Serum Pharmacokinetic (PK) parameter Cmax|Serum Pharmacokinetic (PK) parameter Tmax","Novartis Pharmaceuticals|Novartis","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","319","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CPDR001X2101|2014-003929-17","April 27, 2015","July 1, 2020","July 3, 2020","March 31, 2015",,"April 21, 2020","The Sidney Kimmel Cancer Center at Johns Hopkins Hospital Johns Hopkins, Baltimore, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Novartis Investigative Site, Portland, Oregon, United States|Novartis Investigative Site, Nashville, Tennessee, United States|Novartis Investigative Site, Houston, Texas, United States|Huntsman Cancer Institute Univ. of Utah HCI, Salt Lake City, Utah, United States|Novartis Investigative Site, Toronto, Ontario, Canada|Novartis Investigative Site, Paris, France|Novartis Investigative Site, Toulouse Cedex 9, France|Novartis Investigative Site, Villejuif Cedex, France|Novartis Investigative Site, Essen, Germany|Novartis Investigative Site, Jena, Germany|Novartis Investigative Site, Ulm, Germany|Novartis Investigative Site, Budapest, Hungary|Novartis Investigative Site, Debrecen, Hungary|Novartis Investigative Site, Milano, MI, Italy|Novartis Investigative Site, Rozzano, MI, Italy|Novartis Investigative Site, Modena, MO, Italy|Novartis Investigative Site, Bologna, Italy|Novartis Investigative Site, Napoli, Italy|Novartis Investigative Site, Ashrafieh, Lebanon|Novartis Investigative Site, Amsterdam, Netherlands|Novartis Investigative Site, Leiden, Netherlands|Novartis Investigative Site, Oslo, Norway|Novartis Investigative Site, Gdansk, Poland|Novartis Investigative Site, Konin, Poland|Novartis Investigative Site, Poznan, Poland|Novartis Investigative Site, Rzeszow, Poland|Novartis Investigative Site, Warszawa, Poland|Novartis Investigative Site, Barcelona, Catalunya, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Tainan, Taiwan ROC, Taiwan|Novartis Investigative Site, Taipei, Taiwan|Novartis Investigative Site, Songkhla, Hat Yai, Thailand|Novartis Investigative Site, Bangkok, Thailand|Novartis Investigative Site, Adana, Turkey|Novartis Investigative Site, Edirne, Turkey|Novartis Investigative Site, Istanbul, Turkey|Novartis Investigative Site, Istanbul, Turkey|Novartis Investigative Site, Izmir, Turkey",,"https://ClinicalTrials.gov/show/NCT02404441"
69,"NCT02901548","Phase 2 Durvalumab (Medi4736) for Bacillus Calmette-Guérin (BCG) Refactory Urothelial Carcinoma in Situ of the Bladder",,"Recruiting","No Results Available","Carcinoma in Situ of Bladder|Bladder Cancer","Drug: Durvalumab|Procedure: Cystoscopy with Biopsy","Complete Response Rate at 6 Months|Complete Response Rate at 24 Months","H. Lee Moffitt Cancer Center and Research Institute|AstraZeneca","All","18 Years and older   (Adult, Older Adult)","Phase 2","34","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MCC-18788|ESR-15-11326","February 16, 2017","December 31, 2020","December 31, 2021","September 15, 2016",,"April 10, 2020","Mount Sinai Medical Center Miami, Miami Beach, Florida, United States|H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States",,"https://ClinicalTrials.gov/show/NCT02901548"
70,"NCT04246671","Phase 1/2 Trial of Intravenous TAEK-VAC-HerBy Vaccine Alone and in Combination Treatment in HER2 Cancer Patients",,"Not yet recruiting","No Results Available","Breast Cancer|Gastric Cancer|Cancer","Biological: TAEK-VAC-HerBy","Patients with Dose Limiting Toxicity (DLT)","Bavarian Nordic","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","45","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TAEK-VAC-HerBy-001 Phase 1","June 30, 2020","December 2022","December 2024","January 29, 2020",,"January 29, 2020",,,"https://ClinicalTrials.gov/show/NCT04246671"
71,"NCT04322643","Intermittent Checkpoint Inhibitor Therapy In Patients With Advanced Urothelial Carcinoma",,"Recruiting","No Results Available","Urothelial Carcinoma","Drug: Pembrolizumab|Drug: Atezolizumab|Drug: Durvalumab|Drug: Nivolumab|Drug: Avelumab","Number of participants that sustain a response post CPI suspension|Median Treatment Free Interval (TFI) in months|Overall response rate (ORR)|Progression free survival (PFS)|Overall Survival (OS)","Case Comprehensive Cancer Center","All","18 Years and older   (Adult, Older Adult)","Phase 2","20","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CASE6819","March 23, 2020","May 2021","May 2021","March 26, 2020",,"April 7, 2020","Cleveland Clinic, Case Comprehensive Cancer Center, Cleveland, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT04322643"
72,"NCT03786796","Study of Olaparib in Metastatic Renal Cell Carcinoma Patients With DNA Repair Gene Mutations","ORCHID","Recruiting","No Results Available","Renal Cell Carcinoma|Metastatic Renal Cell Carcinoma|Kidney Cancer|Renal Carcinoma|Kidney Cancer Metastatic","Drug: Olaparib","Objective Response or Stable Disease to Olaparib Therapy at Six Months|Safety of Olaparib Therapy As Determined by the Number of Adverse Events|Median Progression-Free Survival to Olaparib Therapy|Rate of Objective Response to Olaparib Therapy","Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|AstraZeneca","All","18 Years to 120 Years   (Adult, Older Adult)","Phase 2","20","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","J18166|IRB00197147","June 3, 2019","March 2021","March 2022","December 26, 2018",,"June 5, 2019","Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT03786796"
73,"NCT03168139","Olaptesed (NOX-A12) Alone and in Combination With Pembrolizumab in Colorectal and Pancreatic Cancer","Keynote-559","Completed","No Results Available","Metastatic Colorectal Cancer|Metastatic Pancreatic Cancer","Drug: Olaptesed pegol - Monotherapy|Drug: Olaptesed pegol + Pembrolizumab - Combination Therapy","Monotherapy: Pharmacodynamics|Combination Therapy: Safety - adverse events, vital signs, ECG, hematology & safety laboratory|Monotherapy: Safety|Combination Therapy: Disease control rate (DCR)|Combination Therapy: Efficacy - time to event analyses","NOXXON Pharma AG|Merck Sharp & Dohme Corp.","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","20","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SNOXA12C601|2016-003657-15","April 18, 2017","March 25, 2020","March 25, 2020","May 30, 2017",,"April 30, 2020","Nationales Centrum für Tumorerkrankungen (NCT) Heidelberg, Heidelberg, Germany",,"https://ClinicalTrials.gov/show/NCT03168139"
74,"NCT03890952","Translational Study of Nivolumab in Combination With Bevacizumab for Recurrent Glioblastoma",,"Recruiting","No Results Available","Recurrent Adult Brain Tumor","Drug: Nivolumab|Drug: Bevacizumab","Number of indels as determined using mRNA sequencing|Progression-Free Survival (PFS)","Ulrik Lassen|Herlev Hospital|University of Copenhagen|Rigshospitalet, Denmark","All","18 Years and older   (Adult, Older Adult)","Phase 2","40","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","CA209-9UP|2017-003925-13","October 1, 2018","February 1, 2022","August 1, 2022","March 26, 2019",,"March 26, 2019","Rigshospitalet, Copenhagen, Denmark",,"https://ClinicalTrials.gov/show/NCT03890952"
75,"NCT03040791","Nivolumab in Prostate Cancer With DNA Repair Defects (ImmunoProst Trial)","ImmunoProst","Recruiting","No Results Available","Prostate Cancer","Drug: Nivolumab","PSA response rate|Time to PSA progression|PSA Response Rate at 6 and 12 months|Radiological progression-free survival (rPFS)|Time to Radiographic Progression|Progression free survival (PFS)|Overall survival","Hospital Moinhos de Vento|Bristol-Myers Squibb","Male","18 Years and older   (Adult, Older Adult)","Phase 2","29","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","64121317.4.1001.5330","June 1, 2018","July 1, 2020","July 1, 2020","February 2, 2017",,"May 5, 2020","Hospital Moinhos de Vento, Porto Alegre, Rio Grande Do Sul, Brazil|Instituto do Câncer do Estado de São Paulo, Sao Paulo, São Paulo, Brazil",,"https://ClinicalTrials.gov/show/NCT03040791"
76,"NCT04367311","Adjuvant Treatment With Cisplatin-based Chemotherapy Plus Concomitant Atezolizumab in Patients With Stage I (Tumors ≥ 4cm), IIA, IIB, and Select IIIA [T3N1, T4N0-1] Resected Non-small Cell Lung Cancer (NSCLC) and the Clearance of Circulating Tumor DNA (ctDNA)",,"Recruiting","No Results Available","Lung Cancer|NSCLC","Drug: Atezolizumab|Drug: Docetaxel|Drug: Cisplatin|Drug: Pemetrexed","Percentage of patients with undetectable ctDNA after 4 cycles of adjuvant chemotherapy + Atezolizumab plus up to 13 additional cycles of Atezolizumab in patients with stage I (tumors ≥ 4cm), IIA, IIB, and select IIIA [T3N1, T4N0-1]|Percentage of patients with clearance of ctDNA after 4 cycles of adjuvant chemotherapy + Atezolizumab|Percentage of patients with clearance of ctDNA after 8 cycles (4 cycles of adjuvant chemotherapy + Atezolizumab plus 4 additional cycles of Atezolizumab)|Percentage of patients with clearance of ctDNA after 12 cycles (4 cycles of adjuvant chemotherapy + Atezolizumab plus 8 additional cycles of Atezolizumab)|Percentage of patients with clearance of ctDNA during or after adjuvant chemotherapy + Atezolizumab followed by Atezolizumab for up to 13 additional cycles who had no detectable ctDNA after surgery|Percentage of pts with clearance of ctDNA after 4 cycles of adj. chemotherapy + Atezolizumab plus up to 13 additional cycles of Atezolizumab in pts with stage I (tumors ≥ 4 cm), IIA, IIB, and select IIIA [T3N1, T4N0-1] NSCLC who have undergone resection|1 year Disease Free Survival (DFS) in all patients|1 year Disease Free Survival (DFS) in patients with no detectable ctDNA after 4 cycles of adjuvant chemotherapy + Atezolizumab who had detectable ctDNA after surgery.|1 year Disease Free Survival (DFS) in patients with detectable ctDNA after 1 year of adjuvant therapy on study","Nasser Hanna|Genentech, Inc.|Big Ten Cancer Research Consortium","All","18 Years and older   (Adult, Older Adult)","Phase 2","100","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","BTCRC-LUN19-396","May 22, 2020","January 2023","January 2024","April 29, 2020",,"June 3, 2020","Indiana Univeristy Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States",,"https://ClinicalTrials.gov/show/NCT04367311"
77,"NCT03832621","NIVOLUMAB Plus IPILIMUMAB and TEMOZOLOMIDE in Microsatellite Stable, MGMT Silenced Metastatic Colorectal Cancer","MAYA","Recruiting","No Results Available","Metastatic Colorectal Cancer","Drug: Temozolomide|Drug: Nivolumab|Drug: Ipilimumab","Evaluate the efficacy, measured as 8-month PFS rate, of the combination of temozolomide, nivolumab and ipilimumab in patients achieving disease control following 2-month lead-in treatment with single agent TMZ|Estimate the overall response rates (ORR) of the combination regimen of temozolomide, nivolumab and ipilimumab|Estimate duration of response (DoR) of the combination regimen of temozolomide, nivolumab and ipilimumab|Estimate overall survival (OS) of the combination regimen of temozolomide, nivolumab and ipilimumab|Estimate ORR according to an Imaging Independent Central Review, using RECIST 1.1 and modified RECIST criteria|Evaluate the adverse events encountered by patients treated with the combination of temozolomide, nivolumab and ipilimumab|Estimate DoR of the combination regimen of temozolomide, nivolumab and ipilimumab according to an Imaging Independent Central Review|Estimate PFS of the combination regimen of temozolomide, nivolumab and ipilimumab according to an Imaging Independent Central Review|Assess quality of life","Fondazione IRCCS Istituto Nazionale dei Tumori, Milano","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 2","100","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","INT202-18","March 25, 2019","February 2022","February 2022","February 6, 2019",,"May 14, 2019","Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, MI, Italy",,"https://ClinicalTrials.gov/show/NCT03832621"
78,"NCT03277638","Laser Interstitial Thermotherapy (LITT) Combined With Checkpoint Inhibitor for Recurrent GBM (RGBM)",,"Recruiting","No Results Available","Glioblastoma, Adult","Drug: Pembrolizumab at 7 days prior|Drug: Pembrolizumab at 14 days post|Drug: Pembrolizumab at 35 days post|Procedure: Laser Interstitial Thermotherapy","Phase I Objective: Optimal timing of LITT with pembrolizumab|Phase II Objective: Tumor Response|Progression free survival|overall survival|The proportion of patients who achieve progression free survival at 6 months (PFS6)|The proportion of patients who achieve progression free survival at 12 months (PFS12)|The proportion of patients who achieve progression free survival at 24 months (PFS24)","Case Comprehensive Cancer Center","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","34","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CASE3316","November 29, 2017","May 2020","July 2020","September 11, 2017",,"January 3, 2020","University Hospitals, Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT03277638"
79,"NCT03233724","Oral Decitabine and Tetrahydrouridine as Epigenetic Priming for, Pembrolizumab-Mediated Immune Checkpoint Blockade in Patients With Inoperable, or Unresectable Locally Advanced or Metastatic Non-Small Cell Lung Cancers and Esophageal Carcinomas",,"Recruiting","No Results Available","Carcinoma, Non-Small-Cell Lung|Lung Cancer|Non-Small Cell Lung Cancer|Carcinoma, Esophageal","Drug: Decitabine (DAC)|Drug: Tetrahydrouridine (THU)|Drug: Pembrolizumab","Maximum tolerated dose|Overall response rate|Examine if oral DAC-THU modulates DNA methylation, as well as gene, micro-RNA, and endogenous retroviral expression profiles of lungcancer and EsC cells and alters the tumor micro-environment|Examine if oral DAC-THU modulates plasma tumor DNA methylation, circulating tumor cells and peripheral immune subsets","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","75","NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","170140|17-C-0140","April 11, 2018","December 31, 2025","December 31, 2025","July 31, 2017",,"May 13, 2020","National Institutes of Health Clinical Center, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT03233724"
80,"NCT03894007","Improving Pre-operative Systemic Therapy for Human Epidermal Growth Factor Receptor 2 (HER2) Amplified Breast Cancer","PREDIXIIHER2","Recruiting","No Results Available","Early-stage Breast Cancer|HER2-positive Breast Cancer","Drug: Docetaxel|Drug: Carboplatin|Drug: Trastuzumab|Drug: Pertuzumab|Drug: Epirubicin|Drug: Cyclophosphamide|Drug: Atezolizumab|Drug: Trastuzumab emtansine","Rate of pathological objective response to primary medical treatment|Objective response rate|Distant disease-free survival|Event-free survival|Overall survival|Rate of breast conserving surgery|Incidence of treatment-emergent adverse events (Safety)|Differences in PROMs according to EORTC C30|Differences in PROMs according to EORTC BR23|Differences in objective cognitive function|Treatment prediction, PD-L1|Treatment prediction, TMB|Treatment prediction, TILs|Treatment prediction, composition of faeces microbiome|Differences in PROMs","Renske Altena|Karolinska University Hospital","Female","18 Years and older   (Adult, Older Adult)","Phase 2","190","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PREDIX II HER2|2018-004457-24","May 23, 2019","December 2024","December 2034","March 28, 2019",,"February 27, 2020","Sahlgrenska universitetssjukhuset, Göteborg, Sweden|Skånes universitetssjukhus, Malmö, Sweden|Karolinska universitetssjukhuset, Stockholm, Sweden|Länssjukhuset Sundsvall, Sundsvall, Sweden|Norrlands universitetssjukhus, Umeå, Sweden|Örebro universitetssjukhus, Örebro, Sweden",,"https://ClinicalTrials.gov/show/NCT03894007"
81,"NCT02203513","A Phase II Single Arm Pilot Study of the Chk1/2 Inhibitor (LY2606368) in BRCA1/2 Mutation Associated Breast or Ovarian Cancer, Triple Negative Breast Cancer, High Grade Serous Ovarian Cancer, and Metastatic Castrate-Resistant Prostate Cancer",,"Active, not recruiting","No Results Available","Ovarian Cancer|Breast Cancer|Prostate Cancer","Drug: LY2606368","Objective response rate (CR+PR)","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","18 Years and older   (Adult, Older Adult)","Phase 2","107","NIH","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","140156|14-C-0156","January 20, 2015","June 1, 2021","December 20, 2021","July 30, 2014",,"April 24, 2020","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT02203513"
82,"NCT03494322","EACH: Evaluating Avelumab in Combination With Cetuximab in Head and Neck Cancer","EACH","Active, not recruiting","No Results Available","Head and Neck Cancer|Squamous Cell Carcinoma","Drug: Avelumab|Drug: Cetuximab","Safety run-in: Occurrence of dose limiting toxicity|Phase II: Disease control rate at 24 weeks after randomisation|Objective response (iCR or iPR) at 6 and 12 months|Disease control at 6 and 12 months|Best overall response|Duration of response|Overall survival|Time to Progression|Progression free survival|Frequency and severity of adverse events|Treatment related dose delays or treatment discontinuation","University College, London|Merck KGaA, Darmstadt, Germany","All","18 Years and older   (Adult, Older Adult)","Phase 2","130","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","UCL/17/0560","July 20, 2018","September 6, 2021","September 2, 2022","April 11, 2018",,"September 27, 2019","University College Hospital, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03494322"
83,"NCT03570619","Immunotherapy in Patients With Metastatic Cancers and CDK12 Mutations","IMPACT","Recruiting","No Results Available","Metastatic Castration Resistant Prostate Cancer|Metastatic Cancer","Drug: Nivolumab|Drug: Ipilimumab","The proportion of patients with CDK12 loss of function metastatic CRPC (Cohort A) that respond to treatment.|The proportion of patients that respond to treatment in Cohort B.|Radiographic progression free survival time (rPFS)|Progression free survival time (PFS)|Duration of Therapy (DOT)|Time to Progression (TTP)|Overall survival Time|PSA progression free survival time|Time to PSA progression","University of Michigan Rogel Cancer Center|Memorial Sloan Kettering Cancer Center|University of California, San Francisco","All","18 Years and older   (Adult, Older Adult)","Phase 2","40","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","UMCC 2018.050|HUM00145104","December 14, 2018","September 2021","September 2021","June 27, 2018",,"March 4, 2020","University of California San Diego, Moores Cancer Center, San Diego, California, United States|University of California San Francisco, San Francisco, California, United States|H. Lee. Moffitt Cancer Center & Research Institute, Inc., Tampa, Florida, United States|Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States|University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States|Karmanos Cancer Institute, Detroit, Michigan, United States|Siteman Cancer Center at Washington University, Saint Louis, Missouri, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT03570619"
84,"NCT03951415","Durvalumab and Olaparib in Metastatic or Recurrent Endometrial Cancer","DOMEC","Recruiting","No Results Available","Endometrial Neoplasms|Uterine Neoplasms|Endometrium Cancer","Drug: PARP inhibitor and Anti-PD-L1","Progression free survival (PFS)|Objective response rate (ORR)|Overall survival (OS)|Adverse events|Predictive biomarkers in tumor biopsy","Leiden University Medical Center|Amsterdam University Medical Center|Erasmus Medical Center|Maastricht University Medical Center|The Netherlands Cancer Institute|Radboud University|University Medical Center Groningen|UMC Utrecht|AstraZeneca","Female","18 Years and older   (Adult, Older Adult)","Phase 2","55","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","DOMEC","July 8, 2019","July 1, 2023","July 1, 2023","May 15, 2019",,"July 11, 2019","Amsterdam UMC, AMC, Amsterdam, Netherlands|NKI-AVL, Amsterdam, Netherlands|Universitair Medisch Centrum Groningen, Groningen, Netherlands|Leiden University Medical Center, Leiden, Netherlands|Academisch Ziekenhuis Maastricht, Maastricht, Netherlands|RadboudMC, Nijmegen, Netherlands|Erasmus MC, Rotterdam, Netherlands|Universitair Medisch Centrum Utrecht, Utrecht, Netherlands",,"https://ClinicalTrials.gov/show/NCT03951415"
85,"NCT03366844","Breast Cancer Study of Preoperative Pembrolizumab + Radiation",,"Recruiting","No Results Available","Breast Cancer","Drug: Pembrolizumab|Radiation: RT Boost","Number of patients who do not necessitate a delay in standard of care treatment after receiving the investigational combination of preoperative Pembrolizumab and radiation|Changes in Tumor Infiltrating Lymphocytes (TIL)|Pembrolizumab-related adverse events|Immune-related adverse events|Invasive disease-free survival after preoperative radiation and Pembrolizumab|Pathological complete response rate","Stephen Shiao|United States Department of Defense|Cedars-Sinai Medical Center","Female","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","60","Other|U.S. Fed","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IIT2017-07-HO-PembroRT","December 22, 2017","January 1, 2021","January 1, 2021","December 8, 2017",,"March 6, 2020","Cedars-Sinai Medical Center, Los Angeles, California, United States","""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/44/NCT03366844/ICF_000.pdf","https://ClinicalTrials.gov/show/NCT03366844"
86,"NCT04407741","Phase Ⅰ/Ⅱ Study of SHR2554 in Combination With SHR1701 in Patients With Advanced Solid Tumors and B-cell Lymphomas",,"Not yet recruiting","No Results Available","Solid Tumor|Lymphoma","Drug: SHR2554+SHR1701|Drug: SHR1701","Median amount of time subject survives without disease progression following the initiation of treatment|Number of subjects with treatment related adverse events as assessed by CTCAE v5.0.|The percentage of subjects respond to treatment.|Median amount of times subjects alive after treatment","Chinese PLA General Hospital","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 1|Phase 2","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CHN-PLAGH-BT-055","June 1, 2020","June 1, 2022","June 1, 2023","May 29, 2020",,"May 29, 2020","Department of Biotherapeutic, Chinese PLA General Hospital, Beijing, China",,"https://ClinicalTrials.gov/show/NCT04407741"
87,"NCT03472274","DUrvalumab (MEDI4736) and TREmelimumab in NEOadjuvant Bladder Cancer Patients (DUTRENEO)","DUTRENEO","Recruiting","No Results Available","Bladder Cancer","Drug: Durvalumab|Drug: Tremelimumab|Drug: Cisplatin-based neoadjuvant chemotherapy","Antitumor activity|Overall Objective Response Rate|Disease Free Survival|Overall Survival|Incidence of Adverse Events","Fundacion CRIS de Investigación para Vencer el Cáncer|AstraZeneca|Apices Soluciones S.L.","All","18 Years and older   (Adult, Older Adult)","Phase 2","99","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","DUTRENEO|2017-002246-68","October 25, 2018","July 2022","December 2022","March 21, 2018",,"August 28, 2019","ICO Badalona, Badalona, Spain|Hospital Clinic, Barcelona, Spain|Hospital de la Santa Creu i Sant Pau, Barcelona, Spain|ICO L'Hospitalet, L'Hospitalet De Llobregat, Spain|Hospital 12 de Octubre, Madrid, Spain|Hospital Clinico San Carlos, Madrid, Spain|Hospital Ramon y Cajal, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|MD Anderson Cancer Center, Madrid, Spain|Hospital Marqués de Valdecilla, Santander, Spain|Instituto Valenciano de Oncología, Valencia, Spain",,"https://ClinicalTrials.gov/show/NCT03472274"
88,"NCT03171064","Exercise as a Supportive Measure for Patients Undergoing Checkpoint-inhibitor Treatment","Sportivumab","Recruiting","No Results Available","PD-1 Antibodies|Exercise|Melanoma","Behavioral: Resistance and Endurance Exercise","Feasibility of the exercise intervention|Quality of life|Fatigue|Sleep Quality|Depression|Physical Activity Behavior|Cardiopulmonary Fitness|Muscle strength|Pain","University Hospital Heidelberg|Department of Dermatology, Heidelberg University Hospital","All","18 Years and older   (Adult, Older Adult)","Phase 2","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","Sportivumab/S-103/2017","September 5, 2017","November 30, 2020","March 1, 2021","May 31, 2017",,"March 25, 2020","Heidelberg University Clinic, Heidelberg, Germany",,"https://ClinicalTrials.gov/show/NCT03171064"
89,"NCT02671435","A Study of Durvalumab (MEDI4736) and Monalizumab in Solid Tumors",,"Active, not recruiting","No Results Available","Advanced Solid Tumors","Combination Product: Intervention","Occurrence of Drug Limited Toxicities (DLTs)|Number of patients with changes in vital signs from baseline|Occurrence of adverse events (AEs)|Number of patients with changes in electrocariogram (ECG) from baseline|Occurrence of serious adverse events (SAEs)|Number of patients with changes in laboratory parameters from baseline|Objective Response Rate (ORR)|Expression of pre-treatment protein within the tumor microenvironment|Number of subjects who develop anti-drug antibodies|Durva, monalizumab, biologic agent serum peak concentration (cMax) concentration for Pharmacokinetics|Durva and monalizumab serum area under the concentration-time curve (AUC) concentration for Pharmacokinetics|Durva and monalizumab serum clearance (CL) concentration for Pharmacokinetics|Durva and monalizumab serum terminal elimination half-life (t1/2) concentration for Pharmacokinetics|Progression Free Survival (PFS)|Disease Control Rate (DC)|Overall Survival (OS)|Duration of Response (DoR)","MedImmune LLC","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 1|Phase 2","383","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","D419NC00001","February 22, 2016","March 14, 2022","March 14, 2022","February 2, 2016",,"April 20, 2020","Research Site, Birmingham, Alabama, United States|Research Site, Scottsdale, Arizona, United States|Research Site, Duarte, California, United States|Research Site, La Jolla, California, United States|Research Site, Los Angeles, California, United States|Research Site, Sacramento, California, United States|Research Site, Santa Monica, California, United States|Research Site, Aurora, Colorado, United States|Research Site, Tampa, Florida, United States|Research Site, Chicago, Illinois, United States|Research Site, Baltimore, Maryland, United States|Research Site, Boston, Massachusetts, United States|Research Site, Detroit, Michigan, United States|Research Site, New Brunswick, New Jersey, United States|Research Site, Bronx, New York, United States|Research Site, Lake Success, New York, United States|Research Site, New York, New York, United States|Research Site, Providence, Rhode Island, United States|Research Site, Nashville, Tennessee, United States|Research Site, Dallas, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, Salt Lake City, Utah, United States|Research Site, Blacktown, Australia|Research Site, Clayton, Australia|Research Site, Waratah, Australia|Research Site, Bruxelles, Belgium|Research Site, Edegem, Belgium|Research Site, Leuven, Belgium|Research Site, Vancouver, British Columbia, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Marseille CEDEX 5, France|Research Site, Nantes CEDEX 1, France|Research Site, Debrecen, Hungary|Research Site, Milano, Italy|Research Site, Milano, Italy|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Grafton, New Zealand|Research Site, Barcelona, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Málaga, Spain|Research Site, Pamplona, Spain|Research Site, Sevilla, Spain|Research Site, London, United Kingdom|Research Site, Sutton, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02671435"
90,"NCT03200717","Study of Efficacy, Safety, and Quality of Life of Pazopanib in Patients With Advanced and/or Metastatic Renal Cell Carcinoma After Prior Checkpoint Inhibitor Treatment","IO-PAZ","Active, not recruiting","No Results Available","Advanced Renal Cell Carcinoma|Metastatic Renal Cell Carcinoma","Drug: pazopanib","Progression free survival based on local investigator assessment|Overall response rate and clinical benefit rate based on local investigator assessment|Overall survival|Duration of response in patients with confirmed complete response or partial response|Incidence of Treatment-emergent Adverse Events (safety and tolerability)|Change from baseline in FSKI-DRS score|Change from baseline in EQ-5D-5L score","Novartis Pharmaceuticals|Novartis","All","18 Years and older   (Adult, Older Adult)","Phase 2","62","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CPZP034A2410","November 14, 2017","December 18, 2019","July 15, 2021","June 27, 2017",,"May 29, 2020","Roswell Park Cancer Institute, Buffalo, New York, United States|Novartis Investigative Site, Caba, Buenos Aires, Argentina|Novartis Investigative Site, Graz, Austria|Novartis Investigative Site, Salzburg, Austria|Novartis Investigative Site, Wien, Austria|Novartis Investigative Site, Calgary, Alberta, Canada|Novartis Investigative Site, Temuco, Araucania, Chile|Novartis Investigative Site, Santiago, Chile|Novartis Investigative Site, Brno, Czech Republic, Czechia|Novartis Investigative Site, Olomouc, CZE, Czechia|Novartis Investigative Site, Paris, France|Novartis Investigative Site, Saint Herblain cedex, France|Novartis Investigative Site, Strasbourg Cedex, France|Novartis Investigative Site, Valenciennes, France|Novartis Investigative Site, Hamburg, Germany|Novartis Investigative Site, Hannover, Germany|Novartis Investigative Site, Jena, Germany|Novartis Investigative Site, Tübingen, Germany|Novartis Investigative Site, Budapest, Hungary|Novartis Investigative Site, Sevilla, Andalucia, Spain|Novartis Investigative Site, Valencia, Comunidad Valenciana, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, London, United Kingdom|Novartis Investigative Site, Manchester, United Kingdom|Novartis Investigative Site, Preston, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03200717"
91,"NCT03296137","Adoptive Cell Therapy Across Cancer Diagnoses",,"Active, not recruiting","No Results Available","Cancer","Biological: Autologous tumor-infiltrating lymphocytes|Drug: Ipilimumab|Drug: Nivolumab|Drug: proleukin|Drug: Cyclophosphamide|Drug: Fludara","Number and type of reported adverse events|Treatment response, progressive disease|Treatment response, surival|Treatment related immune response","Inge Marie Svane|Herlev Hospital","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 1|Phase 2","25","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AA1720","October 13, 2017","November 6, 2019","June 6, 2020","September 28, 2017",,"January 7, 2020","Center for Cancer immune Therapy (CCIT), Dept. of Hematology and dept. of Oncology, Copenhagen, Denmark",,"https://ClinicalTrials.gov/show/NCT03296137"
92,"NCT02571725","PARP-inhibition and CTLA-4 Blockade in BRCA-deficient Ovarian Cancer",,"Recruiting","No Results Available","Ovarian Cancer|Fallopian Tube Cancer|Peritoneal Neoplasms","Drug: Olaparib|Drug: Tremelimumab","Phase 1: Recommended Phase 2 Dose (RP2D)|Phase 2: Objective response rate (ORR)|Phase 2: Progression free survival (PFS)","New Mexico Cancer Care Alliance","Female","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","50","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","INST 1419","February 2016","February 2020","February 2022","October 8, 2015",,"June 17, 2019","Moffitt Cancer Center, Tampa, Florida, United States|Southwest Gynecologic Oncology Associates, Albuquerque, New Mexico, United States|University of New Mexico Comprehensive Cancer Center, Albuquerque, New Mexico, United States|The Ohio State University, Columbus, Ohio, United States|University of Virginia Cancer Center, Charlottesville, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT02571725"
93,"NCT02635360","Pembrolizumab and Chemoradiation Treatment for Advanced Cervical Cancer",,"Recruiting","No Results Available","Cervical Cancer","Drug: Pembrolizumab|Radiation: Brachytherapy|Drug: Cisplatin","Change in immunologic markers following combination of study drug with chemoradiation|Incidence of dose limiting toxicities|Metabolic Response Rate on PET/CT imaging|Incidence of distant metastases|Progression Free Survival|Overall Survival","Linda R Duska|Merck Sharp & Dohme Corp.|University of Virginia","Female","18 Years and older   (Adult, Older Adult)","Phase 2","88","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","18472|UVA-LACC-PD201","January 2016","May 2020","May 2021","December 18, 2015",,"February 26, 2020","University of South Alabama Mitchell Cancer Institute, Mobile, Alabama, United States|Johns Hopkins, Baltimore, Maryland, United States|Washington University, School of Medicine, Saint Louis, Missouri, United States|Levine Cancer Institute, Charlotte, North Carolina, United States|University of Oklahoma, Oklahoma City, Oklahoma, United States|University of Virginia, Charlottesville, Virginia, United States|INOVA Fairfax Hospital, Falls Church, Virginia, United States|Virginia Commonwealth University, Richmond, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT02635360"
94,"NCT04001413","Therapy for High-Risk HPV 16-Positive Oropharynx Cancer Patients",,"Recruiting","No Results Available","HPV Positive Oropharyngeal Squamous Cell Carcinoma|Oropharynx Cancer|HPV-Related Carcinoma","Drug: MEDI0457|Drug: Durvalumab","Number of participants in whom there is clearance of Human Papiloma Virus (HPV) biomarkers post-intervention|Time to Progression|Safety of Study Drugs","Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|AstraZeneca","All","18 Years and older   (Adult, Older Adult)","Phase 2","66","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","J1918|IRB00179194","September 17, 2019","September 2024","September 2027","June 28, 2019",,"March 4, 2020","Johns Hopkins University, Baltimore, Maryland, United States|Mount Sinai School of Medicine, The Tisch Cancer Institute, New York, New York, United States|Mount Sinai School of Medicine, New York, New York, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT04001413"
95,"NCT04060407","CD24Fc With Ipilimumab and Nivolumab to Decrease irAE (CINDI)","CINDI","Not yet recruiting","No Results Available","Metastatic Melanoma|Renal Cell Carcinoma|Colon Cancer With MSI-H or dMMR","Drug: CD24Fc|Drug: Ipilimumab|Drug: Nivolumab","Safety and tolerability of combination of CD24Fc with Ipilimumab and Nivolumab|Profile of treatment related adverse events|The Objective Response Rate (OPR)|The Progression Free Survival (PFS)|The Overall Survival (OS)","OncoImmune, Inc.|Huntsman Cancer Institute","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","48","Industry|Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CD24-004-CINDI","September 1, 2020","December 30, 2022","December 30, 2023","August 19, 2019",,"June 3, 2020","Huntsman Cancer Institute, Salt Lake City, Utah, United States",,"https://ClinicalTrials.gov/show/NCT04060407"
96,"NCT04167774","A Study to Evaluate Camrelizumab in Combination With Nb-Paclitaxel in Patients With Advanced or Metastatic NSCLC","Compass-001","Recruiting","No Results Available","Non-Small Cell Lung Cancer","Drug: Camrelizumab|Drug: nb-Paclitaxel","Objective Response Rate (ORR)|12-month PFS rate|Progression-free Survival (PFS)|Overall survival (OS)|Duration of Response (DCR)|Duration of Response (DOR)|Incidence of Adverse Events (AEs) in the treatment of Camrelizumab in combination with nb-Paclitaxel","Sun Yat-sen University|Jiangsu HengRui Medicine Co., Ltd.","All","18 Years and older   (Adult, Older Adult)","Phase 2","62","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Compass-001","July 30, 2019","June 30, 2022","September 30, 2022","November 19, 2019",,"November 22, 2019","Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China|The first affiliated hospital of guangzhou medical university, Guangzhou, Guangdong, China|The First Affiliated Hospital/School of Clinical Medicine of Guangdong Pharmaceutical University, Guangzhou, Guangdong, China",,"https://ClinicalTrials.gov/show/NCT04167774"
97,"NCT03608046","Avelumab Combined With Cetuximab and Irinotecan for Treatment Refractory Metastatic Colorectal Microsatellite Stable Cancer","AVETUXIRI","Recruiting","No Results Available","Colorectal Neoplasms, Malignant","Drug: Avelumab|Drug: Cetuximab Injection|Drug: Irinotecan","Tumor response rate|Adverse events","Cliniques universitaires Saint-Luc- Université Catholique de Louvain","All","18 Years to 100 Years   (Adult, Older Adult)","Phase 2","59","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","UCL-mCRC-2018-MS100070-0095","October 3, 2018","December 31, 2023","December 31, 2023","July 31, 2018",,"April 10, 2019","Cliniques Universitaires Saint-Luc, Brussels, Belgium|Grand Hôpital de Charleroi, Charleroi, Belgium",,"https://ClinicalTrials.gov/show/NCT03608046"
98,"NCT04217954","HAIC With FOLFOX and Bevacizumab Plus Intravenous Toripalimab for Advanced BTC",,"Not yet recruiting","No Results Available","Advanced Biliary Tract Cancer","Other: oxaliplatin, 5-fluorouracil and bevacizumab plus Toripalimab","Progression-free survival|overall survival","Peking University","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 2","32","Other","Interventional","Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","FIBTC","May 15, 2020","June 15, 2022","May 15, 2023","January 6, 2020",,"May 13, 2020",,,"https://ClinicalTrials.gov/show/NCT04217954"
99,"NCT03921684","Trial of Nivolumab With FOLFOX After Chemoradiation in Rectal Cancer Patients",,"Recruiting","No Results Available","Rectal Cancer","Drug: Capecitabine|Radiation: Radiation therapy|Drug: mFOLFOX6|Drug: Nivolumab","pathological complete response (pCR) rate|Incidence of Treatment-Emergent Adverse Events (Safety)|Disease Free Survival (DFS)|Overall Survival (OS)","Baruch Brenner|Bristol-Myers Squibb|Rabin Medical Center","All","18 Years and older   (Adult, Older Adult)","Phase 2","29","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CA209-8M4","April 2019","April 2021","October 2025","April 19, 2019",,"April 19, 2019","Rabin Medical Center, Beilinson Hospital, Petach Tikva, Israel",,"https://ClinicalTrials.gov/show/NCT03921684"
100,"NCT04138628","Treatment Of Metastatic Bladder Cancer at the Time Of Biochemical reLApse Following Radical Cystectomy","TOMBOLA","Recruiting","No Results Available","Bladder Cancer|Bladder Cancer, Metastatic","Drug: Atezolizumab","Complete response (CR) after treatment with investigational agent initiated by ctDNA positive status after radical cystectomy (with or without concomitant visible metastases on CT).|Duration of freedom from clinical relapse in Study Subjects showing decrease or stabilization of ctDNA level after treatment with investigational agent|Overall survival after cystectomy in Study Subjects having biochemical relapse|Cancer specific survival after cystectomy in Study Subjects having biochemical relapse|Recurrence free survival after cystectomy in Study Subjects having biochemical relapse|Cancer specific survival after cystectomy in Study Subjects having biochemical relapse stratified for potential predictive biomarkers for response to treatment|Response rate to investigated agent stratified for PD-L1 expression and other predictive biomarkers like TMB, immune cell infiltration, tumor subtypes etc.|Time to recurrence seen on imaging (symptomatic or asymptomatic)","Jørgen Bjerggaard Jensen|Aarhus University Hospital|Herlev Hospital|Rigshospitalet, Denmark|Odense University Hospital|Aalborg University Hospital","All","18 Years and older   (Adult, Older Adult)","Phase 2","282","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","DaBlaCa-14|2019-001679-36","March 24, 2020","August 1, 2022","November 1, 2024","October 24, 2019",,"May 13, 2020","Aalborg Universitetshospital, Aalborg, Denmark|Aarhus University Hospital, Aarhus, Denmark|Rigshospitalet, Copenhagen, Denmark|Herlev Hospital, Herlev, Denmark|Odense Universitetshospital, Odense, Denmark",,"https://ClinicalTrials.gov/show/NCT04138628"
101,"NCT04019964","Nivolumab in Biochemically Recurrent dMMR Prostate Cancer",,"Recruiting","No Results Available","Prostate Cancer|Recurrent Prostate Cancer","Drug: Nivolumab","Percentage of participants with PSA50 response|PSA progression-free survival (PSA-PFS)|Number of participants who achieve undetectable PSA|Metastasis-free survival|Time to initiation of next systemic therapy|Safety and tolerability of Nivolumab in biochemically recurrent prostate cancer as assessed by Incidence of Treatment-Emergent Adverse Events","Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|Bristol-Myers Squibb","Male","18 Years and older   (Adult, Older Adult)","Phase 2","15","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","J1933|IRB00205266|CA209-76M","January 13, 2020","January 2025","January 2025","July 15, 2019",,"January 31, 2020","Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT04019964"
102,"NCT04131621","Nivolumab/Ipilimumab in Second Line CUP-syndrome","CheCUP","Recruiting","No Results Available","Cancer of Unknown Primary Site","Biological: Nivolumab/Ipilimumab","Progression-free survival","University Hospital Heidelberg","All","18 Years and older   (Adult, Older Adult)","Phase 2","194","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CA209-8WY","December 12, 2019","December 2022","December 2022","October 18, 2019",,"April 15, 2020","University of Heidelberg, Heidelberg, Germany",,"https://ClinicalTrials.gov/show/NCT04131621"
103,"NCT03833479","TSR-042 as Maintenance Therapy for Patients With High-risk Locally Advanced Cervical Cancer After Chemo-radiation (ATOMICC)","ATOMICC","Recruiting","No Results Available","Cervical Cancer|Advanced Cancer","Other: No Further Treatment|Drug: TSR-042","Progression Free Survival|Frequency and severity of adverse events (AEs)|Overall survival (OS)|Patient reported outcomes (PROs) of health-related quality of life (HRQOL)|Patient reported outcomes (PROs) of fatigue|Patient reported outcomes (PROs) of pain","Grupo Español de Investigación en Cáncer de Ovario|Tesaro, Inc.|Apices Soluciones S.L.","Female","18 Years and older   (Adult, Older Adult)","Phase 2","132","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GEICO 78-C (ATOMICC)|2018-002155-15","June 28, 2019","July 2023","July 2023","February 7, 2019",,"October 3, 2019","Hospital General Universitario de Elche, Elche, Alicante, Spain|Hospital La Fe, Valencia, Comunidad Valenciana, Spain|Hospital Universitario Donostia- Donostia Unibertsitate Ospitalea, Donostia, Gipuzkoa, Spain|Hospital Álvaro Cunqueiro, Vigo, Pontevedra, Spain|H Vall d'Hebron, Barcelona, Spain|Hospital Clínic, Barcelona, Spain|H Reina Sofía Cordoba, Cordoba, Spain|ICO Girona, Girona, Spain|ICO Hospitalet, Hospitalet del Llobregat, Spain|Hospital Universitario La Paz, Madrid, Spain|Clinica Universitaria de Navarra, Madrid, Spain|Hospital Clínico San Carlos, Madrid, Spain|Hospital Ramon y Cajal, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Clinico Universitario Virgen Arrixaca, Murcia, Spain|Hospital Universitario Morales Meseguer, Murcia, Spain|Hospital Virgen de la Victoria, Málaga, Spain|Hospital Son Espases, Palma De Mallorca, Spain|Hospital Son Llatzer, Palma De Mallorca, Spain|H. Parc Taulí, Sabadell, Spain|Hospital Marqués de Valdecilla, Santander, Spain|Hospital Universitario Virgen del Rocío, Sevilla, Spain|Hospital de Terrassa, Terrassa, Spain|Instituto Valenciano de Oncología, Valencia, Spain|Hospital Clínico Universitario de Valencia, Valencia, Spain",,"https://ClinicalTrials.gov/show/NCT03833479"
104,"NCT03298893","Nivolumab in Association With Radiotherapy and Cisplatin in Locally Advanced Cervical Cancers Followed by Adjuvant Nivolumab for up to 6 Months","NiCOL","Recruiting","No Results Available","Cervical Cancer|Locally Advanced Cervical Cancer","Drug: Nivolumab Injection|Drug: Cisplatin|Radiation: radiotherapy","rate of occurrence of dose-limiting toxicity (DLT)|Objective Response Rate (ORR)|Progression Free Survival (PFS)|Disease Free Survival (DFS)|Incidence of Serious Adverse Events (SAEs) to assess the overall safety profile of the association of nivolumab and pelvic radio-chemotherapy|Incidence of Adverse Events (AEs) to assess the overall safety profile of the association of nivolumab and pelvic radio-chemotherapy|validation of molecular alterations detected by molecular analyses|ctDNA heterogeneity|tumor microenvironment description|tumor PD-L1 immunohistochemistry","Institut Curie|Bristol-Myers Squibb","Female","18 Years to 99 Years   (Adult, Older Adult)","Phase 1|Phase 2","21","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IC 2016-08","November 27, 2017","May 2020","May 2022","October 2, 2017",,"November 25, 2019","Institut Curie, Paris, France|Hopital Européen Georges Pompidou, Paris, France|Institut Curie Hopital René Huguenin, Saint Cloud, France",,"https://ClinicalTrials.gov/show/NCT03298893"
105,"NCT03994744","Assessing Safety and Efficacy of Sintilimab and Metformin Combination Therapy in SCLC",,"Recruiting","No Results Available","Small-cell Lung Cancer|Small Cell Lung Carcinoma|Small Cell Lung Cancer Recurrent|Small Cell Lung Cancer Extensive Stage","Drug: PD-1 inhibitor|Drug: Metformin","Objective response rate of Sintilimab and Metformin(ORR)|Safety of the combination therapy of Sintilimab and Metformin: CTCAE4.03 grading|Median overall survival (OS) time of Sintilimab and Metformin|Median progression free survival(PFS) of Sintilimab and Metformin|Median duration of response (DoR) of Sintilimab and Metformin","Hunan Cancer Hospital|Xiangya Hospital of Central South University|Innovent Biologics (Suzhou) Co. Ltd.","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","68","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HNCH-SCLC-2019260","August 20, 2019","August 1, 2021","July 1, 2022","June 21, 2019",,"August 28, 2019","Hunan Cancer hospital, Changsha, Hunan, China",,"https://ClinicalTrials.gov/show/NCT03994744"
106,"NCT04332653","NT-I7 (Hyleukin-7) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors","KEYNOTE A60","Not yet recruiting","No Results Available","Any Advanced Solid Tumors|Triple Negative Breast Cancer|Non Small Cell Lung Cancer|Small Cell Lung Cancer|Microsatellite Stable Colorectal Cancer|Pancreatic Cancer","Drug: NT-I7|Drug: Pembrolizumab","Phase 1b: Safety and Tolerability of NT-I7 in Combination With Pembrolizumab to Determine the Maximum Tolerated Dose (MTD) and/or the Recommended Phase 2 Dose (RP2D) of NT-I7|Phase 2a: Preliminary Assessment of the Objective Response Rate (ORR) of NT-I7 in Combination with Pembrolizumab|Duration of Objective Response (DOR)|Disease Control Rate (DCR)|Progression Free Survival (PFS)|Overall Survival (OS)|Number of Participants Who Experience an Increase in Anti-Drug Antibodies (ADAs) to NT-I7","NeoImmuneTech","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","168","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NIT-110 (PNA60)","July 15, 2020","June 30, 2022","April 30, 2023","April 3, 2020",,"May 15, 2020","MD Anderson Cancer Center, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT04332653"
107,"NCT02484404","Phase I/II Study of the Anti-Programmed Death Ligand-1 Antibody MEDI4736 in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Cancers",,"Recruiting","No Results Available","Colorectal Neoplasms|Breast Neoplasms","Drug: Olaparib|Drug: Cediranib|Drug: MEDI4736","Ph I Determine the recommended phase II dose (RP2D) and the safety of doublet therapies of MEDI4736/olaparib (MEDI-O) and MEDI4736/cediranib (MEDI-C) in patients with advanced solid tumors|Ph II Determine overall response rate of MED-O and MEDI-C in patients with recurrent ovarian cancer|Ph I doublet tx: determin the safety of the doublets, MEDI+O and MEDI+C|Ph I doublet tx:determine preliminary response rates of the doublets using RECIST v1.1|Ph I doublet tx: determine the pharmacokinetics of the doublets and correlate with safety.|Ph I doublet tx: explore changes in peripheral immune subsets, plasma cytokines and circulating endothelial cells with safety and/or clinical outcome of MEDI+C|Ph I doublet:determine the potential relationship between PD-L1 expression obtained from archival tissue samples and clinical response|Ph I of triplet tx: determine the safety of MEDI+O+C|Ph I of triplet tx: determine preliminary response rates of MEDI+O+C using RECIST v1.1|Ph I of triplet tx:determine the pharmacokinetics of the triplet and correlate with safety.|Ph I of triplet tx: explore changes in peripheral immune subsets, plasma cytokines and circulating endothelial cells with safety and/or clinical outcome of MEDI+O+C|Ph I of triplet tx: determine the potential relationship between PD-L1 expression obtained from archival tissue samples and clinical response|Ph II Cohort 1 OvCa; MEDI+O, MEDI+C and MEDI+O+C arms: To evaluate PFS, safety by CTCAE v4.0, and potential relationship between pretreatment tumor PD-L1 expression obtained from biopsies and clinical response|Ph II Cohort 2 NSCLC; MEDI+O and MEDI+C arms: To determine ORR, and safety by CTCAE v4.0|Ph II Cohort 3 SCLC; MEDI+O arm: To determine PFS and safety by CTCAE v4.0|Ph II Cohort 4 mCRPC; MEDI+O arm: To determine ORR, safety by CTCAE v4.0, duration of response and PSA responses.|Ph II Cohort 5 TNBC; MEDI+O arm: To determine PFS, safety by CTCAE v4.0, and potential relationship between pretreatment tumor PD-L1 expression obtained from biopsies and clinical response","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","384","NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","150145|15-C-0145","June 29, 2015","July 29, 2021","June 29, 2022","June 29, 2015",,"May 15, 2020","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT02484404"
108,"NCT01139775","A Study in Non Small Cell Lung Cancer",,"Completed","Has Results","Non Small Cell Lung Cancer","Drug: Pemetrexed|Drug: Cisplatin|Drug: LY2603618","Phase 2: Progression-Free Survival Time|Phase 1: Recommended Phase 2 Dose of LY2603618|Phase 2: Overall Survival|Phase 2: Overall Tumor Response Rate: Percentage of Participants Who Achieved a Confirmed Best Response of Completed Response (CR) or Partial Response (PR)|Phase 2: Change in Tumor Size|Phase 1: Pharmacokinetic: Maximum Plasma Concentration (Cmax) (LY2603618)|Phase 1: Pharmacokinetic: Cmax (Pemetrexed and Cisplatin)|Phase 1: Pharmacokinetic: Area Under the Plasma Concentration Versus Time Curve (AUC) (LY2603618)|Phase 1: Pharmacokinetic: AUC (Pemetrexed and Cisplatin)|Phase 2: Pharmacokinetic: Cmax (LY2603618)|Phase 2: Pharmacokinetic: AUC (LY2603618)|Phase 2: Change From Baseline to Long-term Follow up in Lung Cancer Symptom Scale (LCSS)|Phase 1: Document Any Antitumor Activity Per Radiological Scans and/or Tumor Markers|Phase 2: Proportion of Participants Receiving Maintenance Therapy|Phase 2: Clinical Benefit Rate: Percentage of Participant Who Achieved a Response of Stable Disease (SD), Partial Response (PR), or Complete Response (CR)","Eli Lilly and Company","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","76","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","13797|I2I-MC-JMMG","February 2011","May 2013","August 2014","June 9, 2010","May 18, 2018","May 18, 2018","For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Mannheim, Baden-Wurttemberg, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Munster, Nordhein-Westfalen, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Coswig, Sachsen, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Berlin, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Frankfurt, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hannover, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Heidelberg, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Homburg, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Immenhausen, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lübeck, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Mainz, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Rheine, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ulm, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Oviedo, Asturias, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Mataro, Barcelona, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Pozuelo de Alarcon, Madrid, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Barcelona, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Barcelona, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Barcelona, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Girona, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Madrid, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Madrid, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Madrid, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sevilla, Spain",,"https://ClinicalTrials.gov/show/NCT01139775"
109,"NCT04348747","Dendritic Cell Vaccines Against Her2/Her3, Cytokine Modulation Regimen, and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer",,"Not yet recruiting","No Results Available","Anatomic Stage IV Breast Cancer AJCC v8|Metastatic Malignant Neoplasm in the Brain|Metastatic Triple-Negative Breast Carcinoma|Prognostic Stage IV Breast Cancer AJCC v8","Biological: Anti-HER2/HER3 Dendritic Cell Vaccine|Drug: Celecoxib|Biological: Pembrolizumab|Biological: Recombinant Interferon Alfa-2b|Drug: Rintatolimod","Central nervous system (CNS) objective response rate (ORR)|Volumetric quantification of brain metastases|Non-CNS (i.e. of systemic disease) response rate|Median CNS progression free survival (PFS)|Non-CNS PFS|Overall PFS|Proportion of patients who have a CNS PFS|Median overall survival (OS)|Incidence of adverse events|Proportion of patients not requiring retreatment for their brain metastasis at 6 months since the first dose of anti-HER2/3 vaccine|Rate of failure of irradiated lesions","Roswell Park Cancer Institute|National Cancer Institute (NCI)","Female","18 Years and older   (Adult, Older Adult)","Phase 2","23","Other|NIH","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","I-19-04120|NCI-2020-01520|P30CA016056","June 1, 2020","April 1, 2022","April 1, 2023","April 16, 2020",,"April 16, 2020","Roswell Park Cancer Institute, Buffalo, New York, United States",,"https://ClinicalTrials.gov/show/NCT04348747"
110,"NCT03288545","A Study of Enfortumab Vedotin Alone or With Other Therapies for Treatment of Urothelial Cancer","EV-103","Recruiting","No Results Available","Carcinoma, Transitional Cell|Urinary Bladder Neoplasms|Urologic Neoplasms|Renal Pelvis Neoplasms|Urothelial Cancer|Ureteral Neoplasms|Urethral Neoplasms","Drug: enfortumab vedotin (EV)|Drug: pembrolizumab|Drug: cisplatin|Drug: carboplatin|Drug: gemcitabine","Type, incidence, severity, seriousness, and relatedness of adverse events (Dose escalation and Expansion Parts 1 to 3; non-randomized la/mUC cohorts only)|Type, incidence, and severity of laboratory abnormalities (Dose escalation and Expansion Parts 1 to 3; non-randomized la/mUC cohorts only)|Pathological complete response (pCR) rate per local pathology review (MIBC coohorts only)|Objective response rate (ORR) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) by blinded independent central review (BICR)|Incidence of dose-limiting toxicity (DLT)|Confirmed ORR by investigator assessment according to RECIST 1.1 (Dose escalation and Expansion Parts 1 to 3; non-randomized la/mUC cohorts only)|ORR by BICR according to RECIST 1.1 (Dose escalation and Expansion Parts 1 to 3; non-randomized la/mUC cohorts only)|Confirmed ORR per the modified RECIST 1.1 for immune-based therapeutics (iRECIST) (Dose escalation and Part 1-3 cohorts with pembrolizumab only)|Disease control rate (DCR) by investigator assessment according to RECIST 1.1 (la/mUC cohorts only)|DCR by BICR according to RECIST 1.1 (la/mUC cohorts only)|DCR by investigator assessment according to iRECIST (Dose escalation and Part 1-3 cohorts using pembrolizumab only)|Duration of response (DOR) by investigator assessment according to RECIST 1.1 (la/mUC cohorts only)|DOR by BICR according to RECIST 1.1 (la/mUC cohorts only)|DOR by investigator assessment according to iRECIST (Dose escalation and Part 1-3 cohorts with pembrolizumab only)|Progression free survival on study therapy (PFS1) by investigator assessment according to RECIST 1.1 (la/mUC cohorts only)|Progression free survival on study therapy (PFS1) by BICR according to RECIST 1.1 (la/mUC cohorts only)|PFS1 by investigator assessment according to iRECIST (Dose expansion and Part 1-3 cohorts with pembrolizumab only)|Progression free survival (PFS) on study therapy by investigator assessment according to RECIST 1.1 (MIBC cohorts only)|Overall survival (OS) (all cohorts)|Pharmacokinetics (PK) parameter for enfortumab vedotin: Maximum concentration (Cmax) (Dose escalation and Expansion Parts 1 to 3; non-randomized (la/mUC cohorts only)|PK parameter for monomethyl auristatin E (MMAE): Cmax (Dose escalation and Expansion Parts 1 to 3; non-randomized la/mUC cohorts only)|PK parameter for enfortumab vedotin: Time to maximum concentration (Tmax) (Dose escalation and Expansion Parts 1 to 3; non-randomized la/mUC cohorts only)|PK parameter for MMAE: Tmax (Dose escalation and Expansion Parts 1 to 3; non-randomized la/mUC cohorts only)|PK parameter for enfortumab vedotin: Area under the concentration-time curve (AUC) (Dose escalation and Expansion Parts 1 to 3; non-randomized la/mUC cohorts only)|PK parameter for MMAE: AUC (Dose escalation and Expansion Parts 1 to 3; non-randomized la/mUC cohorts only)|Incidence of antitherapeutic antibodies (ATA) to enfortumab vedotin (Dose escalation and Expansion Parts 1 to 3; non-randomized la/mUC cohorts only)|pCR rate by central pathology review (MIBC cohorts only)|PaR rate by local pathology review (MIBC cohorts only)|Pathological response (PaR) rate by central pathology review (MIBC cohorts only)|Disease-free survival (DFS) by investigator assessment according to RECIST 1.1 (MIBC cohorts only)|Type, incidence, severity, seriousness, and relatedness of AEs (Randomized Cohort K and MIBC cohorts only)|Type, incidence, and severity of laboratory abnormalities (Randomized Cohort K and MIBC cohorts only)|Percentage of planned surgeries delayed due to treatment-related AEs (MIBC cohorts only)","Astellas Pharma Global Development, Inc.|Seattle Genetics, Inc.|Astellas Pharma Inc","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","407","Industry","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SGN22E-002","October 11, 2017","July 2023","March 2026","September 20, 2017",,"May 14, 2020","Alaska Urological Institute, Anchorage, Alaska, United States|Banner MD Anderson Cancer Center, Gilbert, Arizona, United States|Highlands Oncology Group, Fayetteville, Arkansas, United States|UC San Diego / Moores Cancer Center, La Jolla, California, United States|University of California Irvine - Newport, Orange, California, United States|University of California at San Francisco, San Francisco, California, United States|Stanford Cancer Center / Blood & Marrow Transplant Program, Stanford, California, United States|University of Colorado Hospital / University of Colorado, Aurora, Colorado, United States|Yale Cancer Center, New Haven, Connecticut, United States|University of Miami, Miami, Florida, United States|Winship Cancer Institute / Emory University School of Medicine, Atlanta, Georgia, United States|Decatur Memorial Hospital - Illinois, Decatur, Illinois, United States|Cardinal Bernardin Cancer Center / Loyola University Medical Center, Maywood, Illinois, United States|University of Kansas Cancer Center, Westwood, Kansas, United States|Tulane University Hospital and Clinic, New Orleans, Louisiana, United States|University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States|University of Minnesota, Minneapolis, Minnesota, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|New York University (NYU) Cancer Institute, New York, New York, United States|Weill Cornell Medical College, New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|UNC Lineberger Comprehensive Cancer Center / University of North Carolina, Chapel Hill, North Carolina, United States|Levine Cancer Institute, Charlotte, North Carolina, United States|Case Western Reserve University / University Hospitals Case Medical Center, Cleveland, Ohio, United States|Medical University of South Carolina/Hollings Cancer Center, Charleston, South Carolina, United States|Medical College of Wisconsin (Milwaukee), Milwaukee, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT03288545"
111,"NCT04101812","Pegylated Liposomal Doxorubicin, PD-1 in Treating Muscle Invasive Bladder Cancer",,"Recruiting","No Results Available","Muscle Invasive Bladder Cancer","Drug: pegylated liposomal doxorubicin (PLD)|Drug: PD-1","Disease control rate|Objective response rate|Progression free survival|Overall survival","Tianjin Medical University Second Hospital|CSPC Pharmaceutical Group Limited","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","60","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","DMSMIBC-01","September 17, 2019","May 31, 2020","May 31, 2021","September 24, 2019",,"September 26, 2019","Tianjin Medical Unversity Second Hospital, Tianjin, Tianjin, China",,"https://ClinicalTrials.gov/show/NCT04101812"
112,"NCT03289819","Neoadjuvant Pembrolizumab(Pbr)/Nab-Paclitaxel Followed by Pbr/Epirubicin/Cyclophosphamide in TNBC","NIB","Active, not recruiting","No Results Available","Malignant Neoplasm of Breast","Drug: Pembrolizumab|Drug: nab-paclitaxel|Drug: Epirubicin|Drug: Cyclophosphamide","Pathological Complete Response (pCR) rate|Number of participants with treatment-related adverse events as assessed by CTCAE v4.0|Clinical Response|EORTC QLQ-BR23|EORTC QLQ-C30","Institut fuer Frauengesundheit|Merck Sharp & Dohme Corp.|Celgene Corporation","Female","18 Years and older   (Adult, Older Adult)","Phase 2","50","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IFG-NIB-01|2016-003102-14|U1111-1188-3915","March 23, 2018","May 2020","September 2020","September 21, 2017",,"January 18, 2020","Department of Gynecology, Tübingen University Hospital, Tübingen, Baden-Württemberg, Germany|Department of Gynecology and Obstetrics, Erlangen University Hospital, Erlangen, Bavaria, Germany|Department for Gynecology and Obstetrics, Marienhospital Bottrop gGmbH, Bottrop, North Rhine-Westphalia, Germany|Department of Gynecology and Obstetrics, HELIOS Hospital Berlin Buch GmbH, Berlin, Germany",,"https://ClinicalTrials.gov/show/NCT03289819"
113,"NCT03823625","An Open-label, Randomized, Parallel, Non Comparative, Phase II Trial of Nivolumab Plus Ipilimumab Versus Platinum-based Chemotherapy Plus Nivolumab in Chemonaive Metastatic or Recurrent Squamous-Cell Lung Cancer (SqLC)","SQUINT","Recruiting","No Results Available","Squamous-Cell Lung Cancer","Drug: Nivolumab plus Ipilimumab|Drug: Platinum-based chemotherapy plus Nivolumab","Efficacy in terms of Overall Survival in subjects with Stage IIIB not amenable to radical treatment or Stage IV or recurrent squamous-cell lung carcinoma treated in the study|Biomarkers analysis|Number of participants with treatment-related adverse events as assessed by CTCAE v4.0","Fondazione Ricerca Traslazionale|Clinical Research Technology S.r.l.","All","18 Years and older   (Adult, Older Adult)","Phase 2","112","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SQUINT-FoRT 04","September 13, 2017","February 28, 2021","February 28, 2021","January 30, 2019",,"March 25, 2020","IRCCS - Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST)- Oncologia Medica, Meldola, Forlì- Cesena, Italy|Ospedale ""Infermi"" Rimini, Rimini, Italia, Italy|Centro di Riferimento Oncologico della Basilicata, Rionero In Vulture, Potenza, Italy|Sacro Cuore- Don Calabria Hospital- U.O.C. Oncologia Medica, Negrar, Verona, Italy|Istituto Toscano Tumori Ospedale San Donato- U.O.C. di Oncologia Medica Dipartimento di Oncologia USL-8, Arezzo, Italy|IRCCS A.O.U. San Martino- IST- Istituto Nazionale per la Ricerca sul Cancro- U.O.S. Tumori Polmonari, Genova, Italy|Istituto Europeo di Oncologia - Divisione di Oncologia Toracica, Milano, Italy|A.O.U. Policlinico di Modena- Oncologia Ematologia e Malattie Apparato Respiratorio, Modena, Italy|A.O.R.N dei Colli - Ospedale Monaldi, Napoli, Italy|I.R.C.C.S. Istituto Oncologico Veneto, Padova, Italy|Azienda Ospedaliera Universitaria Paolo Giaccone, Palermo, Italy|Casa di Cura La Maddalena- U.O. Oncologia medica, Palermo, Italy|Azienda Ospedaliera di Perugia- S.C. Oncologia Medica, Perugia, Italy|Ospedale di Ravenna- Oncologia Medica, Ravenna, Italy|IRCCS Arcispedale Santa Maria Nuova, Reggio Emilia, Italy|Azienda Ospedaliera San Camillo-Forlanini, Roma, Italy|Policlinico Universitario ""Campus Biomedico"" di Roma, Roma, Italy|Policlinico 'G.B.Rossi' Borgo Roma - A.O.U. Integrata (Giampaolo Tortora)- Oncologia Medica, Verona, Italy",,"https://ClinicalTrials.gov/show/NCT03823625"
114,"NCT02608684","A Study of Pembrolizumab With Standard Treatment in Patients With Recurrent Platinum-resistant Ovarian Cancer","PemCiGem","Active, not recruiting","Has Results","Ovarian Cancer","Drug: Pembrolizumab|Drug: Gemcitabine|Drug: Cisplatin","Overall Response Rate (ORR)|Overall Response Rate by iRECIST|Progression-free Survival (PFS) at 6 Months and at 12 Months|Time to Progression|Duration of Response|Overall Survival (OS)|Frequency and Intensity of Adverse Events (CTCAE v.4), Deemed at Least Possibly Related to Study Participation","Cedars-Sinai Medical Center|Merck Sharp & Dohme Corp.","Female","18 Years and older   (Adult, Older Adult)","Phase 2","21","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IIT2015-13-Walsh-PemCiGem","February 2016","May 17, 2019","May 2020","November 20, 2015","March 17, 2020","March 27, 2020","Cedars-Sinai Medical Center, Los Angeles, California, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/84/NCT02608684/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02608684"
115,"NCT03833440","Precision Immuno-Oncology for Advanced Non-small Cell Lung Cancer Patients With PD-1 ICI Resistance","PIONeeR","Recruiting","No Results Available","Non-small Cell Lung Cancer","Drug: Durvalumab (MEDI4736)|Drug: Monalizumab (IPH2201|Drug: Oleclumab (MEDI9447)|Drug: AZD6738|Drug: DOCETAXEL","the 12-week Disease Control Rate|Overall Response Rate|Progression-free survival (PFS)|PFS Ratio|Overall Survival (OS)|Duration of Response","Assistance Publique Hopitaux De Marseille","All","18 Years and older   (Adult, Older Adult)","Phase 2","120","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2018-21|2018-000914-39","October 8, 2019","October 2023","February 2024","February 7, 2019",,"March 4, 2020","Assistance Publique Hopitaux de Marseille, Marseille, France",,"https://ClinicalTrials.gov/show/NCT03833440"
116,"NCT03801304","Trial to Evaluate Safety and Efficacy of Vinorelbine With Metronomic Administration in Combination With Atezolizumab as Second-line Treatment for Patients With Stage IV Non-small Cell Lung Cancer","VinMetAtezo","Recruiting","No Results Available","Non-small Cell Lung Cancer","Drug: Atezolizumab|Drug: Vinorelbine","Occurrence of death or progression of the disease|Emergence of adverse events (Safety and tolerability)|Occurrence of death|Objective Response Rate|Following of the quality of life","University Hospital, Brest|Groupe Français de Pneumo-Cancérologie|Roche Farma, S.A|Pierre Fabre Medicament","All","18 Years and older   (Adult, Older Adult)","Phase 2","71","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","29BRC18-0005 (VinMetAtezo)","January 24, 2019","July 24, 2020","July 24, 2022","January 11, 2019",,"March 25, 2020","CH Aix en Provence, Aix-en-Provence, France|CHRU de Brest - Hôpital Morvan, Brest, France|CLCC Caen, Caen, France|CH de Créteil, Créteil, France|Ch La Roche Sur Yon, La Roche Sur Yon, France|CHU de Limoges - Hôpital DUPUYTREN, Limoges, France|CH Lorient, Lorient, France|CH MEAUX, Meaux, France|CHU Montpellier, Montpellier, France|CH Pringy, Pringy, France|CH Quimper, Quimper, France|CHU de Rennes, Rennes, France|CHU Rouen, Rouen, France|CH Saint-Brieuc, Saint-Brieuc, France|Hia Saint Anne, Toulon, France|CH Villefranche sur Saône, Villefranche-sur-Saône, France",,"https://ClinicalTrials.gov/show/NCT03801304"
117,"NCT03901573","High-Risk Skin Cancers With Atezolizumab Plus NT-I7",,"Recruiting","No Results Available","Melanoma|Merkel Cell Carcinoma|Cutaneous Squamous Cell Carcinoma","Drug: NT-I7|Drug: atezolizumab","Safety and Tolerability of NT-I7 in combination with atezolizumab to determine the maximum tolerated dose (MTD) and/or the recommended Phase 2 dose (RP2D) of NT-I7|To evaluate immunogenicity of NT-I7 and atezolizumab|Preliminary assessment of the Objective Response Rate (ORR) of NT-I7 in combination with atezolizumab|Preliminary assessment the Disease Control Rate (DCR) of NT-I7 in combination with atezolizumab|Preliminary assessment the Duration of Objective Response (DOR) of NT-I7 in combination with atezolizumab|Preliminary assessment the Progression Free Survival (PFS) of NT-I7 in combination with atezolizumab|Preliminary assessment the Overall Survival (OS) of NT-I7 in combination with atezolizumab","NeoImmuneTech|Immune Oncology Network","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","84","Industry|Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NIT-106|ION-02","December 26, 2019","February 2024","May 2024","April 3, 2019",,"February 7, 2020","Dana Farber, Boston, Massachusetts, United States|Washington University, Saint Louis, Missouri, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|Mt Sinai, New York, New York, United States|Cleveland Clinic, Cleveland, Ohio, United States|Providence Portland Medical Center, Portland, Oregon, United States",,"https://ClinicalTrials.gov/show/NCT03901573"
118,"NCT03755440","PD-1 Antibody in EBV Positive Metastatic Gastric Cancer Patients.",,"Enrolling by invitation","No Results Available","Gastric Cancer Stage IV|EBV","Drug: PD-1 antibody (SHR-1210)","Response rate|Progression-Free Survival (PFS)|Overall Survival (OS)|Disease Control Rate (DCR)","Sun Yat-sen University","All","18 Years and older   (Adult, Older Adult)","Phase 2","20","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","EBVaGC-SYSUCC","December 1, 2018","December 31, 2020","December 31, 2020","November 28, 2018",,"November 7, 2019","Cancer center of Sun Yat-sen University, Guangzhou, Guangdong, China",,"https://ClinicalTrials.gov/show/NCT03755440"
119,"NCT04267549","Conversion Therapy of Sintilimab in Combination With Apatinib and Chemotherapy in Unresectable Gastric Cancer",,"Recruiting","No Results Available","Gastric Cancer Stage","Drug: sintilimab|Drug: apatinib|Drug: S1|Drug: Nab paclitaxel","R0-surgery conversion rate|adverse event|R0 surgery rate|Overall response rate ( ORR)|overall survival (OS)|Progression-free survival (PFS)","Tianjin Medical University Cancer Institute and Hospital","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 2","30","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","E20207","December 1, 2019","December 30, 2020","December 30, 2021","February 13, 2020",,"February 13, 2020","Department of Gastrointestinal Medical Oncology, Tianjin Medical University Cancer Hospital, Tianjin, Tianjin, China",,"https://ClinicalTrials.gov/show/NCT04267549"
120,"NCT04379596","Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2+ Gastric Cancer (DESTINY-Gastric03)","DG-03","Not yet recruiting","No Results Available","Gastric Cancer","Drug: Fluorouracil (5-FU)|Drug: Capecitabine|Biological: Durvalumab|Drug: Oxaliplatin|Biological: Trastuzumab|Drug: Trastuzumab deruxtecan|Drug: Cisplatin","Part 1: Occurrence of adverse events (AEs) and serious adverse events (SAEs)|Part 2: Objective Response Rate (ORR)|Part 1: Objective Response Rate (ORR)|Part 2: Occurrence of adverse events (AEs) and serious adverse events (SAEs)|Duration of Response (DoR)|Disease Control Rate (DCR)|Progression Free Survival (PFS)|Overall survival (OS)|Serum concentration of T-DXd, total anti-HER2 antibody, and MAAA-1181a in all arms|Serum concentration of durvalumab in study arms including T-DXd in combination with durvalumab|Presence of ADAs for T-DXd and durvalumab (in study arms including T-DXd and durvalumab)","AstraZeneca|Daiichi Sankyo Company, Limited 3-5-1 Nihonbashihoncho, Chuo-ku, Tokyo","All","18 Years to 130 Years   (Adult, Older Adult)","Phase 1|Phase 2","220","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","D967LC00001","May 25, 2020","December 27, 2022","December 27, 2022","May 7, 2020",,"May 7, 2020","Research Site, New York, New York, United States|Research Site, Toronto, Ontario, Canada|Research Site, Berlin, Germany|Research Site, Frankfurt, Germany|Research Site, Frankfurt, Germany|Research Site, Hamburg, Germany|Research Site, Hamburg, Germany|Research Site, Leipzig, Germany|Research Site, Mannheim, Germany|Research Site, München, Germany|Research Site, Milano, Italy|Research Site, Milano, Italy|Research Site, Napoli, Italy|Research Site, Padova, Italy|Research Site, Verona, Italy|Research Site, Seongnam, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Madrid, Spain|Research Site, Santander, Spain|Research Site, Sevilla, Spain|Research Site, Kaohsiung, Taiwan|Research Site, Taipei, Taiwan|Research Site, Taipei, Taiwan|Research Site, Taoyuan, Taiwan",,"https://ClinicalTrials.gov/show/NCT04379596"
121,"NCT04139317","Safety and Efficacy of Capmatinib (INC280) Plus Pembrolizumab vs Pembrolizumab Alone in NSCLC With PD-L1≥ 50%",,"Recruiting","No Results Available","Non-small Cell Lung Cancer (NSCLC)","Drug: Capmatinib|Biological: Pembrolizumab","Progression-free survival (PFS) based on local investigator assessment as per RECIST 1.1|Objective response rate (ORR) based on local investigator assessment as per RECIST 1.1|Disease control rate (DCR) based on local investigator assessment as per RECIST 1.1|Time-to-response (TTR) based on local investigator assessment as per RECIST 1.1|Duration of response (DOR) based on local investigator assessment as per RECIST 1.1|Overall survival (OS)|Antidrug antibodies (ADA) of pembrolizumab|AUC of Capmatinib derived from plasma capmatinib concentration|Ctrough of Pembrolizumab derived from serum pembrolizumab concentration|Cmax of Capmatinib derived from plasma capmatinib concentration|Tmax of Capmatinib derived from plasma capmatinib concentration","Novartis Pharmaceuticals|Novartis","All","18 Years and older   (Adult, Older Adult)","Phase 2","96","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CINC280I12201","January 22, 2020","March 28, 2023","March 28, 2023","October 25, 2019",,"April 21, 2020","Novartis Investigative Site, Shepparton, Victoria, Australia|Novartis Investigative Site, Yvoir, Belgium|Novartis Investigative Site, Kolkata, West Bengal, India|Novartis Investigative Site, Delhi, India|Novartis Investigative Site, Nagoya, Aichi, Japan|Novartis Investigative Site, Yokohama-city, Kanagawa, Japan|Novartis Investigative Site, Kuching, Sarawak, Malaysia|Novartis Investigative Site, Barcelona, Cataluña, Spain|Novartis Investigative Site, Valencia, Comunidad Valenciana, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Changhua, Taiwan",,"https://ClinicalTrials.gov/show/NCT04139317"
122,"NCT03331562","A SU2C Catalyst® Trial of a PD1 Inhibitor With or Without a Vitamin D Analog for the Maintenance of Pancreatic Cancer",,"Active, not recruiting","No Results Available","Pancreatic Cancer|Pancreas Adenocarcinoma|Advanced Pancreatic Cancer|Metastatic Pancreatic Cancer|Metastatic Pancreatic Adenocarcinoma","Drug: Pembrolizumab|Drug: paricalcitol|Drug: placebo","Percent of patients with radiographic disease progression according to RECIST 1.1 at 6 months from initiation of trial treatment|Incidence of treatment-related toxicities as assessed by CTCAE v4.0 from cycle1/day 1 through 30 days after the last dose of trial treatment.|Difference in overall survival (OS) in patients administered the combination of paricalcitol plus pembrolizumab versus pembrolizumab alone|Change in tumor mutational landscape and transcriptional programs using unbiased genome-wide sequencing|Cellular VDR targets in the immune microenvironment with PD1 blockade","Translational Genomics Research Institute|Stand Up To Cancer|Merck Sharp & Dohme Corp.","All","18 Years and older   (Adult, Older Adult)","Phase 2","24","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","TGen 17-001|MISP# 56240","December 27, 2017","December 30, 2020","June 15, 2021","November 6, 2017",,"February 17, 2020","HonorHealth Research Institute, Scottsdale, Arizona, United States|City of Hope National Medical Center, Duarte, California, United States|The University of Kansas Cancer Center, Westwood, Kansas, United States|Atlantic Medical Group-Oncology Morristown Medical Center, Morristown, New Jersey, United States|Baylor University Medical Center Charles A. Sammons Cancer Center, Dallas, Texas, United States|Froedtert Hospital and Medical College of Wisconsin, Milwaukee, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT03331562"
123,"NCT04262687","Chemotherapy and Immunotherapy as Treatment for MSS Metastatic Colorectal Cancer With High Immune Infiltrate","POCHI","Not yet recruiting","No Results Available","Colorectal Cancer Metastatic|High Immune Infiltrate|Microsatellite Stable","Drug: Capecitabine|Drug: Oxaliplatin|Drug: Bevacizumab|Drug: Pembrolizumab","Evaluate the efficacy of pembrolizumab in combination with XELOX and bevacizumab as 1st line treatment of microsatellite stable (MSS) metastatic colorectal cancer (mCRC) with a high immune infiltrate|Overall survival|Serious adverse events evaluated according to NCI-CTC v4.0|Histological response in case of secondary resection|Outcome of tumour markers","Federation Francophone de Cancerologie Digestive","All","18 Years and older   (Adult, Older Adult)","Phase 2","55","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","FFCD 1703 POCHI","April 30, 2020","December 31, 2022","December 31, 2023","February 10, 2020",,"February 10, 2020","Centre Hospitalier d'Abbeville, Abbeville, France|CHU Amiens-Picardie, Amiens, France|Ico - Site Paul Papin - Angers, Angers, France|Hôpital Privé - Pays de Savoie, Annemasse, France|Hopital Prive D'Antony, Antony, France|CH Henri Duffaut, Avignon, France|Ch Cote Basque, Bayonne CEDEX, France|Ch de Beauvais, Beauvais, France|Chu Jean Minjoz, Besançon, France|Polyclinique de Bordeaux Nord, Bordeaux CEDEX, France|Institut Bergonié BORDEAUX, Bordeaux, France|Hôpital Morvan Institut de cancérologie, Brest Cedex 2, France|Centre Maurice Tubiana, Caen, France|Centre Francois Baclesse, Caen, France|Infirmerie Protestante de Lyon, Caluire-et-Cuire, France|Médipole de Savoie, Challes-les-Eaux, France|Hopital Prive Paul D'Egine, Champigny-sur-Marne, France|Chauny Centre Hospitalier, Chauny, France|CH de CHOLET, Cholet, France|CHU d'Estaing CLERMONT FERRAND, Clermont Ferrand, France|Hopitaux Civils de Colmar, Colmar, France|Clinique Saint Come, Compiègne CEDEX, France|Clinique de Flandre, Coudekerque-Branche, France|GHPSO Site de Creil, Creil, France|Hôpital Henri Mondor, Créteil CEDEX, France|Hopital Francois Mitterrand, Dijon CEDEX, France|Centre Georges-Francois Leclerc, Dijon, France|CHU GRENOBLE ALPES - Hôpital Albert Michallon, Grenoble, France|Polyclinique de Blois - 3Eme Etage, La Chaussee St Victor, France|CHD Vendée - La Roche-sur-Yon, La Roche-sur-Yon, France|Chu Dupuytren - Limoges, Limoges, France|Hôpital Du Scorff - Chbs, Lorient CEDEX, France|Hôpital Prive Jean Mermoz, Lyon, France|Chu Lyon Sud - Pierre Benite, Lyon, France|Hopital Europeen Marseille, Marseille CEDEX 03, France|Chu La Timone, Marseille CEDEX 5, France|Hopital Saint Joseph, Marseille, France|Groupe Hospitalier de l'Est Francilien - MEAUX, Meaux, France|HOPITAL LAYNE - CH de MONT DE MARSAN, Mont-de-Marsan, France|Centre Azureen de Cancerologie, Mougins, France|Hopital Prive Arnault Tzanck, Mougins, France|Polyclinique de Gentilly, Nancy, France|CHU Carémeau, Nîmes, France|Institut Mutualiste Montsouris, Paris, France|Hôpital Europeen Georges Pompidou, Paris, France|Groupe Hospitalier Diaconesses Croix Saint Simon, Paris, France|CENTRE HOSPITALIER de PAU, Pau CEDEX, France|Polyclinique FRANCHEVILLE, Perigueux, France|Centre Hospitalier SAINT-JEAN de PERPIGNAN, Perpignan, France|Chu de Poitiers - La Miletrie, Poitiers, France|Chu Robert Debre, Reims CEDEX, France|Institut Jean Godinot, Reims, France|Chu de Pontchaillou - Rennes, Rennes CEDEX 9, France|Hopital Drome Nord, Romans-sur-Isère, France|Ico - Site René Gauducheau, Saint-Herblain, France|Centre Hospitalier de St Malo, Saint-Malo, France|Chu de Saint Etienne-Hopital Nord - Service Hge, Saint-Priest-en-Jarez, France|Polyclinique Saint Claude, Saint-Quentin, France|Clinique Charcot - Sainte Foy Les Lyon, Sainte-Foy-lès-Lyon, France|Clinique Sainte Anne, Strasbourg, France|CAC - Paul Strauss / ICAN STRASBOURG, Strasbourg, France|HAUTEPIERRE CHU de STRASBOURG, Strasbourg, France|Hopital Foch, Suresnes, France|Polyclinique de L'Ormeau, Tarbes, France|Hopital Sainte Musse, Toulon, France|CHU TROUSSEAU de TOURS, Tours CEDEX 9, France|CENTRE HOSPITALIER de VALENCIENNES, Valenciennes, France|Institut de Cancerologie de Lorraine, Vandœuvre-lès-Nancy, France|Hopital Paul Brousse, Villejuif, France",,"https://ClinicalTrials.gov/show/NCT04262687"
124,"NCT03950271","SHR-1210 Combined With Trastuzumab , Oxaliplatin and Capecitabine for Neoadjuvant Therapy of Gastric Adenocarcinoma/Gastroesophageal Junction Adenocarcinoma",,"Recruiting","No Results Available","Gastric Cancer","Drug: SHR-1210 Combined With Trastuzumab , Oxaliplatin and Capecitabine","Disease Free Survival（DFS）|Objective Response Rate (ORR)|Overall survival(OS)|pathological complete response (pCR) rate","Henan Cancer Hospital","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","25","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GCCG7","January 21, 2020","December 1, 2020","June 1, 2022","May 15, 2019",,"May 29, 2020","Henan Cancer Hospital, Zhengzhou, Henan, China",,"https://ClinicalTrials.gov/show/NCT03950271"
125,"NCT03810339","Toripalimab as Monotherapy in Participants With POLE or POLD-1 Mutated and Non-MSI-H Advanced Solid Tumors",,"Recruiting","No Results Available","Solid Tumor|Advanced Cancer","Drug: Toripalimab","Objective Response Rates (ORR)|Overall Survival (OS)|Progression free survival (PFS)|Adverse Events (AEs)","Sun Yat-sen University","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","35","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PPM","January 15, 2019","December 30, 2020","December 30, 2021","January 18, 2019",,"January 22, 2019","Cancer center of Sun Yat-sen University, Guangzhou, Guangdong, China",,"https://ClinicalTrials.gov/show/NCT03810339"
126,"NCT04263051","Evaluation of UCPVax Plus Nivolumab as Second Line Therapy in Advanced Non Small Cell Lung Cancer","Optim-UCPVax","Not yet recruiting","No Results Available","Advanced Non-small Cell Lung Cancer","Drug: UCPVax + Nivolumab|Drug: standard chemotherapy","6 months Progression-Free Survival (PFS) rate","Centre Hospitalier Universitaire de Besancon|Bristol-Myers Squibb","All","18 Years and older   (Adult, Older Adult)","Phase 2","111","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","P/2019/451","April 1, 2020","April 1, 2025","April 1, 2025","February 10, 2020",,"February 19, 2020","CHU of Besançon, Besançon, France|CHU Bordeaux, Bordeaux, France|Centre Georges François Leclerc, Dijon, France|Institut de Cancérologie Privé CCGM, Montpellier, France|CH Mulhouse, Mulhouse, France|Institut Jean Godinot, Reims, France|Institut de Cancérologie de l'Ouest, Saint-Herblain, France",,"https://ClinicalTrials.gov/show/NCT04263051"
127,"NCT04101357","Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT411",,"Not yet recruiting","No Results Available","Solid Tumor|Extensive-stage Small Cell Lung Cancer","Drug: BNT411|Drug: Atezolizumab|Drug: Carboplatin|Drug: Etoposide","Incidence of DLTs|Incidence of TEAEs|Incidence of IMP dose reductions|Incidence of IMP treatment discontinuations due to toxicity|Maximum Plasma Concentration (Cmax) of PK assessments|Area under the curve (AUC) of PK assessments|Objective Response Rate (ORR)|Disease Control Rate (DCR)|Duration of Response (DOR)","BioNTech Small Molecules GmbH","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","60","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","BNT411-01","June 2020","June 2022","December 2023","September 24, 2019",,"November 15, 2019",,,"https://ClinicalTrials.gov/show/NCT04101357"
128,"NCT03817736","Sequential TransArterial Chemoembolization and Stereotactic RadioTherapy With ImmunoTherapy for Downstaging Hepatocellular Carcinoma for Hepatectomy","START-FIT","Recruiting","No Results Available","HCC","Procedure: TACE|Radiation: SBRT|Drug: Immune Checkpoint Inhibitor","Number of Patients Amendable to Curative Surgical Interventions|Response rate measured by mRECIST criteria|Time to progression (TTP)|Progression-free survival (PFS)|Overall survival (OS)|European Organization for Research and Treatment of Cancer Core Quality of Life Questionnaire (EORTC-QLQ-C30) Score|Functional Assessment of Cancer Therapy-Hepatobiliary (FACT-Hep) Score|Incidence of Study-Related Adverse Events [Safety and Tolerability]|Pathological response","The University of Hong Kong|Merck KGaA, Darmstadt, Germany","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","33","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","UW 18-541","March 1, 2019","February 3, 2022","February 5, 2024","January 25, 2019",,"March 5, 2020","Department of Clinical Oncology, Hong Kong, Hong Kong",,"https://ClinicalTrials.gov/show/NCT03817736"
129,"NCT03971409","Avelumab With Binimetinib, Utomilumab, or Anti-OX40 Antibody PF-04518600 in Treating Triple Negative Breast Cancer","InCITe","Recruiting","No Results Available","Stage III Breast Cancer|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer|Stage IV Breast Cancer|Invasive Breast Carcinoma|Recurrent Breast Carcinoma|Triple-Negative Breast Carcinoma","Biological: Anti-OX40 Antibody PF-04518600|Drug: Avelumab|Drug: Binimetinib|Biological: Utomilumab","Best Overall Response Rate (BORR) Assessed by Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1|Overall Response Rate (ORR) Assessed by Immune-Related RECIST (iRECIST)|Clinical Benefit Rate (CBR) Assessed by RECIST Version 1.1|Median Progression-free Survival (PFS) Assessed by RECIST Version 1.1|Median Overall Survival|Incidence of Adverse Events Assessed by Common Terminology Criteria for Adverse Events (CTCAE) v.5.0|Change in Quality of Life at 8 Weeks Assessed by Patient-Reported Outcomes Measurement Information System (PROMIS) Global Health Measure|Change in Quality of Life Over Treatment Duration Assessed by PROMIS Global Health Measure|Change in Symptoms (Self-Reported Toxicities) at 8 Weeks Assessed by Patient-Reported Outcomes - Common Terminology Criteria for Adverse Events (PRO-CTCAE)|Change in Symptoms (Self-Reported Toxicities) Over Treatment Duration Assessed by PRO-CTCAE|Change in Ability to Participate in Social Roles and Activities at 8 Weeks Assessed by PROMIS|Change in Ability to Participate in Social Roles and Activities Over Treatment Duration Assessed by PROMIS|Change in Treatment Satisfaction at 8 Weeks Assessed by the Treatment Satisfaction Questionnaire for Medication (TSQM)|Change in Treatment Satisfaction Over Treatment Duration Assessed by the TSQM","Hope Rugo, MD|Translational Breast Cancer Research Consortium|Hoosier Cancer Research Network|Array BioPharma|Pfizer|Breast Cancer Research Foundation|Johns Hopkins University|University of California, San Francisco","All","18 Years and older   (Adult, Older Adult)","Phase 2","150","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","187519|NCI-2019-01531|TBCRC 047|BRE16-279","July 3, 2019","June 1, 2020","June 1, 2023","June 3, 2019",,"November 1, 2019","University of California, San Francisco, San Francisco, California, United States|Mayo Clinic, Rochester, Minnesota, United States|UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States|Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT03971409"
130,"NCT03983759","Study of Sintlimab Maintenance Therapy in Patients With Extensive Small Cell Lung Cancer",,"Not yet recruiting","No Results Available","Small Cell Lung Cancer|Extensive Disease|Adoptive Cellular Immunotherapy|Chemotherapy|Maintenance","Drug: sintilimab maintenance","median survival time|progression-free survival|objective response rate of sintilimab|adverse events rate of sintilimab","Henan Cancer Hospital","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 2","40","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HenanCH immunotherapy002","June 20, 2019","May 31, 2021","May 31, 2021","June 12, 2019",,"June 13, 2019","Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, Henan, China",,"https://ClinicalTrials.gov/show/NCT03983759"
131,"NCT03789110","NIMBUS: Nivolumab Plus Ipilimumab in Metastatic Hypermutated HER2-negative Breast Cancer",,"Recruiting","No Results Available","Breast Cancer","Drug: Nivolumab|Drug: Ipilimumab","Overall Response Rate of nivolumab in combination with ipilimumab|Overall Response Rate of the combination according to immune-related response criteria|Clinical Benefit Rate|Progression Free Survival|Overall Survival","Dana-Farber Cancer Institute|Bristol-Myers Squibb","All","18 Years and older   (Adult, Older Adult)","Phase 2","30","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","18-561","March 8, 2019","April 19, 2022","October 19, 2022","December 28, 2018",,"April 28, 2020","Dana-Farber Cancer Institute, Boston, Massachusetts, United States|University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States",,"https://ClinicalTrials.gov/show/NCT03789110"
132,"NCT04282109","Study to Assess the Efficacy and Safety of Nivolumab in Combination With Paclitaxel in Subjects With Head and Neck Cancer Unable for Cisplatin-based Chemotherapy (NIVOTAX)","NIVOTAX","Not yet recruiting","No Results Available","Recurrent Head and Neck Squamous Cell Carcinoma|Head and Neck Cancer Stage IV","Drug: Nivolumab + Paclitaxel|Drug: Cetuximab + Paclitaxel","Two years overall survival (OS)|Progression Free Survival (PFS)|Overall response rate (ORR)|Disease control rate (DCR)|Duration of response (DoR)|Rate of progressive disease (PD) at 6 months|Five years overall survival (5y-OS)|Overall survival in patients ≥ 70 years.|Progression free survival in patients ≥ 70 years.|Overall response rate in patients ≥ 70 years.|Overall survival based on PDL1 expression (CPS).|Progression free survival based on PDL1 expression (CPS).|Overall response rate based on PDL1 expression (CPS).|Overall survival based on HPV (OPC).|Progression free survival based on HPV (OPC).|Overall response rate based on HPV (OPC).|Overall survival based on cisplatin refractory.|Progression free survival based on cisplatin refractory.|Overall response rate based on cisplatin refractory.|Overall survival based on cisplatin ineligibility.|Progression free survival based on cisplatin ineligibility.|Overall response rate based on cisplatin ineligibility.|Overall survival based on Karnofsky.|Progression free survival based on Karnofsky.|Overall response rate based on Karnofsky.|Percentage of patients with AEs|Percentage of patients with Grade 3 and Grade 4 AEs|Percentage of patients with SAEs|Percentage of patients who discontinued due to AEs|Percentage of patients with each AE by grade","Grupo Español de Tratamiento de Tumores de Cabeza y Cuello|Bristol-Myers Squibb|Apices Soluciones S.L.","All","18 Years and older   (Adult, Older Adult)","Phase 2","141","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TTCC-2019-01/CA209-7HE|2019-002922-60","March 2020","August 2023","September 2026","February 24, 2020",,"February 24, 2020","Hospital Universitario Marqués de Valdecilla, Santander, Cantabria, Spain|Hospital Universitario Donostia- Donostia Unibertsitate Ospitalea, San Sebastián, San Sebastían, Spain|Centro Oncoloxico de Galicia, A Coruña, Spain|Hospital Universitari Germans Trias i Pujol de Badalona, Badalona, Spain|Hospital Clínic de Barcelona, Barcelona, Spain|Institut Català D´Oncologia- Hospital Duran i Reynals, Barcelona, Spain|Hospital Universitari de Girona Dr. Josep, Girona, Spain|Hospital Universitario Virgen de las Nieves, Granada, Spain|Hospital Universitario Lucus Augusti, Lugo, Spain|Hospital Clínico San Carlos, Madrid, Spain|Hospital 12 de Octubre, Madrid, Spain|Hospital Universitario Regional de Málaga, Málaga, Spain|Complejo Hospitalario de Navarra, Pamplona, Spain|Complejo Asistencial Universitario de Salamanca, Salamanca, Spain|Hospital Universitario Virgen del Rocío, Sevilla, Spain|Hospital Virgen de la Salud, Toledo, Spain|Hospital Clínico Universitario de Valencia, Valencia, Spain|Hospital Universitario y Politécnico la Fe, Valencia, Spain|Hospital Clínico Universitario Lozano, Zaragoza, Spain|Hospital Universitario Miguel Servet, Zaragoza, Spain",,"https://ClinicalTrials.gov/show/NCT04282109"
133,"NCT02992912","Atezolizumab With Stereotactic Ablative Radiotherapy in Patients With Metastatic Tumours","SABR-PDL1","Recruiting","No Results Available","Patients With Metastatic Tumours (Colorectal Cancer, Non-small Lung Cancer, Renal Cell Carcinoma or Sarcoma )","Drug: Anti-PD-L1 antibody atezolizumab|Procedure: SABR","Progression Free Survival","Gustave Roussy, Cancer Campus, Grand Paris","All","18 Years and older   (Adult, Older Adult)","Phase 2","187","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2015-005464-42|2335/2015","October 17, 2016","October 2020","October 2020","December 14, 2016",,"February 19, 2020","Gustave Roussy, Villejuif, Val De Marne, France",,"https://ClinicalTrials.gov/show/NCT02992912"
134,"NCT01037790","PHASE II TRIAL OF THE CYCLIN-DEPEDENT KINASE INHIBITOR PD 0332991 IN PATIENTS WITH CANCER",,"Completed","No Results Available","Adult Solid Tumor|Adenocarcinoma of the Colon|Adenocarcinoma of the Rectum|Adult Central Nervous System Germ Cell Tumor|Adult Teratoma|Benign Teratoma|Estrogen Receptor-negative Breast Cancer|Estrogen Receptor-positive Breast Cancer|Familial Testicular Germ Cell Tumor|HER2-negative Breast Cancer|HER2-positive Breast Cancer|Male Breast Cancer|Ovarian Immature Teratoma|Ovarian Mature Teratoma|Ovarian Monodermal and Highly Specialized Teratoma|Progesterone Receptor-negative Breast Cancer|Progesterone Receptor-positive Breast Cancer|Recurrent Breast Cancer|Recurrent Colon Cancer|Recurrent Extragonadal Germ Cell Tumor|Recurrent Extragonadal Non-seminomatous Germ Cell Tumor|Recurrent Extragonadal Seminoma|Recurrent Malignant Testicular Germ Cell Tumor|Recurrent Melanoma|Recurrent Ovarian Germ Cell Tumor|Recurrent Rectal Cancer|Stage III Extragonadal Non-seminomatous Germ Cell Tumor|Stage III Extragonadal Seminoma|Stage III Malignant Testicular Germ Cell Tumor|Stage III Ovarian Germ Cell Tumor|Stage IV Breast Cancer|Stage IV Colon Cancer|Stage IV Extragonadal Non-seminomatous Germ Cell Tumor|Stage IV Extragonadal Seminoma|Stage IV Melanoma|Stage IV Ovarian Germ Cell Tumor|Stage IV Rectal Cancer|Testicular Immature Teratoma|Testicular Mature Teratoma","Drug: PD-0332991|Other: pharmacological study","Response rates|Safety and tolerability|Pharmacodynamic effects on tumor and non-tumor tissue|Relationship between selected biomarkers, pharmacokinetics, and/or efficacy and safety outcomes|Population pharmacokinetic for PD 0332991 and correlation with efficacy outcomes","Abramson Cancer Center of the University of Pennsylvania","All","18 Years and older   (Adult, Older Adult)","Phase 2","304","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","UPCC 03909|NCI-2009-01467","October 2009","October 2019","October 2019","December 23, 2009",,"April 7, 2020","Abramson Cancer Center of The University of Pennsylvania, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT01037790"
135,"NCT03838848","KN046 in Patients With Advanced Non-small Cell Lung Cancer",,"Recruiting","No Results Available","Stage IV Non-small Cell Lung Cancer","Drug: KN046","ORR|DOR","Jiangsu Alphamab Biopharmaceuticals Co., Ltd","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","149","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","KN046-201","May 5, 2019","March 2021","March 2022","February 12, 2019",,"May 7, 2019","Shanghai Pulmonary Hospital, Shanghai, China",,"https://ClinicalTrials.gov/show/NCT03838848"
136,"NCT02403193","Trial of PBF-509 and PDR001 in Patients With Advanced Non-small Cell Lung Cancer (NSCLC)","AdenONCO","Recruiting","No Results Available","Non-small Cell Lung Cancer (NSCLC)","Drug: PBF-509_80 mg|Drug: PBF-509_160 mg|Drug: PBF-509_320 mg|Drug: PBF-509_640 mg|Drug: Combo PBF-509 (160 mg) + PDR001|Drug: Combo PBF-509 (320 mg) + PDR001|Drug: Combo PBF-509 (640 mg) + PDR001|Drug: RP2D (PBF-509+PDR001)_immuno naïve|Drug: Experimental: RP2D (PBF-509+PDR001)_immuno treated","Maximum Tolerated Dose (MTD) of PBF-509 as single agent|Maximum Tolerated Dose (MTD) of the combination (PBF-509+PDR001) treatment|Time to PBF-509 peak concentration in plasma ""Tmax""|Time to PBF-509 peak concentration in plasma at steady state ""Tmax,ss""|PBF-509 peak concentration in plasma ""Cmax""|PBF-509 peak concentration in plasma at steady state""Cmax,ss""|The area under PBF-509 plasma concentration-time curve to infinite time ""AUC(0-inf)""|The area under PBF-509 plasma concentration-time curve up to time 't' ""AUC(0-t)""|The area under PBF-509 plasma concentration-time curve over the dosing interval ""AUC(0-τ)""|PBF-509 half-life in plasma "" t½""|PBF-509 apparent volume of distribution following extravascular administration""Vd/F""|PBF-509 total body clearance following extravascular administration ""Cl/F""|The PBF 509 accumulation index ""Rac""|Efficacy as measured by Objective response rate (ORR)|Efficacy as measured by Disease control rate (DCR)|Efficacy as measured by duration of response (DoR)|Efficacy as measured by progression-free survival (PFS)|Efficacy as measured by overall survival (OS)","Palobiofarma SL|Novartis|H. Lee Moffitt Cancer Center and Research Institute","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","92","Industry|Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MC18321","October 2015","October 2020","December 2020","March 31, 2015",,"November 6, 2018","H.Lee Moffitt Cancer center, Tampa, Florida, United States",,"https://ClinicalTrials.gov/show/NCT02403193"
137,"NCT03322384","UCDCC#271: Phase I/II Trial of Epacadostat, Intralesional SD101, Radiotherapy in Patients With Lymphoma",,"Recruiting","No Results Available","Advanced Solid Tumors|Lymphoma","Drug: epacadostat|Drug: SD-101|Radiation: Radiotherapy","Maximum tolerated dose (MTD)|Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]|Abscopal Response Rate","University of California, Davis","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","56","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1057229|UCDCC#271","January 17, 2018","October 1, 2020","October 1, 2021","October 26, 2017",,"March 25, 2019","University of California Davis Comprehensive Cancer Center, Sacramento, California, United States",,"https://ClinicalTrials.gov/show/NCT03322384"
138,"NCT02926768","Phase I/II Study of CK-101 in NSCLC Patients and Other Advanced Solid Tumors",,"Active, not recruiting","No Results Available","Lung Neoplasms|Carcinoma, Non-Small-Cell Lung|Lung Diseases|Adenocarcinoma","Drug: CK-101","Phase I: Incidence of dose-limiting toxicities (DLTs)|Phase II: Objective response rate (ORR): Defined as the rate of complete responses [CR] or partial responses [PR] per RECIST Version 1.1 as assessed by an independent central review|Phase II: Evaluation of tumor response based on disease control rate as assessed by RECIST 1.1|Phase II: Evaluation of tumor response based on duration of response as assessed by RECIST 1.1|Phase II: Evaluation of tumor response based on tumor shrinkage as assessed by RECIST 1.1|Phase II: Evaluation of tumor response based on progression free survival as assessed by RECIST 1.1|Phase I: Change from baseline in QT/QTc interval|Phase I: Plasma concentrations of CK-101 following dosing with CK-101 as assessed by area under the curve|Phase I: Plasma concentrations of CK-101 following dosing with CK-101 as assessed by maximum concentration|Phase I: Plasma concentrations of CK-101 following dosing with CK-101 as assessed by elimination half-life","Checkpoint Therapeutics, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","136","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CK-101-101","September 2016","June 2020","December 2020","October 6, 2016",,"January 22, 2020","Research Site, Sarasota, Florida, United States|Research Site, Saint Louis, Missouri, United States|Research Site, Hackensack, New Jersey, United States|Research Site, Nashville, Tennessee, United States|Research Site, Greenslopes, Queensland, Australia|Research Site, Grafton, Auckland, New Zealand|Research Site, Christchurch, New Zealand|Research Site, Wellington, New Zealand|Research Site, Bydgoszcz, Kujawsko-Pomorskie, Poland|Research Site, Bydgoszcz, Kujawsko-Pomorskie, Poland|Research Site, Lublin, Lubelskie, Poland|Research Site, Białystok, Podlaskie, Poland|Research Site, Poznań, Wielkopolskie, Poland|Research Site, Szczecin, Zachodniopomorskie, Poland|Research Site, Pathumwan, Bangkok, Thailand|Research Site, Ratchathewi District, Bangkok, Thailand|Research Site, Bangkok Noi District, Bangkok, Thailand|Research Site, Muang District, Chiang Mai, Thailand|Research Site, Khon Kaen, Thailand|Research Site, Muang, Phitsanulok, Thailand",,"https://ClinicalTrials.gov/show/NCT02926768"
139,"NCT04047186","Neoadjuvant Immunotherapy in Early Stage Non-small-cell Lung Cancer Presenting as Synchronous Ground-glass Nodules",,"Not yet recruiting","No Results Available","Multiple Pulmonary Nodules","Drug: Nivolumab Injection","pathological response rate|treatment-related adverse events","Tongji Hospital","All","18 Years and older   (Adult, Older Adult)","Phase 2","50","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2019CR107","October 1, 2019","April 30, 2024","December 31, 2024","August 6, 2019",,"August 6, 2019","Tongji Hospital Affiliated to Huazhong Technology Hospital, Wuhan, Hubei, China",,"https://ClinicalTrials.gov/show/NCT04047186"
140,"NCT03925246","Efficacy of Nivolumab for Recurrent IDH Mutated High-Grade Gliomas","REVOLUMAB","Recruiting","No Results Available","High Grade Glioma|Brain Cancer","Drug: Nivolumab","24 weeks progression-free survival (PFS24w) rate, documented by RANO criteria|Progression-Free survival at 24 weeks (PFS24w) rate estimated by iRANO criteria|Median progression-free survival (median-PFS) assessed by RANO criteria|Median progression-free survival (median-PFS) assessed by iRANO criteria|Overall survival (OS)|Overall response rate (ORR) assessed by RANO criteria|Overall response rate (ORR) assessed by iRANO criteria|Duration of response assessed by RANO criteria|Duration of response assessed by iRANO criteria|Longitudinal changes in quality of life (EORTC QLQ-C30 and BN20)|Safety: Type, frequency and severity of adverse events and serious adverse events","Assistance Publique - Hôpitaux de Paris|Bristol-Myers Squibb","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 2","39","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","P160923J|2017-004140-38","July 30, 2019","December 2021","December 2022","April 24, 2019",,"August 8, 2019","Groupe Hospitalier Pitié-Salpêtrière, Paris, France",,"https://ClinicalTrials.gov/show/NCT03925246"
141,"NCT04340882","Phase 2 TaxRamPem for Patients With Metastatic or Recurrent NSCLC Who Progressed on Platinum-Doublet and PD-1/PD-L1 Blockade","TaxRamPem","Not yet recruiting","No Results Available","Metastatic Non-Small Lung Cell Cancer|Recurrent Non-Small Lung Cell Cancer|Stage IV Lung Cancer AJCC v8|Stage IVA Lung Cancer AJCC v8|Stage IVB Lung Cancer AJCC v8","Drug: Docetaxel|Biological: Pembrolizumab|Biological: Ramucirumab","6-month progression-free survival (PFS) rate|Incidence of adverse events|Overall response rate|Overall survival (OS)","Emory University|National Cancer Institute (NCI)|Merck Sharp & Dohme Corp.","All","18 Years and older   (Adult, Older Adult)","Phase 2","41","Other|NIH|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","STUDY00000030|NCI-2020-01134|WINSHIP4950-20|P30CA138292","June 1, 2020","April 25, 2022","May 31, 2022","April 10, 2020",,"May 29, 2020","Winship Cancer Institute of Emory University, Atlanta, Georgia, United States",,"https://ClinicalTrials.gov/show/NCT04340882"
142,"NCT03696212","Grapiprant (ARY-007) and Pembrolizumab in Patients With Advanced or Metastatic Post-PD-1/L1 NSCLC Adenocarcinoma",,"Recruiting","No Results Available","Non-small Cell Lung Cancer Adenocarcinoma","Drug: grapiprant and pembrolizumab","Safety and tolerability of grapiprant in combination with pembrolizumab|Define the recommended phase 2 dose (RP2D) of grapiprant combined with pembrolizumab|Objective response rate (ORR)|Progression-free survival (PFS)|Overall survival (OS)|Duration of treatment (DoT)|Disease control rate (DCR)|Duration of response (DoR)|PK of grapiprant: AUC|PK of grapiprant: Cmax|Plasma decay half-life (t1/2)|Apparent oral clearance (CL/F)|Peak to trough ratio|Observed accumulation ratio|Pharmacodynamic immune effects in paired tumor biopsies","Arrys Therapeutics|Merck Sharp & Dohme Corp.","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","25","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ARYS-002","January 8, 2019","September 2020","September 2020","October 4, 2018",,"April 5, 2019","Stanford University Medical Center, Stanford, California, United States|Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States|University of Pennsylvania Abramson Cancer Center, Philadelphia, Pennsylvania, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|Virginia Cancer Specialists, Fairfax, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT03696212"
143,"NCT03554473","M7824 and Topotecan or Temozolomide in Relapsed Small Cell Lung Cancers",,"Recruiting","No Results Available","Carcinoma, Small Cell|Lung Cancer|Small Cell Lung Cancer","Drug: M7824|Drug: Topotecan|Drug: Temozolomide","Efficacy|Safety|PFS, DOR and OS","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","67","NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","180110|18-C-0110","September 11, 2018","January 15, 2023","January 15, 2024","June 13, 2018",,"April 24, 2020","National Institutes of Health Clinical Center, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT03554473"
144,"NCT02798406","Combination Adenovirus + Pembrolizumab to Trigger Immune Virus Effects","CAPTIVE","Active, not recruiting","No Results Available","Brain Cancer|Brain Neoplasm|Glioma|Glioblastoma|Gliosarcoma|Malignant Brain Tumor|Neoplasm, Neuroepithelial|Neuroectodermal Tumors|Neoplasm by Histologic Type|Neoplasm, Nerve Tissue|Nervous System Diseases","Biological: DNX-2401|Biological: pembrolizumab","Objective response rate (ORR)|Overall survival (OS)|Time to tumor response|Duration of response","DNAtrix, Inc.|Merck Sharp & Dohme Corp.","All","18 Years and older   (Adult, Older Adult)","Phase 2","49","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2401BT-002P","June 2016","December 2020","June 2021","June 14, 2016",,"January 2, 2020","University of Arkansas for Medical Sciences (UAMS), Little Rock, Arkansas, United States|UCLA Medical Center, Los Angeles, California, United States|Northwestern University, Chicago, Illinois, United States|University of Minnesota Neurosurgery, Minneapolis, Minnesota, United States|Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Weill-Cornell Medicine New York-Presbyterian, New York, New York, United States|UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States|Cleveland Clinic, Cleveland, Ohio, United States|Ohio State University James Cancer Center, Columbus, Ohio, United States|Lehigh Valley Health Network, Allentown, Pennsylvania, United States|Texas Oncology Austin-Midtown, Austin, Texas, United States|MD Anderson Cancer Center, Houston, Texas, United States|Huntsman Cancer Institute, Salt Lake City, Utah, United States|University Health Network, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT02798406"
145,"NCT03164772","Phase 1/2 Study of Combination Immunotherapy and mRNA Vaccine in Subjects With NSCLC",,"Recruiting","No Results Available","Metastatic Non-small Cell Lung Cancer|NSCLC","Drug: Durvalumab|Drug: Tremelimumab|Biological: BI 1361849","Number of Adverse Events|Objective Response Rate (ORR)|Progression Free Survival (PFS)|Duration of Response (DoR)|Overall Survival (OS)","Ludwig Institute for Cancer Research|Cancer Research Institute, New York City|Boehringer Ingelheim|MedImmune LLC|CureVac AG|PharmaJet, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","56","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","LUD2014-012-VAC","December 20, 2017","March 2021","December 2024","May 24, 2017",,"March 10, 2020","Research Facility, Gilbert, Arizona, United States|Research Facility, Tampa, Florida, United States|Research Facility, Detroit, Michigan, United States|Research Facility, New York, New York, United States|Research Facility, Milwaukee, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT03164772"
146,"NCT02923934","A Phase II Trial of Ipilimumab and Nivolumab for the Treatment of Rare Cancers",,"Active, not recruiting","No Results Available","Gastrointestinal Cancer|Neuroendocrine Tumours|Malignant Female Reproductive System Neoplasm","Drug: Ipilimumab|Drug: Nivolumab","To determine the clinical efficacy of the combination treatment of ipilimumab with nivolumab in rare cancers.|To identify whether a common predictive biomarker or immune signature can be identified in responding patients that can occur irrespective of tumour type.","Olivia Newton-John Cancer Research Institute|Bristol-Myers Squibb","All","18 Years and older   (Adult, Older Adult)","Phase 2","120","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ONJ2016-001","August 22, 2017","August 2023","December 2023","October 5, 2016",,"February 12, 2020","Border Medical Oncology Unit, Albury, New South Wales, Australia|Blacktown Hospital, Sydney, New South Wales, Australia|Monash Health, Clayton, Victoria, Australia|Austin Health, Heidelberg, Victoria, Australia|Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia",,"https://ClinicalTrials.gov/show/NCT02923934"
147,"NCT03439891","Sorafenib and Nivolumab in Treating Participants With Unresectable, Locally Advanced or Metastatic Liver Cancer",,"Recruiting","No Results Available","Stage III Hepatocellular Carcinoma AJCC v8|Stage IIIA Hepatocellular Carcinoma AJCC v8|Stage IIIB Hepatocellular Carcinoma AJCC v7|Stage IIIC Hepatocellular Carcinoma AJCC v7|Stage IV Hepatocellular Carcinoma AJCC v8|Stage IVA Hepatocellular Carcinoma AJCC v8|Stage IVB Hepatocellular Carcinoma AJCC v8","Other: Laboratory Biomarker Analysis|Biological: Nivolumab|Drug: Sorafenib","Maximum tolerated dose (MTD) (Part 1)|Overall response rate (ORR) assessed using Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 (Part 2)|Duration of response (DOR)|Incidence of treatment-related adverse classified using NCI CTCAE version 4.03|ORR assessed by RECIST 1.1 for overall study|Overall survival (OS)|Progression-free survival (PFS)|Rate of immune-related adverse event (irAE) for combination","Robin Kate Kelley|Bayer|Bristol-Myers Squibb|University of California, San Francisco","All","18 Years and older   (Adult, Older Adult)","Phase 2","40","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","174523|NCI-2018-00051","April 16, 2018","May 31, 2022","May 31, 2022","February 20, 2018",,"March 31, 2020","University of California, Davis, Sacramento, California, United States|University of California, San Francisco, San Francisco, California, United States",,"https://ClinicalTrials.gov/show/NCT03439891"
148,"NCT03669523","Denosumab and Nivolumab Combination as 2d-line Therapy in Stage IV NSC Lung Cancer With Bone Metastases (DENIVOS)","DENIVOS","Recruiting","No Results Available","Carcinoma, Non-Small-Cell Lung|Bone Metastases","Drug: Denosumab-nivolumab combination","Overall Response Rate (ORR) according to the PD-L1-expression rate (threshold set at 1%)|Disease-control rate (DCR)|Overall survival|Progression-free survival|Overall Response Rate for the entire population|Overall Response Rate according to the histological type (adenocarcinoma versus squamous cell)|Time to the first Skeletal-Related Event in months|Incidence of adverse events, serious adverse events, deaths and biological abnormalities","Centre Hospitalier Annecy Genevois|French Lung Cancer Group","All","18 Years and older   (Adult, Older Adult)","Phase 2","86","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","P_2017_007|2018-001105-85","November 6, 2018","September 2022","December 2023","September 13, 2018",,"February 28, 2020","CH du Pays d'Aix, Aix-en-Provence, France|Chu Angers, Angers, France|Centre Hospitalier de La Cote Basque, Bayonne, France|Centre Hospitalier de Beauvais, Beauvais, France|Centre Hospitalier Fleyriat, Bourg-en-Bresse, France|CHU Morvan - Institut de Cancérologie et d'Hématologie, Brest, France|Centre François Baclesse, Caen, France|CH Intercommunal, Créteil, France|Ch Intercommunal Elbeuf Louvier Val de Reuil, Elbeuf, France|CH Intercommunal des Alpes du Sud, Gap, France|Hôpital Robert Boulin, Libourne, France|Chu Dupuytren, Limoges, France|CH régional, Longjumeau, France|CH F.Quesnay, Mantes-la-Jolie, France|CH Marne La Vallée, Marne-La-Vallée, France|Hopital Européen, Marseille, France|Hopital Nord APHM, Marseille, France|CH Meaux, Meaux, France|Centre Catalan d'Oncologie, Perpignan, France|CH Annecy-Genevois, Pringy, France|CHU Hôpital Pontchailloux, Rennes, France|CHU Rouen, Rouen, France|CHU La Réunion - Site de Bellepierre, Saint-Denis, France|Groupe Hospitalier Sud Réunion - CHU de la Réunion, Saint-Pierre, France|Institut de Cancérologie de la Loire, Saint-Priest-en-Jarez, France|CLCC Paul Strauss, Strasbourg, France|Centre Hospitalier de Bigorre, Tarbes, France|Hôpital d'Instruction des Armées Saint-Anne, Toulon, France|CHITS Toulon Sainte-Musse, Toulon, France|Hôpital André Mignot Centre Hospitalier de Versailles, Versailles, France|CH Villefranche sur Saone, Villefranche-sur-Saône, France",,"https://ClinicalTrials.gov/show/NCT03669523"
149,"NCT04212221","MGD013 Monotherapy and Combination With Brivanib Dose Escalation and Expansion Study in Advanced Liver Cancer Patients",,"Recruiting","No Results Available","Advanced Hepatocellular Carcinoma (HCC)","Drug: MGD013 monotherapy|Drug: MGD013 in combination with Brivanib Alaninate","Dose-limiting toxicities (DLTs)|Adverse Events Assessed by CTCAE Criteria|Objective response rate (ORR)|Disease control rate (DCR)|Time to tumor progression (TTP)|Duration of response (DoR)|Progression-free survival (PFS)|Overall survival (OS)","Zai Lab (Shanghai) Co., Ltd.","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1|Phase 2","300","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ZL-MGD013-202","April 20, 2020","December 2022","June 2023","December 26, 2019",,"April 24, 2020","Prince of Wales Hospital, Hong Kong, Hong Kong, China",,"https://ClinicalTrials.gov/show/NCT04212221"
150,"NCT03740893","PHOENIX DDR/Anti-PD-L1 Trial: A Pre-surgical Window of Opportunity and Post-surgical Adjuvant Biomarker Study of DNA Damage Response Inhibition and/or Anti-PD-L1 Immunotherapy in Patients With Neoadjuvant Chemotherapy Resistant Residual Triple Negative Breast Cancer","PHOENIX","Recruiting","No Results Available","Breast Neoplasm","Drug: AZD6738|Drug: Olaparib|Drug: Durvalumab","Cohorts B and C co-primary endpoint #1: Change in mean proliferation index (as measured by tumour cell Ki67 immunohistochemistry) post WOP intervention within post-treatment biopsy compared to pre-treatment baseline biopsy.|Cohorts B and C co-primary endpoint #2: Changes in the proliferation gene expression signature post WOP intervention within the post-treatment biopsy compared to pre-treatment baseline biopsy.|Cohort D co-primary endpoint #1: Change in CD8+ TILs post anti-PD-L1 immunotherapy within the post-treatment biopsy compared to pre-treatment baseline biopsy, assessed using immunohistochemistry.|Cohort D co-primary endpoint #2: Changes in the interferon gamma-positive (IFNγ+) signature post WOP intervention within the post-treatment biopsy compared to pre-treatment baseline biopsy.|Incidence of adverse events during trial treatment|Changes in phosphorylation of ATR and its downstream effectors|Changes in biomarkers of DNA Damage Response (DDR) and adaptive and innate response|Assessment of associated expression of co‐inhibitory immune checkpoint receptors|Assessment of associated expression of co‐inhibitory immune checkpoint ligands|Assessment of frequency and function of tumour‐infiltrating lymphocyte subsets|Assessment of frequency and function of tumour‐infiltrating myeloid cells subsets|Changes in the levels of Th1/IFNg response|Immune cell population sub-set characterisation|Assess change in Ki67+:CD8+ ratio within the post-treatment biopsy sample compared to pre-treatment baseline biopsy.","Institute of Cancer Research, United Kingdom|AstraZeneca","All","18 Years and older   (Adult, Older Adult)","Phase 2","81","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","ICR-CTSU/2017/10065|2018-002077-21","October 15, 2019","March 2023","December 2025","November 14, 2018",,"February 21, 2020","Royal Bournemouth Hospital, Bournemouth, Dorset, United Kingdom|Bristol Haematology and Oncology Centre, Bristol, England, United Kingdom|King's College Hospital, London, England, United Kingdom|Christie Hospital NHS Trust, Manchester, England, United Kingdom|Belfast City Hospital, Belfast, Northern Ireland, United Kingdom|Velindre Cancer Center at Velinde Hospital, Cardiff, Wales, United Kingdom|Queen Elizabeth Hospital, University Hospitals Birmingham NHS Trust, Birmingham, United Kingdom|Guy's and St Thomas' Hospital NHS Foundation Trust, London, United Kingdom|Weston Park Hospital, Sheffield, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03740893"
151,"NCT04301011","Study of TBio-6517, Given Intratumorally, Alone or in Combination With Pembrolizumab, in Solid Tumors","RAPTOR","Not yet recruiting","No Results Available","Solid Tumor|Triple Negative Breast Cancer|Microsatellite Stable Colorectal Cancer","Biological: TBio-6517|Biological: Pembrolizumab","Incidence of adverse events when TBio-6517 administered by direct injection into tumor(s) alone at each dose level|Incidence of adverse events when TBio-6517 administered by direct injection into tumor(s) when combined with pembrolizumab|Maximum tolerated dose (MTD) or Maximum feasible dose (MFD) and determination of the recommended Phase 2 dose (RP2D) of TBio-6517 alone and in combination with pembrolizumab.|Percentage of overall response rate (ORR) by RECIST 1.1 at the RP2D|Percentage of overall response rate (ORR) by immunotherapy RECIST (iRECIST) at the RP2D|Number and severity of adverse events at the RP2D|Median overall survival (OS)|Median Duration of Response (DoR)|Proportion of patients with a response (ORR)|Median Disease Control Rate (DCR)|Time to tumor progression (TTP)|Median progression free survival","Turnstone Biologics, Corp.|Takeda","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","84","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TBio-6517-ITu-001","April 20, 2020","August 20, 2022","December 30, 2022","March 9, 2020",,"March 9, 2020","Mayo Clinic, Phoenix, Arizona, United States|Mayo Clinic, Jacksonville, Florida, United States|Sylvester Comprehensive Cancer Center / UMHC, Miami, Florida, United States|University of Kansas Medical Center, Kansas City, Kansas, United States|Mayo Clinic, Rochester, Minnesota, United States|The Billings Clinic, Billings, Montana, United States|University of Texas MD Anderson Cancer Center, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT04301011"
152,"NCT03945773","Study of Cabozantinib as 2nd Line Treatment in Subjects With Locally Advanced or Metastatic Renal Cell Carcinoma (RCC) With a Clear-Cell Component Who Progressed After 1st Line Treatment With Checkpoint Inhibitors","CaboPoint","Recruiting","No Results Available","Locally Advanced or Metastatic Renal Cell Carcinoma","Drug: Cabozantinib","Objective response rate (ORR)|Time to response (TTR)|Duration of response (DOR)|Disease control rate (DCR)|Progression-free survival (PFS)|Change in disease-related symptoms|Overall survival (OS)","Ipsen","All","18 Years and older   (Adult, Older Adult)","Phase 2","250","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","F-FR-60000-023|2018-002820-18","January 8, 2020","February 1, 2022","January 1, 2023","May 10, 2019",,"May 29, 2020","Medical University of Vienna AKH, Vienna, Austria|CHRU Besançon, Besançon, France|CHU Bordeaux Saint André, Bordeaux, France|Centre Jean Perrin, Clermont-Ferrand, France|Centre Léon Bérard, Lyon, France|Institut Paoli Calmettes, Marseille, France|CHU de Nîmes - Institut de Cancérologie du Gard, Nîmes, France|Institut Mutualiste Montsouris, Paris, France|Hôpital Georges Pompidou, Paris, France|Centre Hospitalier Lyon Sud, Pierre-Bénite, France|Institut de Cancérologie de l'Ouest, Saint-Herblain, France|CHU Strasbourg, Strasbourg, France|Institut Claudius Régaud, Toulouse, France|CHU Bretonneau, Tours, France|Gustave Roussy, Villejuif, France|Universitätsmedzin Charité, Berlin, Germany|University Hospital Carl Gustav Carus Dresden, Dresden, Germany|University Clinic Erlanger, Erlangen, Germany|Universitätsklinikum Essen, Essen, Germany|Klinikum der J.W. Goethe, Frankfurt, Germany|University Cancer Center Hamburg Eppendorf, Hamburg, Germany|Medizinische Hochschule Hannover, Hannover, Germany|Klinikum Der Friedrich-Schiller-Universitaet Jena, Jena, Germany|Universitätsklinikum Schleswig-Holstein, Lübeck, Germany|Otto-von-Guericke-Universität University hospital Magdeburg, Magdeburg, Germany|University, Hospital Münster, Münster, Germany|Caritas Krankenhaus St.Josef Klinik für Urologie, Regensburg, Germany|University Hospital Tuebingen, Tübingen, Germany",,"https://ClinicalTrials.gov/show/NCT03945773"
153,"NCT03281369","A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) or Esophageal Cancer (Morpheus-Gastric and Esophageal Cancer)",,"Recruiting","No Results Available","Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma or Esophageal Carcinoma","Drug: 5-Fluorouracil (5-FU)|Drug: Leucovorin|Drug: Oxaliplatin|Drug: Atezolizumab|Drug: Cobimetinib|Biological: Ramucirumab|Drug: Paclitaxel|Biological: PEGylated recombinant human hyaluronidase (PEGPH20)|Drug: BL-8040|Drug: Linagliptin|Drug: Cisplatin|Drug: Tiragolumab","Percentage of Participants With Objective Response, as Determined by Investigator According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 (v1.1)|Percentage of Participants with Adverse Events (AEs)|For Arm 1L-A : Percentage of Participants with Serious and Non-serious Treatment-related AEs|Progression-Free Survival (PFS), as Determined by Investigator According to RECIST v1.1|Overall Survival (OS)|Percentage of Participants Who Are Alive at Month 6 and at Month 12|Duration of Response, as Determined by Investigator According to RECIST v1.1|Percentage of Participants With Disease Control, as Determined by the Investigator per RECIST v1.1|Serum Concentration of Atezolizumab|Plasma Concentration of Cobimetinib|Plasma Concentration of PEGPH20|Plasma Concentration of BL-8040|Plasma Concentration of Linagliptin|Percentage of Participants With Anti-Drug Antibody (ADA) to Atezolizumab|Percentage of Participants With ADA to PEGPH20|Percentage of Participants With ADA to BL-8040|Percentage of Participants With Objective Response, in Participants with TIGIT-Positive Tumors by IHC (Esophageal Cancer Cohort Only)|Percentage of Participants With Objective Response, in Participants With PD-L1 IC/TC-Positive Tumors by IHC (Esophageal Cancer Cohort Only)","Hoffmann-La Roche|Halozyme Therapeutics|BioLineRx, Ltd.","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","410","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","YO39609|2016-004529-17","October 13, 2017","November 13, 2021","November 13, 2021","September 13, 2017",,"May 20, 2020","Mayo Clinic Cancer Center, Scottsdale, Arizona, United States|Uni of Southern California; Norris Comprehensive Cancer Ctr, Los Angeles, California, United States|Dana-Farber Cancer Institute - Gastrointestinal Cancer Treatment Center, Boston, Massachusetts, United States|Mayo Clinic - Rochester; Breast Cancer Center, Rochester, Minnesota, United States|Columbia University Medical Center, New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Tennessee Oncology, Nashville, Tennessee, United States|The University of Texas MD Anderson Cancer Center, Houston, Texas, United States|Gustave Roussy Cancer Campus, Villejuif, France|Universitaetsklinikum Essen; Westdeutsches Tumorzentrum; Innere Klinik (Tumorforschung), Essen, Germany|Krankenhaus Nordwest GmbH - Institut Fuer Klinisch-Onkologische Forschung (IKF), Frankfurt am Main, Germany|Universitatsklinik Heidelberg; Universitätshautklinik und Nationales Centrum für Tumorerkrankungen, Heidelberg, Germany|Seoul National University Hospital (SNUH) - Medical Oncology Center, Jongno -Gu, Korea, Republic of|Yonsei University College of Medicine (YUCM)-Yonsei Cancer Center; Cancer Metastasis Research Center, Seodaemun-Gu, Korea, Republic of|Seoul National University Bundang Hospital, Seongnam-si, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|University of Ulsan College of Medicine - Asan Medical Center (AMC) - Asan Cancer Center (ACC), Songpa-gu, Korea, Republic of|The Catholic University of Korea St. Vincent's Hospital, Suwon-si,, Korea, Republic of|Het Nederlands Kanker Instituut Antoni Van Leeuwenhoek Ziekenhuis, Amsterdam, Netherlands|Universidad de Navarra - Clinica Universitaria de Navarra (CUN), Pamplona, Navarra, Spain|Hospital Universitari Vall dHebron; Oncology, Barcelona, Spain|National Cheng Kung University Hospital, Tainan, Taiwan|Taipei Veterans General Hospital, Taipei City, Taiwan|National Taiwan University Hospital (NTUH) - Cancer Research Center, Zhongzheng Dist., Taiwan|The Royal Marsden, London, United Kingdom|The Royal Marsden NHS Foundation Trust - Royal Marsden Hospital (RMH) - Sutton, Sutton, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03281369"
154,"NCT03865511","MEchanisms of Resistance in EGFR Mutated Nonpretreated Advanced Lung Cancer Receiving OSimErtib","MELROSE","Recruiting","No Results Available","Non-small Cell Lung Cancer","Drug: TAGRISSO® 80mg (Osimertinib)|Genetic: Tumor biopsies|Genetic: ctDNA analysis","Examination of the genetic profile at the point of disease progression in EGFRm+ (mutated Epidermal Growth Factor Receptor) patients receiving osimertinib as first-line EGFR TKI therapy compared to baseline.|Clinical objective : To assess efficacy of Osimertinib|Clinical objective : To assess efficacy of Osimertinib: Duration of Response (DoR): Disease Control Rate (DCR)|Clinical objective : To assess safety of Osimertinib with Monitoring of Adverse events (grade 3 and 4)|Biological objective : To evaluate the consequence of osimertinib treatment on the expression of targets of immune check point inhibitors|Biological objective : To evaluate diagnostic accuracy of ctDNA to detect mutation|Biological objective : To observe if the presence of ctDNA at baseline is a prognostic factor of clinical progression disease|Biological objective : To demonstrate that the early kinetics of ctDNA is an indicator of response to osimertinib|Biological objective : To measure the biological progression (bPFS) in patients treated with osimertinib|Biological objective : To compare the genetic profile of the ctDNA and the tumor biopsy|Biological objective : To compare the kinetic of appearance of EGFR mutation and radiological and clinical progression disease","Nantes University Hospital|AstraZeneca","All","18 Years and older   (Adult, Older Adult)","Phase 2","66","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","RC18_0287","April 9, 2019","April 2024","July 2024","March 7, 2019",,"May 14, 2019","Crlcc Francois Baclesse, Caen, France|CH de Cholet, Cholet, France|CHD Vendée, La Roche-sur-Yon, France|CH Le Mans, Le Mans, France|Hôpital Calmette CHRU de Lille, Lille, France|AP-HM Hôpital Nord Marseille, Marseille, France|CH DU MOENCHSBERG - Hôpital Emile Muller, Mulhouse, France|CHU de Nantes, Nantes, France|Institut Curie, Paris, France|AP-HP Hôpital Tenon, Paris, France|Chru Pontchaillou, Rennes, France|Chits Ch Sainte Musse, Toulon, France",,"https://ClinicalTrials.gov/show/NCT03865511"
155,"NCT03959761","Tolerance of Intraperitoneal (IP) Nivolumab After Extensive Debulking Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Ovarian Carcinoma","ICONIC","Not yet recruiting","No Results Available","Ovarian Cancer","Drug: Intraperitoneal (IP) nivolumab infusion","Safety profile of the Intraperitoneal (IP) nivolumab treatment|Changes over time in disease progression|Changes in toxicity as assessed by the Common Terminology Criteria (CTC) scale- Surgery|Changes over time in toxicity as assessed by the Common Terminology Criteria (CTC) scale- Intraperitoneal (IP) nivlumab infusion|Changes in tolerance of post procedure intravenous (IV) chemotherapy- Surgery|Changes over time in tolerance of post procedure intravenous (IV) chemotherapy- Intraperitoneal (IP) nivlumab infusion","Hospices Civils de Lyon","Female","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","32","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","69HCL18_0802|2018-004408-21","July 31, 2019","January 31, 2021","November 30, 2021","May 22, 2019",,"May 24, 2019","Hospices Civils de Lyon, Lyon, France",,"https://ClinicalTrials.gov/show/NCT03959761"
156,"NCT04037462","Induction of Sensecence Using Dexamethasone to Re-sensitize NSCLC to Anti-PD1 Therapy",,"Not yet recruiting","No Results Available","Non-Small Cell Lung Cancer|Immunotherapy","Drug: Dexamthasone","Reduction in FLT-PET signal|Response rate","VA Office of Research and Development|Wayne State University|University of Michigan|Barbara Ann Karmanos Cancer Institute","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","39","U.S. Fed|Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CSDR-002-18F","August 1, 2020","July 31, 2022","April 1, 2024","July 30, 2019",,"May 11, 2020","VA Ann Arbor Healthcare System, Ann Arbor, MI, Ann Arbor, Michigan, United States",,"https://ClinicalTrials.gov/show/NCT04037462"
157,"NCT03337698","A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer)","Morpheus Lung","Recruiting","No Results Available","Carcinoma, Non-Small-Cell Lung","Drug: Atezolizumab|Drug: Cobimetinib|Drug: RO6958688|Drug: Docetaxel|Drug: CPI-444|Drug: Pemetrexed|Drug: Carboplatin|Drug: Gemcitabine|Drug: Linagliptin|Drug: Tocilizumab|Drug: Ipatasertib|Drug: Idasanutlin|Drug: Bevacizumab","Percentage of Participants with Objective Response|Progression Free Survival (PFS)|Overall Survival After Randomization|Percentage of Participants Who Are Alive at Month 6 and at Month 12|Duration of Response|Disease Control|Percentage of Participants with Adverse Events","Hoffmann-La Roche","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","305","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","BO39610|2017-001267-21","January 2, 2018","February 1, 2022","April 16, 2022","November 9, 2017",,"March 17, 2020","Smilow Cancer Hospital at Yale New Haven, New Haven, Connecticut, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Columbia University Medical Center; Research Pharmacy, Irving Pavillion, Ip 7-749, New York, New York, United States|Sarah Cannon Research Institute, Nashville, Tennessee, United States|Peter Mac Callum Cancer Center, East Melbourne, Victoria, Australia|Centre Léon Bérard, Lyon, France|Hopital de la Timone, Marseille, France|Institut Universitaire du Cancer de Toulouse-Oncopole; PHARMACIE, Toulouse, France|Rambam Medical Center; Oncology, Haifa, Israel|Rabin Medical Center, Petach Tikva, Israel|Chaim Sheba Medical Center; Oncology Dept, Ramat Gan, Israel|Seoul National University Hospital, Seoul, Korea, Republic of|Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of|University of Ulsan College of Medicine - Asan Medical Center (AMC) - Asan Cancer Center (ACC), Songpa-gu, Korea, Republic of|Clínica Universidad de Navarra, Pamplona, Navarra, Spain|Hospital Universitari Vall d'Hebron, Barcelona, Spain|Fundación Jimenez Díaz, Madrid, Spain|South Texas Accelerated Research Therapeutics Madrid - CIOCC - Universitario Sanchinarro, Madrid, Spain|Barts Cancer Institute, London, United Kingdom|Royal Marsden Hospital; Institute of Cancer Research, Sutton, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03337698"
158,"NCT03853317","QUILT-3.063: A Study of N-803, haNK and Avelumab in Patients With Merkel Cell Carcinoma That Has Progressed After Checkpoint Therapy",,"Recruiting","No Results Available","Merkel Cell Carcinoma","Biological: Avelumab|Biological: N-803|Biological: haNK™","Overall Response Rate (ORR)|Duration of Response (DOR)|PFS|Overall Survival (OS)|Disease-Specific Survival (DSS)|Disease Control Rate (DCR)|Quality of Life Questionnaire","NantKwest, Inc.|NantCell, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 2","43","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","QUILT-3.063","February 24, 2020","March 2022","March 2022","February 25, 2019",,"March 19, 2020","Chan Soon-Shiong Institute for Medicine, El Segundo, California, United States|University of Miami, Sylvester Comprehensive Cancer Center, Miami, Florida, United States|Miami Cancer Institute - Baptist Health, Miami, Florida, United States|Washington University School of Medicine in St. Louis, Saint Louis, Missouri, United States",,"https://ClinicalTrials.gov/show/NCT03853317"
159,"NCT04066595","Cabozantinib in Patients With Locally Advanced or Metastatic Urothelial Cell Carcinoma.","CabUC","Recruiting","No Results Available","Urothelial Carcinoma","Drug: Cabozantinib","Objective response rate after 6 months of cabozantinib treatment|Progression-free survival (PFS)|1-year survival|Overall survival|Clinical benefit rate|Response duration|Number of Participants with Adverse Events (AEs)|Number of Participants Who Discontinue Study Treatment Due to Adverse Events (AEs)","Johannes Gutenberg University Mainz|Interdisciplinary Center Clinical Trials (IZKS), University Medical Center Mainz","All","18 Years and older   (Adult, Older Adult)","Phase 2","88","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CabUC","February 10, 2020","September 30, 2023","September 30, 2024","August 26, 2019",,"February 13, 2020","Department of Urology of the University Medical Center Mainz, Mainz, Germany",,"https://ClinicalTrials.gov/show/NCT04066595"
160,"NCT02073123","Study of IDO Inhibitor in Combination With Checkpoint Inhibitors for Adult Patients With Metastatic Melanoma",,"Active, not recruiting","No Results Available","Metastatic Melanoma|Stage III Melanoma|Stage IV Melanoma","Drug: Indoximod|Drug: Ipilimumab|Drug: Nivolumab|Drug: Pembrolizumab","Overall Incidence of Adverse Events as a Measure of Safety and Tolerability|Phase 2 Dosing|Overall Response Rate|Number of Participants with Adverse Events as a Measure of Safety and Tolerability|Overall Survival|Mechanisms of activity/resistance to IDO/CTLA-4 inhibitor therapy|Progression Free Survival|Disease control rate","NewLink Genetics Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","132","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NLG2103","July 2014","January 17, 2018","June 13, 2019","February 27, 2014",,"April 25, 2019","Augusta University, Augusta, Georgia, United States|University of Iowa Hospital and Clinics, Iowa City, Iowa, United States|Mayo Clinic, Rochester, Minnesota, United States|New Mexico Cancer Center Alliance, Albuquerque, New Mexico, United States|Penn State Hershey Cancer Institue, Hershey, Pennsylvania, United States|Huntsman Cancer Institute, Salt Lake City, Utah, United States",,"https://ClinicalTrials.gov/show/NCT02073123"
161,"NCT03711188","A Study of IMM-101 in Combination With Checkpoint Inhibitor Therapy in Advanced Melanoma",,"Recruiting","No Results Available","Melanoma","Drug: Nivolumab|Drug: Ipilimumab|Drug: IMM-101","Overall Response Rate (ORR) using RECIST 1.1|The profile of adverse events experienced|Progression free survival (PFS)|Overall survival (OS)|Overall survival (OS) at one year|Patients with values outside normal range and within normal range at post baseline assessments|Local tolerability measured as injection site reactions","Immodulon Therapeutics Ltd","All","18 Years and older   (Adult, Older Adult)","Phase 2","26","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IMM-101-015","October 4, 2018","July 1, 2021","July 1, 2021","October 18, 2018",,"March 9, 2020","St George's University Hospitals NHS Foundation Trust, London, United Kingdom|The Christie Hospital, Manchester, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03711188"
162,"NCT03993379","PROCLAIM: CX-072-002: Study of PD-L1 Probody Therapeutic CX-072 in Combination With Other Anticancer Therapy in Adults With Solid Tumors",,"Active, not recruiting","No Results Available","Solid Tumor|Unresectable or Metastatic Melanoma","Drug: CX-072|Drug: Ipilimumab","Overall response rate by RECIST v 1,1|The percentage of patients experiencing Treatment Related Adverse Events|The numbers of patients experiencing anti-tumor activity by irRECIST","CytomX Therapeutics","All","18 Years and older   (Adult, Older Adult)","Phase 2","3","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CTMX-M-072-002","September 12, 2019","January 2021","January 2023","June 20, 2019",,"April 10, 2020","City of Hope National Medical Center, Duarte, California, United States|The Angeles Clinic and Research Institute, Los Angeles, California, United States|Beacon Cancer Care, Coeur d'Alene, Idaho, United States|University of Chicago, Chicago, Illinois, United States|Norton Cancer Institute, Louisville, Kentucky, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|NYC Cancer Institute, New York, New York, United States|Columbia Medical Center, New York, New York, United States|Oregon Health & Science Center, Portland, Oregon, United States|Providence Portland Medical Center, Portland, Oregon, United States|UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States|Inova Dwight and March Schar Cancer Institute, Fairfax, Virginia, United States|Virginia Cancer Specialists, Fairfax, Virginia, United States|Multicare Institute for Research and Innovation, Spokane, Washington, United States|Sunshine Coast University Private Hospital, Sunshine Coast, Queensland, Australia|Ballarat Oncology and Haematology Services, Wendouree, Victoria, Australia|Asan Medical Center, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Severance Hospital Yonsei University Health System, Seoul, Korea, Republic of|The Netherlands Cancer Institute, Amsterdam, Netherlands|University Medical Center Groningen, Groningen, Netherlands|ICO Hospitalet, Hospital Duran I Reynals, Barcelona, Spain|Hospital Clinic de Barcelona. Servicio Oncologia Medica, Barcelona, Spain|Hospital Universitario La Paz, Madrid, Spain|START- Madrid, Madrid, Spain|Clinica Universitaria de Navarra, Pamplona, Spain",,"https://ClinicalTrials.gov/show/NCT03993379"
163,"NCT03678883","9-ING-41 in Patients With Advanced Cancers",,"Recruiting","No Results Available","Cancer|Lymphoma|Pancreatic Cancer|Glioblastoma Multiforme|Sarcoma|Breast Cancer|Bladder Cancer|Renal Cancer|Ovarian Cancer|Refractory Cancer|Refractory Neoplasm|Refractory Non-Hodgkin Lymphoma|Refractory Brain Tumor|Pancreatic Adenocarcinoma|Resistant Cancer|Neoplasm Metastasis|Neoplasm of Bone|Neoplasm, Breast|Neoplasm of Lung|Neoplasms,Colorectal|Neoplasms Pancreatic|Malignant Glioma|Malignancies|Malignancies Multiple|Bone Metastases|Bone Neoplasm|Bone Cancer|Pancreas Cancer|Pancreatic Neoplasms|Breast Neoplasms","Drug: 9-ING-41|Drug: Gemcitabine - 21 day cycle|Drug: Doxorubicin.|Drug: Lomustine|Drug: Carboplatin.|Drug: Nab paclitaxel.|Drug: Paclitaxel.|Drug: Gemcitabine - 28 day cycle|Drug: Irinotecan","Parts 1/2: Number of participants with treatment-related adverse events as assessed by CTCAE v4.03","Actuate Therapeutics Inc.|Developmental Therapeutics Consortium","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","350","Industry|Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1801","January 4, 2019","November 2022","November 2022","September 20, 2018",,"May 28, 2020","UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States|Miami Cancer Institute, Miami, Florida, United States|Moffitt Cancer Center, Tampa, Florida, United States|Winship Cancer Institute, Atlanta, Georgia, United States|Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois, United States|Kansas University Cancer Center, Kansas City, Kansas, United States|University of Michigan, Ann Arbor, Michigan, United States|Mayo Clinic, Rochester, Minnesota, United States|Rhode Island Hospital, Providence, Rhode Island, United States|Sanford Research, Sioux Falls, South Dakota, United States|Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States|Fred Hutchinson Cancer Research Center, Seattle, Washington, United States|Netherlands Cancer Institute, Amsterdam, Netherlands",,"https://ClinicalTrials.gov/show/NCT03678883"
164,"NCT03349450","DPX-Survivac and Checkpoint Inhibitor in DLBCL","SPiReL","Recruiting","No Results Available","Adult Diffuse Large Cell Lymphoma|Recurrent|Adult Refractory Diffuse Large B-Cell Lymphoma","Biological: DPX-Survivac|Biological: Pembrolizumab|Drug: Cyclophosphamide 50mg","To document the objective response rate using modified Cheson criteria to treatment with DPX-Survivac and low dose cyclophosphamide administered together with Pembrolizumab in participants with recurrent, survivin-expressing B cell lymphomas|To document changes in tumour volume using waterfall analyses|To document the toxicity profile|To document duration of response using modified Cheson criteria.|To document time to next treatment","Sunnybrook Health Sciences Centre|ImmunoVaccine Technologies, Inc. (IMV Inc.)|Merck Sharp & Dohme Corp.","All","18 Years and older   (Adult, Older Adult)","Phase 2","25","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","0891","March 13, 2018","May 2020","May 2021","November 21, 2017",,"July 24, 2019","Tom Baker Cancer Centre - Alberta Health Services, Calgary, Alberta, Canada|Nova Scotia Health Authority: Queen Elizabeth II Health Sciences Centre, Halifax, Nova Scotia, Canada|Ottawa Hospital Research Institute, Ottawa, Ontario, Canada|Sunnybrook Health Sciences Centre, Odette Cancer Centre, Toronto, Ontario, Canada|McGill University Health Centre, Montréal, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT03349450"
165,"NCT03332498","Pembrolizumab in Combination With Ibrutinib for Advanced, Refractory Colorectal Cancers",,"Active, not recruiting","No Results Available","Colon Cancer|Colorectal Cancer|Colorectal Carcinoma|Colon Disease","Drug: Pembrolizumab|Drug: Ibrutinib","Phase I - Recommended Phase II Dose (RP2D)|Phase II - Disease Control Rate at 4 Months","H. Lee Moffitt Cancer Center and Research Institute|Janssen Scientific Affairs, LLC|Merck Sharp & Dohme Corp.","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","40","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MCC-19091","January 24, 2018","February 2021","February 2022","November 6, 2017",,"February 6, 2020","H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States",,"https://ClinicalTrials.gov/show/NCT03332498"
166,"NCT01870596","Cytarabine With or Without SCH 900776 in Treating Adult Patients With Relapsed Acute Myeloid Leukemia",,"Completed","Has Results","Adult Acute Megakaryoblastic Leukemia|Adult Acute Monoblastic Leukemia|Adult Acute Monocytic Leukemia|Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11|Adult Acute Myeloid Leukemia With Maturation|Adult Acute Myeloid Leukemia With Minimal Differentiation|Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); RUNX1-RUNX1T1|Adult Acute Myeloid Leukemia With t(9;11)(p22;q23); MLLT3-MLL|Adult Acute Myeloid Leukemia Without Maturation|Adult Acute Myelomonocytic Leukemia|Adult Erythroleukemia|Adult Pure Erythroid Leukemia|Alkylating Agent-Related Acute Myeloid Leukemia|Recurrent Adult Acute Myeloid Leukemia","Drug: Cytarabine|Drug: CHK1 Inhibitor SCH 900776|Other: Laboratory Biomarker Analysis","Response Rate(CR/CRi) Rate","National Cancer Institute (NCI)","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","32","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NCI-2013-01097|J1319|9362|U01CA070095|P30CA006973","May 2013","December 2014","December 2014","June 6, 2013","September 1, 2016","September 1, 2016","Mayo Clinic in Arizona, Scottsdale, Arizona, United States|Blood and Marrow Transplant Group of Georgia, Atlanta, Georgia, United States|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Hospital, Baltimore, Maryland, United States|Johns Hopkins University/Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States|Mayo Clinic, Rochester, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT01870596"
167,"NCT02797977","A Phase 1/2 Trial of SRA737 in Combination With Gemcitabine Plus Cisplatin or Gemcitabine Alone in Subjects With Advanced Cancer",,"Active, not recruiting","No Results Available","Advanced Solid Tumors","Drug: SRA737, gemcitabine, cisplatin|Drug: SRA737, gemcitabine","Number of subjects with adverse events as assessed by CTCAE4.03|Maximum tolerated dose of SRA737 administered in combination with gemcitabine|Recommended Phase 2 dose of SRA737 in combination with gemcitabine.","Sierra Oncology, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","153","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SRA737-02","July 2016","January 2020","March 2020","June 14, 2016",,"January 3, 2020","Hospital Universitario Vall d'Hebron, Barcelona, Spain|Hospital Clinic de Barcelona, Barcelona, Spain|START Madrid, Madrid, Spain|Hospital Universitario 12 de Octobre, Madrid, Spain|Hospital Universitario Virgen de la Victoria, Málaga, Spain|Biomedical Research Institute INCLIVA, Valencia, Spain|Royal Marsden Hospital, Sutton, London, United Kingdom|Belfast City Hospital, Belfast, Northern Ireland, United Kingdom|Oxford University Hospitals, Headington, Oxford, United Kingdom|Velindre Cancer Centre, Cardiff, Whitchurch, United Kingdom|The Clatterbridge Cancer Centre, Bebington, Wirral, United Kingdom|The Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom|Leeds Teaching Hospital of St James University Hospital, Leeds, United Kingdom|University Hospital of Leceister NHS TRUST, Leicester, United Kingdom|Guy's and St Thomas', London, United Kingdom|Sarah Cannon Research Institute, London, United Kingdom|University College London, London, United Kingdom|The Christie NHS Foundation Trust, Manchester, United Kingdom|Freeman Hospital, Newcastle upon Tyne, United Kingdom|Sheffield Teaching Hospitals, Sheffield, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02797977"
168,"NCT03633110","Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine",,"Active, not recruiting","No Results Available","Cutaneous Melanoma|Non-small Cell Lung Cancer|Squamous Cell Carcinoma of the Head and Neck|Urothelial Carcinoma|Renal Cell Carcinoma","Biological: GEN-009 Adjuvanted Vaccine|Drug: Nivolumab|Drug: Pembrolizumab","Incidence of Treatment-Emergent Adverse Events|T-cell responses to GEN-009 adjuvanted vaccine|Antitumor activity of GEN-009 in Part B","Genocea Biosciences, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","99","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GEN-009-101","August 29, 2018","December 2022","December 2022","August 16, 2018",,"May 6, 2020","UC San Diego Moores Cancer Center, La Jolla, California, United States|John Wayne Cancer Institute - Providence Saint John's Health Center, Santa Monica, California, United States|University of Colorado, Anschutz Cancer Pavilion, Aurora, Colorado, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Karmanos Cancer Institute, Detroit, Michigan, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|Columbia University Medical Center - Herbert Irving Pavilion, New York, New York, United States|Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States|The Sarah Cannon Research Institute, Nashville, Tennessee, United States|The University of Texas MD Anderson Cancer Center, Houston, Texas, United States|University of Wisconsin Carbone Cancer Center, Madison, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT03633110"
169,"NCT04356872","The Combination of Sintilimab and AI (Doxorubicin, ADM/Ifosfamide, IFO) for the First Line Treatment of Select Type of Metastatic/Unresectable Soft Tissue Sarcoma",,"Recruiting","No Results Available","Sarcoma, Soft Tissue","Drug: Sintilimab|Drug: Doxorubicin Hydrochloride|Drug: Ifosfamide","overall response rate, ORR|progression free survival, PFS|adverse events, AE|overall survival, OS","Fudan University|Zhejiang Cancer Hospital|Tongji Hospital|Xijing Hospital|Shanghai Zhongshan Hospital","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","45","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SAIS","April 8, 2020","March 30, 2022","March 30, 2023","April 22, 2020",,"April 22, 2020","Fudan University, Cancer Hospital, Shanghai, Shanghai, China",,"https://ClinicalTrials.gov/show/NCT04356872"
170,"NCT03377400","Definitive CCRT Combined With Durvalumab and Tremelimumab for Inoperable Esophageal Cancer",,"Active, not recruiting","No Results Available","Esophageal Squamous Cell Carcinoma","Drug: Durvalumab","Progression-free survival","Samsung Medical Center","All","19 Years and older   (Adult, Older Adult)","Phase 2","40","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SMC 2017-06-138","December 14, 2017","December 30, 2020","June 30, 2021","December 19, 2017",,"December 10, 2019","Samsung Medical Center, Seoul, MA, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT03377400"
171,"NCT03108495","Study of LN-145, Autologous Tumor Infiltrating Lymphocytes in the Treatment of Patients With Cervical Carcinoma",,"Recruiting","No Results Available","Cervical Carcinoma","Biological: LN-145|Biological: LN-145 + pembrolizumab","Cohort 1: Objective Response Rate|Cohort 2: Objective Response Rate|Cohort 3: Adverse Events|Cohort 4: Efficacy and Adverse Events|Cohort 5: Efficacy and Adverse Events|Cohort 1: Duration of Response|Cohort 2: Duration of Response|Cohort 3: Objective Response Rate|Cohort 3: Duration of Response|Cohort 1: Disease Control Rate|Cohort 2: Disease Control Rate|Cohort 3: Disease Control Rate|Cohort 1: Progression-Free Survival|Cohort 2: Progression-Free Survival|Cohort 3: Progression-Free Survival|Cohort 1: Overall Survival|Cohort 2: Overall Survival|Cohort 3: Overall Survival|Cohort 1: Adverse Events|Cohort 2: Adverse Events","Iovance Biotherapeutics, Inc.","Female","18 Years and older   (Adult, Older Adult)","Phase 2","138","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","C-145-04|2016-003447-11","June 22, 2017","December 2021","December 2026","April 11, 2017",,"May 15, 2020","St. Joseph's Hospital and Medical Center Center For Women's Health, Phoenix, Arizona, United States|University of Southern California, Los Angeles, California, United States|University of California San Diego, San Diego, California, United States|Sylvester Comprehensive Cancer Center, Miami, Florida, United States|University of Florida Health Cancer Center, Orlando, Florida, United States|University of South Florida H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States|Augusta University, Augusta, Georgia, United States|University of Chicago, Chicago, Illinois, United States|James Graham Brown Cancer Center, Louisville, Kentucky, United States|LSU Health Sciences Center, New Orleans, Louisiana, United States|The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States|Karmanos Cancer Institute, Detroit, Michigan, United States|Rutgers University, Newark, New Jersey, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|Cleveland Clinic, Cleveland, Ohio, United States|The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States|UPMC Cancer Center, Pittsburgh, Pennsylvania, United States|MD Anderson Cancer Center, Houston, Texas, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States|Centre Hospitalier Lyon Sud, Pierre Bénite, Rhone-alpes, France|Centre Léon Bérard, Lyon, France|Gustave Roussy Cancer Campus, Villejuif Cedex, France|Universitätsklinikum Erlangen, Erlangen, Bayern, Germany|Universitätsklinikum Carl Gustav Carus, Dresden, Sachsen, Germany|Istituto Europeo di Oncologia, Miano, Milano, Italy|Academisch Medisch Centrum, Amsterdam, AZ, Netherlands|Clínica Universidad de Navarra, Pamplona, Navarra, Spain|Hospital Universitari Vall d'Hebrón, Barcelona, Spain|Institut Català d'Oncologia, Barcelona, Spain|Hospital General Universitario Gregorio Marañon, Madrid, Spain|Hospital Universitario Madrid Sanchinarro, Madrid, Spain|Inselspital, Bern, Switzerland|Centre Hospitalier Universitaire Vaudois Lausanne - Centre Pluridisciplinaire d'Oncologie, Lausanne, Switzerland|Bristol Haematology and Oncology Centre, Bristol, England, United Kingdom|Sarah Cannon Research Institute London, London, England, United Kingdom|University College London Hospitals NHS Foundation Trust, London, England, United Kingdom|NHS Greater Glasgow and Clyde, Glasgow, Scotland, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03108495"
172,"NCT02690948","Pembrolizumab With or Without Vismodegib in Treating Metastatic or Unresectable Basal Cell Skin Cancer",,"Completed","Has Results","Skin Basal Cell Carcinoma","Biological: Pembrolizumab|Drug: Vismodegib","Overall Response Rate (ORR)|Percentage of Participants Experiencing Adverse Events|Related Adverse Events|Duration of Response (DOR)|Overall Survival (OS)|Progression-free Survival (PFS)","Anne Chang|Merck Sharp & Dohme Corp.|National Cancer Institute (NCI)|Stanford University","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","16","Other|Industry|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB-34925|NCI-2015-01869|350|P30CA124435|SKIN0031","February 1, 2016","November 30, 2017","August 29, 2018","February 24, 2016","March 8, 2019","March 8, 2019","Stanford University School of Medicine, Palo Alto, California, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/48/NCT02690948/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02690948"
173,"NCT04034225","Addition of SNS-301 to Ongoing Checkpoint Inhibitor Treatment in Metastatic/Recurrent SCCHN",,"Recruiting","No Results Available","Squamous Cell Carcinoma of the Head and Neck","Drug: SNS-301|Drug: Pembrolizumab","Adverse events of SNS-301 in addition to pembrolizumab|Objective response rate by RECIST and iRECIST|Duration of response by RECIST 1.1 and iRECIST|Disease control rate by RECIST 1.1 and iRECIST|Progression free survival by RECIST 1.1 and iRECIST|Overall survival|Antigen-specific response|T cell and B cell activation response|Myeloid derived suppressor cell analysis|TCR sequencing|Immune gene transcript profiling|Profiling of pro-inflammatory/immunosuppressive molecules","Sensei Biotherapeutics, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","30","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SNS-301-2-2","November 11, 2019","February 1, 2021","February 1, 2022","July 26, 2019",,"May 26, 2020","University of California - San Francisco, San Francisco, California, United States|Christiana Care, Newark, Delaware, United States|Georgetown University, Washington, District of Columbia, United States|Emory University, Atlanta, Georgia, United States|Rush University, Chicago, Illinois, United States|Washington University, Saint Louis, Missouri, United States|Mt. Sinai, New York, New York, United States|New Orleans Clinical Research, Knoxville, Tennessee, United States|University of Wisconsin, Madison, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT04034225"
174,"NCT02718820","Pembrolizumab Plus Docetaxel for the Treatment of Recurrent or Metastatic Head and Neck Cancer",,"Active, not recruiting","No Results Available","Head and Neck Carcinoma","Drug: Docetaxel|Drug: Pembrolizumab","Overall response rate|Best overall response categories i.e. complete response (CR), partial response (PR), stable disease (SD) and progressive disease (PD) given in percentages of the total study population|Individual duration of response over time|To report changes in the in health-related quality-of-life scores per patient measured according to the European Organisation for Research and Treatment of Cancer (EORTC) quality of life questionnaire (QLQ) C-30 scoring manual|To report changes in the in health-related quality-of-life scores per patient measured according to the European Organisation for Research and Treatment of Cancer (EORTC) quality of life questionnaire (QLQ) H&N35 scoring manual|Median Overall Survival (OS)|Number of participants with treatment-related adverse events as assessed by CTCAE v4.0|Median Progression Free Survival (PFS)","Medical University of Vienna","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","22","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PemDoc II","March 2016","August 2020","August 2020","March 24, 2016",,"February 7, 2020","Medical University of Vienna, Vienna, Austria",,"https://ClinicalTrials.gov/show/NCT02718820"
175,"NCT03944915","De-Escalation Therapy for Human Papillomavirus Negative Disease","DEPEND","Recruiting","No Results Available","Human Papilloma Virus|Squamous Cell Carcinoma|Squamous Cell Carcinoma of the Head and Neck|HPV-Related Squamous Cell Carcinoma|HNSCC","Drug: Carboplatin|Drug: Paclitaxel|Drug: Nivolumab|Radiation: Radiation|Drug: Hydroxyurea Pill|Drug: 5-fluorouracil|Drug: Filgrastim Injection|Drug: Cisplatin","Deep Response Rate (DRR)|Progression Free Survival rate (PFS)|Overall Survival rate (OS)|Locoregional control after completing chemoradiation|Distant control after completing chemoradiation","University of Chicago","All","18 Years and older   (Adult, Older Adult)","Phase 2","36","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB19-0162","August 26, 2019","July 1, 2022","July 1, 2024","May 10, 2019",,"October 9, 2019","University Of Chicago Medicine Comprehensive Cancer Center, Chicago, Illinois, United States",,"https://ClinicalTrials.gov/show/NCT03944915"
176,"NCT03728465","Evaluation of Safety and Efficacy of Patients With Four and More Symptomatic Brain Metastases of Melanoma",,"Recruiting","No Results Available","Metastatic Melanoma|Brain Metastases","Biological: Nivolumab|Biological: Ipilimumab","Intracranial Control Rate after 6 months of treatment|Overall survival|Progression-free survival|Stereotactic irradiation or surgery of brain metastases after partial tumor remission|Tolerability according to NCI-CTCAE-Criteria|Best Overall Response Rate with Complete Respone (CR)|Best Overall Response Rate with Partial Response (PR)|Cognitive function evaluation by standardized diagnostic procedures|Quality of life evaluation with RAND 36-Item Health Survey 1.0","University Hospital Tuebingen","All","18 Years and older   (Adult, Older Adult)","Phase 2","68","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CA209-429","April 10, 2018","September 2021","September 2024","November 2, 2018",,"November 6, 2018","Elbe Kliniken Stade - Buxtehude GmbH, Buxtehude, Germany|Universitätsklinik Carl Gustav Carus Dresden, Dresden, Germany|HELIOS Klinikum Erfurt, Erfurt, Germany|Universitätsklinikum Essen, Essen, Germany|Universitätsklinikum Heidelberg, Heidelberg, Germany|Gesellschaft für Klinische Forschung Ludwigshafen mbH, Ludwigshafen, Germany|Universitätsklinikum Mannheim, Mannheim, Germany|Klinikum rechts der Isar, München, Germany|Harzklinikum Dorothea Christiane Erxleben GmbH, Quedlinburg, Germany|Universitätsklinikum Regensburg, Regensburg, Germany|Universitätsklinikum Tübingen, Tübingen, Germany",,"https://ClinicalTrials.gov/show/NCT03728465"
177,"NCT03780608","This Study is a Phase II Study of AZD6738 in Combination With Durvalumab in Patients With Solid Tumor (Cohort A (N=30): GC Who Have Failed Secondary Chemotherapy Treatments Regimen; Cohort B (B=30): Melanoma Patients Who Have Failed to IO)",,"Recruiting","No Results Available","Gastric Adenocarcinoma|Malignant Melanoma","Drug: AZD6738|Drug: Durvalumab","ORR","Samsung Medical Center","All","19 Years and older   (Adult, Older Adult)","Phase 2","60","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2018-07-075","July 30, 2019","December 1, 2020","December 1, 2021","December 19, 2018",,"December 30, 2019","Samsung Medical Center, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT03780608"
178,"NCT03754179","Dabrafenib/Trametinib/Hydroxychloroquine for Advanced Pretreated BRAF V600 Mutant Melanoma","COMBI-R2","Recruiting","No Results Available","Melanoma","Drug: Dabrafenib|Drug: Trametinib|Drug: Hydroxychloroquine","Ph. 1: incidence of adverse events of DAB, TRA and HCQ|Ph. 2 Arm A: objective response rate (ORR) of DAB, TRA and HCQ|Ph. 1: objective response rate (ORR) of DAB, TRA and HCQ|Ph. 1: progression-free survival (PFS) on DAB, TRA and HCQ|Ph. 1: overall survival (OS) on DAB, TRA and HCQ|Ph. 1: value of BRAF V600 mutant circulating tumor DNA (ctDNA) as a predictive and/or prognostic marker during treatment DAB, TRA and HCQ|Ph. 2 Arm B: objective response rate 1 (ORR 1) of DAB and TRA prior to the addition of HCQ at progression of disease|Ph. 2 Arm B: objective response rate 2 (ORR 2) of DAB and TRA following the addition of HCQ at progression of disease|Ph. 2 Arm A: progression-free survival (PFS) on DAB, TRA and HCQ|Ph. 2 Arm A: overall survival (OS) on DAB, TRA and HCQ|Ph. 2 Arm B: progression-free survival 1 (PFS 1) on DAB and TRA prior to the addition of HCQ|Ph. 2 Arm B: progression-free survival 2 (PFS 2) on DAB and TRA following the addition of HCQ|Ph. 2 Arm B: overall survival 1 (OS 1) on DAB and TRA prior to the addition of HCQ|Ph. 2 Arm B: overall survival 2 (OS 2) on DAB and TRA following the addition of HCQ|Ph. 2 Arm B: overall survival 3 (OS 3) on DAB and TRA following the addition of HCQ|Ph. 2 Arm A and B: incidence of adverse events of DAB, TRA and HCQ|Ph. 2 Arm A and B: value of BRAF V600 mutant circulating tumor DNA (ctDNA) as a predictive and/or prognostic marker during treatment with DAB, TRA and HCQ","Universitair Ziekenhuis Brussel|University Hospital, Ghent","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","63","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2017-BN-004","January 23, 2018","February 1, 2020","December 1, 2020","November 27, 2018",,"December 7, 2018","UZ Brussel, Jette, Brabant, Belgium",,"https://ClinicalTrials.gov/show/NCT03754179"
179,"NCT02054520","Immunotherapy Study for Patients With Stage IV Melanoma",,"Active, not recruiting","Has Results","Stage IV Melanoma|Metastatic Melanoma","Drug: HyperAcute®-Melanoma (HAM) Immunotherapy|Drug: Ipilimumab|Drug: Pembrolizumab|Drug: Nivolumab","Safety and Tolerability Assessed by Development of AEs and Laboratory Parameters|Clinical Response Rate|Clinical Activity|Anti-tumor Immune Response|Immune Activation|Anti-Tumor Mechanism","NewLink Genetics Corporation|Lumos Pharma","All","18 Years and older   (Adult, Older Adult)","Phase 2","47","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NLG0304|1303-1217","June 2014","April 5, 2018","May 1, 2033","February 4, 2014","April 29, 2020","May 28, 2020","Oncology Specialists, Niles, Illinois, United States|University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States|University of Kansas Cancer Center, Westwood, Kansas, United States|Wake Forest Baptist Health, Winston-Salem, North Carolina, United States|University of Tennessee Medical Center, Knoxville, Tennessee, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/20/NCT02054520/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02054520"
180,"NCT04134390","Study of Cabozantinib Efficacy, Safety and Tolerability in Metastatic Renal Carcinoma in Aged Fragile Patients: CABOMAYOR Study","CABOMAYOR","Recruiting","No Results Available","Old Age; Debility|Renal Carcinoma Metastatic","Drug: Cabozantinib","Objective Response Rate (ORR)|Incidence of Treatment-Emergent Adverse Events|Disease Control Rate (DCR)|Progression Free Survival (PFS)|Overall Survival (OS)","Spanish Oncology Genito-Urinary Group|Apices Soluciones S.L.","All","70 Years and older   (Older Adult)","Phase 2","50","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CABOMAYOR|2019-001639-30","February 17, 2020","December 2022","December 2022","October 22, 2019",,"March 2, 2020","Hospital de Ciudad Real, Ciudad Real, Spain|ICO L'Hospitalet, L'Hospitalet De Llobregat, Spain|Hospital Insular de Gran Canarias, Las Palmas De Gran Canaria, Spain|Hospital Lucus Augusti, Lugo, Spain|Hospital Infanta Sofia, Madrid, Spain|Hospital Universitario de Donostia, San Sebastián, Spain|Fundación Instituto Valenciano de Oncologia, Valencia, Spain|Hospital Doctor Peset, Valencia, Spain|Hospital Universitario La Fe, Valencia, Spain|Hospital Clinico de Valladolid, Valladolid, Spain",,"https://ClinicalTrials.gov/show/NCT04134390"
181,"NCT03354962","Induction of Immune-mediated aBscOpal Effect thrOugh STEreotactic Radiation Therapy in Metastatic Melanoma Patients Treated by PD-1 + CTLA-4 Inhibitors (BOOSTER MELANOMA)",,"Recruiting","No Results Available","Melanoma","Combination Product: Nivolumab + Ipilimumab|Combination Product: Combined treatment schema","Phase I: Dose Limiting Toxicities (DLT) incidence.|Phase I: Abscopal effect.|Phase II: The primary endpoint is the rate of patients alive without progression at 6 months.|Phase I: Safety will be evaluated using NCI CTCAE V4.03 criteria.|Phase II: Progression Free Survival (PFS) is defined as the time from inclusion until progression or death.|Phase II: Safety will be evaluated using NCI CTCAE V4.03.|Phase II: Pattern of response rate will be followed in irradiated and non-irradiated lesions separately by CT-scan evaluation using RECIST V1.1.","Institut Claudius Regaud","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","120","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","17 CUTA 11","October 15, 2018","September 2022","March 2024","November 28, 2017",,"August 8, 2019","Chu Bordeaux, Bordeaux, France|Centre Oscar Lambret, Lille, France|Centre Eugene Marquis, Rennes, France|Institut Universitaire du Cancer de Toulouse - Oncopole, Toulouse, France",,"https://ClinicalTrials.gov/show/NCT03354962"
182,"NCT03161756","Evaluation of Denosumab in Combination With Immune Checkpoint Inhibitors in Patients With Unresectable or Metastatic Melanoma","CHARLI","Recruiting","No Results Available","Melanoma Stage Iv|Melanoma Stage Iii|Melanoma","Drug: Denosumab|Drug: Nivolumab|Drug: Ipilimumab","Median Progression-Free Survival|Occurrence of Grade 3 and 4 Selected Immune-related Adverse Events (irAEs) of interest|Rate of Grade 3 and 4 irAEs|Best Overall Response According to RECIST 1.1|Progression-Free Survival|Overall Survival|Toxicity Profiles of the Checkpoint-Denosumab Combinations|Occurrence of Treatment Discontinuation Due to Toxicity","Melanoma and Skin Cancer Trials Limited|Peter MacCallum Cancer Centre, Australia|Amgen|Bristol-Myers Squibb","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","72","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","01.15","December 7, 2017","June 2021","June 2023","May 22, 2017",,"January 6, 2020","Border Medical Oncology Research Unit, Albury, New South Wales, Australia|Bendigo Health, Bendigo, New South Wales, Australia|Calvary Mater Newcastle, Waratah, New South Wales, Australia|Royal Brisbane and Women's Hospital, Herston, Queensland, Australia|Royal Hobart Hospital, Hobart, Tasmania, Australia|Box Hill Hospital, Box Hill, Victoria, Australia|Austin Health, Heidelberg, Victoria, Australia|Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia",,"https://ClinicalTrials.gov/show/NCT03161756"
183,"NCT03899428","Immune Checkpoint Therapy vs Target Therapy in Reducing Serum HBsAg Levels in Patients With HBsAg+ Advanced Stage HCC",,"Recruiting","No Results Available","Hepatocellular Carcinoma","Drug: Durvalumab|Drug: Sorafenib|Drug: Lenvatinib|Drug: Regorafenib|Drug: Cabozantinib","Time to decline to ≥ 2 log10 IU/mL of serum HBsAg|Time to loss of serum HBsAg|Time to development of anti-HBsAg|Progression-free survival (PFS) per RECIST 1.1|Objective response rate (ORR) per RECIST 1.1|Overall survival (OS)|Adverse events assessed in terms of seriousness, severity, and relationship to the study material according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0","Humanity & Health Medical Group Limited","All","18 Years and older   (Adult, Older Adult)","Phase 2","30","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","VICI-5","May 2, 2019","December 31, 2021","March 31, 2022","April 2, 2019",,"February 18, 2020","Humanity & Health Research Centre, Hong Kong, Hong Kong SAR, Hong Kong",,"https://ClinicalTrials.gov/show/NCT03899428"
184,"NCT03426657","Radiotherapy With Double Checkpoint Blockade of Locally Advanced HNSCC",,"Recruiting","No Results Available","Locally Advanced Head and Neck Squamous Cell Carcinoma","Combination Product: Durvalumab + Tremelimumab + RT","Assessment of the number of participants receiving the protocol treatment until cycle 6 of antibody treatment|Assessment of the predictive character of changes of CD8+ tumor infiltrating immune cells after induction chemo-immunotherapy|Assessment of the absence of any dose-limiting toxicities|Progression free survival|Pathologically confirmed response|Overall survival","University of Erlangen-Nürnberg Medical School","All","18 Years to 100 Years   (Adult, Older Adult)","Phase 2","120","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CheckRad-CD8","September 20, 2018","April 2021","April 2022","February 8, 2018",,"June 21, 2019","Klinik Chemnitz gGmbH, Chemnitz, Germany|Dresden, Onkologische Gemeinschaftspraxis, Dresden, Germany|Düsseldorf, Universitätsklinikum, Klinik für Strahlentherapie und Radiologische Onkologie, Düsseldorf, Germany|Erlangen, Universitätsklinikum Strahlenklinik, Erlangen, Germany|Frankfurt, Universitätsklinikum, Klinik für Strahlentherapie und Onkologie, Frankfurt, Germany|Magdeburg, Universitätsklinikum, Magdeburg, Germany|Regensburg, Universitätsklinikum, Klinik für Strahlentherapie, Regensburg, Germany|Universitätsklinikum Ulm, Ulm, Germany",,"https://ClinicalTrials.gov/show/NCT03426657"
185,"NCT03384836","Propranolol Hydrochloride and Pembrolizumab in Treating Patients With Stage IIIC-IV Melanoma That Cannot Be Removed by Surgery",,"Recruiting","No Results Available","Stage IIIC Cutaneous Melanoma AJCC v7|Stage IV Cutaneous Melanoma AJCC v6 and v7","Other: Laboratory Biomarker Analysis|Biological: Pembrolizumab|Drug: Propranolol Hydrochloride","Dose limiting toxicities (DLT) defined as any grade 3 or higher hematological or non-hematological toxicity that is probably or definitely related to treatment according to Common Terminology Criteria for Adverse Events version 4.03 (Phase Ib)|Overall response rate (ORR) per immune-related Response Evaluation Criteria in Solid Tumors (irRECIST) version 1.1 (Phase II)|Overall survival (OS) (Phase II)|PFS (Phase II)|Progression free survival (PFS) (Phase II)","Roswell Park Cancer Institute|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","47","Other|NIH","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","I 53217|NCI-2017-02210|P30CA016056","January 31, 2018","October 11, 2020","October 11, 2021","December 27, 2017",,"February 26, 2020","Roswell Park Cancer Institute, Buffalo, New York, United States|Penn State Milton S. Hershy Medical Center Cancer Institute, Hershey, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT03384836"
186,"NCT04229459","Trial of Nivolumab and Cetuximab After Chemoradiation in Esophageal Squamous Cell Carcinoma Patients.",,"Recruiting","No Results Available","Esophageal Squamous Cell Carcinoma","Drug: Cisplatin|Drug: 5-FU|Radiation: Radiation therapy|Drug: Cetuximab|Drug: Nivolumab","pathological complete response (pCR) rate|Progression Free Survival (PFS)|Incidence of Treatment-Emergent Adverse Events (Safety)|Overall survival (OS)","Baruch Brenner|Bristol-Myers Squibb|Merck Serono International SA|Rabin Medical Center","All","18 Years and older   (Adult, Older Adult)","Phase 2","31","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CA209-76W / MS062202_0103","December 30, 2019","December 2022","June 2027","January 18, 2020",,"January 18, 2020","Rabin Medical Center, Petach Tikva, Israel",,"https://ClinicalTrials.gov/show/NCT04229459"
187,"NCT02935361","Guadecitabine and Atezolizumab in Treating Patients With Advanced Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia That Is Refractory or Relapsed",,"Recruiting","No Results Available","Chronic Myelomonocytic Leukemia|Myelodysplastic Syndrome|Recurrent Acute Myeloid Leukemia With Myelodysplasia-Related Changes","Drug: Atezolizumab|Drug: Guadecitabine","Incidence of dose-limiting toxicities evaluated according to National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 (Phase I)|Overall response (complete response [CR] + partial response + marrow CR + hematological improvement) (Phase II)|Incidence of grade 3 or higher adverse events and grade 2 toxicities that do not resolve after 3 weeks assessed by CTCAE 4.0|Overall response rate (Phase II)|Overall survival|Percentage of patients who were transfusion-dependent on study entry who become transfusion-independent|Progression free survival|Time to best response","University of Southern California|National Cancer Institute (NCI)|Van Andel Research Institute","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","72","Other|NIH","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","9L-16-3|NCI-2016-01233|P30CA014089","November 2, 2016","November 2, 2020","November 2, 2021","October 17, 2016",,"July 8, 2019","USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States|University of Maryland Medical Center, Baltimore, Maryland, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|Temple University Hospital, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT02935361"
188,"NCT03522584","Durvalumab, Tremelimumab and Hypofractionated Radiation Therapy in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma",,"Recruiting","No Results Available","Metastatic Head and Neck Squamous Cell Carcinoma|Recurrent Head and Neck Squamous Cell Carcinoma","Biological: Durvalumab|Other: Laboratory Biomarker Analysis|Radiation: Stereotactic Body Radiation Therapy|Biological: Tremelimumab|Procedure: Hypofractionated Image-Guided Radiation Therapy","Incidence of adverse effects graded according to Common Terminology Criteria for Adverse Events (CTCAE) v. 4.0|Response rate|Progression-free survival|Overall survival","University of Washington|National Cancer Institute (NCI)|AstraZeneca","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","20","Other|NIH|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","9881|NCI-2018-00540|P30CA015704|RG1717067","May 17, 2018","February 15, 2021","February 15, 2021","May 11, 2018",,"April 8, 2020","Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT03522584"
189,"NCT03113266","Safety and Efficacy of Toripalimab for Patients With Locally Advanced or Metastatic Bladder Urothelial Carcinoma",,"Recruiting","No Results Available","Bladder Urothelial Carcinoma","Biological: humanized anti-PD-1 monoclonal antibody toripalimab","Objective response rate (ORR) by RECIST 1.1 and irRECIST|Duration of response (DOR) by RECIST1.1 and irRECIST|Progression free survival (PFS) by RECIST1.1 and irRECIST|Overall survival (OS)|Immunogenicity of anti-PD-1 monoclonal antibody|Number of participants with treatment-related adverse events as assessed by CTCAE v4.0","Shanghai Junshi Bioscience Co., Ltd.","All","18 Years and older   (Adult, Older Adult)","Phase 2","370","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Junshi-JS001-009","April 6, 2017","February 2020","February 2022","April 13, 2017",,"March 11, 2019","Beijing Cancer Hospital, Beijing, Beijing, China",,"https://ClinicalTrials.gov/show/NCT03113266"
190,"NCT03317457","Durvalumab and Tremelimumab Compared to Doxorubicin in Patients With Advanced or Metastatic Soft Tissue Sarcoma","MEDISARC","Recruiting","No Results Available","Metastatic Adult Soft Tissue Sarcoma|Recurrent Adult Soft Tissue Sarcoma","Biological: Durvalumab and Tremelimumab|Drug: Doxorubicin","overall survival (OS)|AEs / SAEs and Treatment Emergent Adverse Events according to CTCAE 4.03|Objective Response Rate (ORR) according to RECIST 1.1 criteria|OS mile stone rate at 24 months|Duration of response|progression-free survival (PFS)|Quality of life QLQ-C30","AIO-Studien-gGmbH|AstraZeneca","All","18 Years and older   (Adult, Older Adult)","Phase 2","100","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AIO-STS-0415|2016-004750-15","December 15, 2017","June 2020","June 2022","October 23, 2017",,"May 6, 2019","Medizinische Hochschule Hannover, Hannover, Germany",,"https://ClinicalTrials.gov/show/NCT03317457"
191,"NCT03563729","Melanoma Metastasized to the Brain and Steroids","MEMBRAINS","Recruiting","No Results Available","Malignant Melanoma","Drug: Pembrolizumab Injection [Keytruda]|Drug: Ipilimumab Injection [Yervoy]|Drug: Nivolumab Injection [Opdivo]|Drug: Encorafenib|Drug: Binimetinib|Drug: Dabrafenib|Drug: Trametinib","6 months progression-free survival rate|6 months overall survival rate|Overall progression-free survival|Overall survival|Overall response rate|Extracranial response rate|Intracranial response rate|Intracranial clinical benefit rate|Blood and tissue biomarkers of response and progression","Inge Marie Svane|Herlev Hospital","All","18 Years and older   (Adult, Older Adult)","Phase 2","80","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MM1807","June 6, 2018","June 1, 2021","June 6, 2025","June 20, 2018",,"March 12, 2020","Herlev Universityhospital, Herlev, Hovedstaden, Denmark|Aarhus Universityhospital, Aarhus, Midt, Denmark|Odense Universityhospital, Odense, Syd, Denmark",,"https://ClinicalTrials.gov/show/NCT03563729"
192,"NCT03644550","Anti-Mesothelin Immunotoxin LMB-100 Followed by Pembrolizumab in Malignant Mesothelioma",,"Recruiting","No Results Available","Mesothelioma","Drug: LMB-100|Biological: Pembrolizumab","Objective response rate","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","18 Years and older   (Adult, Older Adult)","Phase 2","38","NIH","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","180136|18-C-0136","December 4, 2018","August 31, 2021","February 28, 2023","August 23, 2018",,"May 7, 2020","National Institutes of Health Clinical Center, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT03644550"
193,"NCT03337841","Pembrolizumab as Neoadjuvant Treatment in HCC",,"Not yet recruiting","No Results Available","Hepatocellular Carcinoma","Drug: Pembrolizumab","One-year recurrence-free survival rate|Recurrence free survival|Overall survival|Objective response rate after neoadjuvant phase|Tumor markers|Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]","Kindai University|Merck Sharp & Dohme Corp.","All","20 Years and older   (Adult, Older Adult)","Phase 2","50","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","AURORA study","November 10, 2017","October 31, 2019","October 31, 2020","November 9, 2017",,"November 9, 2017",,,"https://ClinicalTrials.gov/show/NCT03337841"
194,"NCT04116658","First-in-Human, Phase 1b/2a Trial of a Multipeptide Therapeutic Vaccine in Patients With Progressive Glioblastoma","ROSALIE","Not yet recruiting","No Results Available","Glioblastoma, Adult","Biological: Multiple dose of EO2401","Safety and tolerability of EO2401: National Cancer Institute-Common Terminology Criteria for AEs (NCI-CTCAE) v5.0|Evaluation of survival|Assessment of the immunogenicity of EO2316, EO2317, EO2318 (Three components of the therapeutic vaccine), and Universal Cancer Peptide that compose EO2401","Enterome|Covance","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","32","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","EOGBM1-18","July 2020","August 2023","August 2023","October 4, 2019",,"March 30, 2020","Dana Farber Cancer Institute, Boston, Massachusetts, United States|Centre Georges François Leclerc, Dijon, France|Hôpital Pitié-Salpétrière, Paris, France|Klinik und Poliklinik für Neurologie Universitätsklinikum Bonn, Bonn, Germany|Universitätsklinikum Frankfurt Goethe-Universität Dr. Senckenbergisches Institut für Neuroonkologie, Frankfurt am Main, Germany|Neurologische Klinik & Nationales Zentrum für Tumorenerkrankungen Heidelberg Universitätsklinikum Heidelberg, Heidelberg, Germany|Medizinische Fakultät Mannheim der Universität Heidelberg, Mannheim, Germany|Zentrum für Neuroonkologie Universitätsklinikum Tübingen, Tübingen, Germany|Hospital Universitari Vall d'Hebron, Barcelona, Spain|Institit Catala D'Oncologia - Hospital Duran i Reynals, Hospitalet De Llobregat, Spain",,"https://ClinicalTrials.gov/show/NCT04116658"
195,"NCT03951597","Combined Therapy Using Oxaliplatin and Gemcitabine Chemotherapy, Lenvatinib and PD1 Antibody (JS001) for Patients With Advanced and Unresectable Intrahepatic Cholangiocarcinoma",,"Active, not recruiting","No Results Available","Cholangiocarcinoma, Intrahepatic","Drug: combined therapy using oxaliplatin and gemcitabine chemotherapy, Lenvatinib and PD1 antibody (JS001)","Objective response rate|safety: the potential side effects|overall survival|Progression free survival","Shanghai Zhongshan Hospital","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","30","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","zs-ICC-2019","May 10, 2019","January 10, 2020","November 10, 2020","May 15, 2019",,"April 24, 2020","Zhongshan Hospital, Shanghai, Shanghai, China",,"https://ClinicalTrials.gov/show/NCT03951597"
196,"NCT02557321","PV-10 in Combination With Pembrolizumab for Treatment of Metastatic Melanoma",,"Recruiting","No Results Available","Melanoma","Drug: PV-10|Drug: Pembrolizumab","Safety and tolerability of the combination regimen assessed by adverse events (AEs)|Progression Free Survival (PFS)|Objective Response Rate (ORR)|Change in immune biomarkers|Overall Survival (OS)","Provectus Biopharmaceuticals, Inc.|Provectus Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","192","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PV-10-MM-1201","October 2015","April 2021","November 2023","September 23, 2015",,"March 5, 2020","Cedars-Sinai Medical Center, Los Angeles, California, United States|Moffitt Cancer Center, Tampa, Florida, United States|Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States|Oregon Health & Science University, Portland, Oregon, United States|St Luke's University Health Network, Easton, Pennsylvania, United States|MD Anderson Cancer Center, Houston, Texas, United States|Princess Alexandra Hospital, Brisbane, Queensland, Australia",,"https://ClinicalTrials.gov/show/NCT02557321"
197,"NCT02535078","Phase 1b/2 Study of the Combination of IMCgp100 With Durvalumab and/or Tremelimumab in Cutaneous Melanoma",,"Recruiting","No Results Available","Malignant Melanoma","Drug: IMCgp100|Drug: durvalumab|Drug: tremelimumab","Progression-free survival|Objective response rate|Overall survival","Immunocore Ltd|MedImmune LLC","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","183","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IMCgp100-201","November 2015","May 2022","August 2022","August 28, 2015",,"April 21, 2020","The Angeles Clinic and Research Institute, Los Angeles, California, United States|University of California, Los Angeles, Los Angeles, California, United States|University of Colorado Cancer Center, Aurora, Colorado, United States|University of Chicago, Chicago, Illinois, United States|Washington University in St. Louis, Saint Louis, Missouri, United States|Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Duke University Cancer Center, Durham, North Carolina, United States|Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States|Tenessee Oncology, Nashville, Tennessee, United States|Princess Margaret Hospital, Toronto, Ontario, Canada|Herlev og Gentofte Hospital, Herlev, Denmark|Universitaetsklinikum Heidelberg, Heidelberg, Baden Wuerttemberg, Germany|Universitaetsklinikum Essen, Essen, Nordrhein Westfalen, Germany|Universitaetsklinikum Koeln, Koeln, Nordrhein Westfalen, Germany|Universitaetsklinikum Carl Gustav Carus TU Dresden, Dresden, Sachsen, Germany|Istituto Tumori Napoli Fondazione G. Pascale, Napoli, Italy|Addenbrooke's Hospital, Cambridge, Cambridgeshire, United Kingdom|The Christie, Department of Oncology, Manchester, Greater Manchester, United Kingdom|Churchill Hospital, Oxford, Headington, United Kingdom|Beatson West of Scotland Cancer Centre, Glasgow, Strathclyde, United Kingdom|Royal Marsden Hospital, Sutton, Surrey, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02535078"
198,"NCT03379012","Testosterone in Metastatic Renal Cell Carcinoma Patients","FARETES","Completed","No Results Available","Metastatic Renal Cell Carcinoma","Drug: Testosterone undecanoate and sunitinib or pazopanib","Fatigue|Safety and tolerability|Quality of life|Overall rate of adverse events|Testosterone serum concentrations|Red blood cell count and Hemoglobin concentration|Serum calcium concentration|ECOG PS|Overall survival","Kidney Cancer Research Bureau","Male","18 Years and older   (Adult, Older Adult)","Phase 2","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","KCRB08022016","February 8, 2016","January 30, 2018","July 30, 2019","December 20, 2017",,"October 22, 2019","A.I. Kryzhanovsky Krasnoyarsk Cancer Center, Krasnoyarsk, Russian Federation|Kidney Cancer Research Bureau, Moscow, Russian Federation|RUDN University, Moscow, Russian Federation|City Clinical Oncology Center, Saint Petersburg, Russian Federation",,"https://ClinicalTrials.gov/show/NCT03379012"
199,"NCT04059224","TraMel-WT: A Trial of Trametinib in Patients With Advanced Pretreated BRAFV600 Wild-type Melanoma","TraMel-WT","Recruiting","No Results Available","Stage IV Melanoma|Stage III Melanoma","Drug: Trametinib|Drug: Dabrafenib","Arm A: objective response rate on trametinib and dabrafenib|Arm B: objective response rate on trametinib and dabrafenib|Arm A: progression-free survival on trametinib and dabrafenib|Arm A: overall survival on trametinib and dabrafenib|Arm B: progression-free survival on trametinib and dabrafenib|Arm B: overall survival on trametinib and dabrafenib|Arms A and B: incidence of adverse events on trametinib and dabrafenib","Universitair Ziekenhuis Brussel","All","18 Years and older   (Adult, Older Adult)","Phase 2","58","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2018-BN-001","January 28, 2019","June 2021","June 2022","August 16, 2019",,"August 20, 2019","Universitair Ziekenhuis Brussel, Jette, Brussels, Belgium",,"https://ClinicalTrials.gov/show/NCT04059224"
200,"NCT03297593","Nivolumab in Combination With Ipilimumab in Patients With Metastatic Renal Cell Carcinoma",,"Recruiting","No Results Available","Renal Cell Carcinoma","Drug: nivolumab|Drug: ipilimumab","Overall response rate (ORR)|Progression-free survival (PFS)|Duration of response (DOR)|Time to treatment failure (TTF)|Overall survival (OS)|Adverse events (AEs)","Swiss Group for Clinical Cancer Research","All","18 Years and older   (Adult, Older Adult)","Phase 2","74","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SAKK 07/17","December 13, 2017","November 30, 2020","December 1, 2037","September 29, 2017",,"May 27, 2020","Kantonsspital Aarau, Aarau, Switzerland|Kantonsspital Baden, Baden, Switzerland|Universitätsspital Basel, Basel, Switzerland|Inselspital Bern, Bern, Switzerland|Kantonsspital Baselland Bruderholz, Bruderholz, Switzerland|Kantonsspital Graubünden, Chur, Switzerland|Spital Thurgau, Frauenfeld, Switzerland|HFR - Hôpital cantonal, Fribourg, Switzerland|Hôpitaux Universitaires de Genève, Genève, Switzerland|Centre hospitalier universitaire vaudois - CHUV, Lausanne, Switzerland|Luzerner Kantonsspital, Luzern, Switzerland|Kantonsspital St. Gallen, St. Gallen, Switzerland|Kantonsspital Winterthur, Winterthur, Switzerland|UniversitätsSpital Zürich, Zürich, Switzerland",,"https://ClinicalTrials.gov/show/NCT03297593"
201,"NCT03685448","ANZUP - Non-clear Cell Post Immunotherapy CABozantinib (UNICAB)","UNICAB","Recruiting","No Results Available","Renal Cell Carcinoma|Papillary Renal Cell Carcinoma Type 1|Papillary Renal Cell Carcinoma Type 2|Chromophobe Renal Cell Carcinoma|Sarcomatoid Renal Cell Carcinoma|Xp11.2 Translocation-Related Renal Cell Carcinoma","Drug: Cabozantinib","The objective response rate (ORR), as assessed by RECIST 1.1.|The number of participants with adverse events that are related to study drug, as assessed and graded by CTCAE v5.0.|Progression-free survival (PFS), as assessed by RECIST1.1.|The number of patients alive at the end of the study, as assessed by date of death. Overall survival (OS) is defined as the time between the date of registration to part 1 of the study and the date of death due to any cause.","Australian and New Zealand Urogenital and Prostate Cancer Trials Group","All","18 Years and older   (Adult, Older Adult)","Phase 2","48","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ANZUP1802","April 11, 2019","April 30, 2022","April 30, 2024","September 26, 2018",,"September 20, 2019","Border Medical Oncology Research Unit / The Border Cancer Hospital, Albury, New South Wales, Australia|Campbelltown Hospital, Campbelltown, New South Wales, Australia|St George Hospital, Kogarah, New South Wales, Australia|Macquarie University Hospital, Macquarie Park, New South Wales, Australia|Calvary Mater Newcastle, Newcastle, New South Wales, Australia|Northern Cancer Institute, St Leonards, New South Wales, Australia|Royal Brisbane & Women's Hospital, Herston, Queensland, Australia|Flinders Medical Centre, Bedford Park, South Australia, Australia|Adelaide Cancer Centre / Ashford Cancer Centre Research / Cancer Care SA, Kurralta Park, South Australia, Australia|Box Hill Hospital - Eastern Health, Box Hill, Victoria, Australia|Monash Medical Centre, Clayton, Victoria, Australia",,"https://ClinicalTrials.gov/show/NCT03685448"
202,"NCT03709147","Metformin Plus/Minus Fasting Mimicking Diet to Target the Metabolic Vulnerabilities of LKB1-inactive Lung Adenocarcinoma","FAME","Not yet recruiting","No Results Available","Advanced LKB1-inactive Lung Adenocarcinoma","Drug: Metformin Hydrochloride|Drug: Cisplatin|Drug: Carboplatin|Drug: Pemetrexed|Dietary Supplement: Fasting-mimicking diet","Progression-free survival|Grade 3/4 adverse events (AEs)|Treatment-related adverse events|Patient compliance to the experimental treatment|Objective response rate (ORR)|Overall survival (OS)|Effect of the experimental treatment on plasma glucose levels|Effect of the experimental treatment on serum insulin levels|Effect of the experimental treatment on serum IGF-1 levels|Effect of the experimental treatment on plasma fatty acids|Effect of the experimental treatment on urinary ketones|Impact of plasma glucose modifications on progression free survival|Impact of serum insulin modifications on progression free survival|Impact of serum IGF-1 modifications on progression free survival|Impact of urinary ketone bodies on progression free survival|Impact of lipid profile modifications on progression free survival","Marina Garassino|Fondazione IRCCS Istituto Nazionale dei Tumori, Milano","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","88","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","INT 45/18","October 30, 2018","September 10, 2023","September 10, 2023","October 17, 2018",,"October 31, 2018","Marina Chiara Garassino, Milan, Italy",,"https://ClinicalTrials.gov/show/NCT03709147"
203,"NCT04310709","Combination of Regorafenib and Nivolumab in Unresectable Hepatocellular Carcinoma","RENOBATE","Not yet recruiting","No Results Available","Carcinoma, Hepatocellular|Hepatoma","Drug: Regorafenib/Nivolumab","Response rate|Adverse events|Progression-free survival|Overall survival","Asan Medical Center|Samsung Medical Center|Bundang CHA Hospital","All","19 Years and older   (Adult, Older Adult)","Phase 2","42","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","RENOBATE","May 30, 2020","May 30, 2022","May 30, 2023","March 17, 2020",,"March 17, 2020","Asan Medical Center, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT04310709"
204,"NCT02259231","RTA 408 Capsules in Patients With Melanoma - REVEAL",,"Completed","No Results Available","Melanoma|Unresectable (Stage III) Melanoma|Metastatic (Stage IV) Melanoma","Drug: Omaveloxolone Capsules (2.5 mg/capsule)|Drug: Ipilimumab (3 mg/kg)|Drug: Nivolumab (240 mg)|Drug: Omaveloxolone Capsules (10 mg/capsule)|Drug: Omaveloxolone Capsules (50 mg/capsule)","Measure of overall response rate using RECIST (Response Evaluation Criteria in Solid Tumors) of the Phase 2 dose of omaveloxolone with nivolumab","Reata Pharmaceuticals, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","41","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","RTA 408-C-1401","October 2014","May 9, 2018","July 23, 2018","October 8, 2014",,"May 9, 2019","Southern Cancer Center, Mobile, Alabama, United States|Highlands Oncology Group, Fayetteville, Arkansas, United States|University of Colorado Cancer Center, Anschutz Cancer Pavilion, Aurora, Colorado, United States|Christiana Hospital Helen F. Graham Cancer Center, Newark, Delaware, United States|Goergetown-Lombardi Comprehensive Cancer Center, Washington, District of Columbia, United States|H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Atlantic Melanoma Center, Morristown, New Jersey, United States|Duke Cancer Institute, Durham, North Carolina, United States|MD Anderson Cancer Center, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT02259231"
205,"NCT03047473","Avelumab in Patients With Newly Diagnosed Glioblastoma Multiforme","SEJ","Active, not recruiting","No Results Available","Glioblastoma Multiforme of Brain","Biological: avelumab","Safety and tolerability according to emergent adverse event leading to avelumab interruption or termination|iRANO criteria","Clinique Neuro-Outaouais","All","18 Years and older   (Adult, Older Adult)","Phase 2","30","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CNO-006","March 10, 2017","September 2022","September 2022","February 9, 2017",,"October 30, 2019","Clinique Neuro-Outaouais, Gatineau, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT03047473"
206,"NCT04183088","Regorafenib Plus Tislelizumab as First-line Systemic Therapy for Patients With Advanced Hepatocellular Carcinoma",,"Not yet recruiting","No Results Available","Advanced Hepatocellular Carcinoma","Drug: Tislelizumab+regorafenib for part 1;Tislelizumab+regorafenib for group 1 of part 2; Placebo+regorafenib for group 2 of part 2.","Safety cohort: 14 participants with treatment related serious adverse events as assessed by Common Terminology Criteria for Adverse Events (CTCAE) V5.0.|Randomized cohorts: Objective response rate (ORR) (co-primary)|Randomized cohorts: Progression-free survival (PFS) (co-primary)|Safety cohort: safety as assessed by 25 participants experiencing who incidence and severity of total AE, liver related AE, and immune-related AE.|Safety cohort: Proportion of 25 participants who may escalate the dose of regorafenib (continuous dosing) during study drug treatment|Safety cohort: Objective response rate (ORR)|Randomized cohort: safety as assessed by 100 participants experiencing who incidence and severity of total AE, liver related AE, and immune-related AE.|Randomized cohort: Objective response rate (ORR)|Safety cohort: progression-free survival (PFS)|Randomized cohort: progression-free survival (PFS)","National Taiwan University Hospital|National Taiwan University Hospital, Yun-Lin Branch","All","20 Years and older   (Adult, Older Adult)","Phase 2","125","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","201911021MIFB","March 1, 2020","March 1, 2024","March 1, 2025","December 3, 2019",,"January 2, 2020",,,"https://ClinicalTrials.gov/show/NCT04183088"
207,"NCT03598816","PolyImmune {Durvalumab (MEDI4736) and Tremelimumab} & Vaccine Orchestrated Treatment for Patients With Advanced/Metastatic Renal Cell Carcinoma","PIVOT-RCC","Not yet recruiting","No Results Available","Renal Cell Carcinoma","Drug: Durvalumab|Drug: Tremelimumab|Device: TDS-IM v1.0 System|Biological: Neoantigen DNA Vaccine|Procedure: Research blood draw","Safety of the combination of durvalumab & tremelimumab with or without neoantigen DNA vaccine when given to patients with renal cell carcinoma as measured by the percentage of patients with adverse events of grade 3 or higher|Response rate in patients with renal cell carcinoma treated with durvalumab and tremelimumab with or without neoantigen DNA vaccine by RECIST 1.1 as measured by percentage of patients with radiographic complete response or partial response|Rate of progression-free survival (PFS) in patients with renal cell carcinoma treated with durvalumab and tremelimumab with or without neoantigen DNA vaccine|Rate of overall survival (OS) in patients with renal cell carcinoma treated with durvalumab and tremelimumab with or without neoantigen DNA vaccine","Washington University School of Medicine|MedImmune LLC","All","18 Years and older   (Adult, Older Adult)","Phase 2","48","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","202003083","June 30, 2020","October 31, 2022","March 31, 2024","July 26, 2018",,"April 24, 2020","Washington University School of Medicine, Saint Louis, Missouri, United States",,"https://ClinicalTrials.gov/show/NCT03598816"
208,"NCT04017897","The Combination of Anti-PD-1 With Radiotherapy in Previously Untreated Metastatic Melanoma",,"Recruiting","No Results Available","Melanoma","Drug: The combination of radiotherapy with anti-PD1 (pembrolizumab or nivolumab)","Overall response rate (ORR)|treatment-related adverse events (TRAE)|rate of progression-free survival (PFS)|overall survival (OS)|disease control rate (DCR)","Yonsei University","All","20 Years to 80 Years   (Adult, Older Adult)","Phase 2","52","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","4-2019-0461","July 3, 2019","July 2022","July 2022","July 12, 2019",,"July 12, 2019","Department of Surgery, Yonsei University College of Medicine, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT04017897"
209,"NCT03013101","Safety and Efficacy of Recombinant Humanized Anti-PD-1 mAb for Patients With Locally Advanced or Metastatic Melanoma",,"Active, not recruiting","No Results Available","Advanced Melanoma|Metastatic Melanoma","Biological: humanized anti-PD-1 monoclonal antibody toripalimab","Objective response rate (ORR) by RECIST 1.1 and irRECIST Objective response rate (ORR) by RECIST 1.1 and irRECIST|Duration of response (DOR) by RECIST1.1 and irRECIST|Progression free survival (PFS) by RECIST1.1 and irRECIST|Overall survival (OS)|Immunogenicity of anti-PD-1 monoclonal antibody|Number of participants with treatment-related adverse events as assessed by CTCAE v4.0","Shanghai Junshi Bioscience Co., Ltd.","All","18 Years and older   (Adult, Older Adult)","Phase 2","128","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Junshi-JS001-BJZL-II","December 28, 2016","September 16, 2018","December 2021","January 6, 2017",,"March 11, 2019","Beijing Cancer Hospital, Beijing, Beijing, China|Sun Yat-sen University Cancer center, Guangzhou, Guangdong, China|Wuhan Union Hospital, Wuhan, Hubei, China|The 81st Hospital of Chinese People's Liberation Army, Nanjing, Jiangsu, China|The First Hospital of Jilin University, Changchun, Jilin, China|Yunnan Cancer Hospital, Kunming, Yunnan, China",,"https://ClinicalTrials.gov/show/NCT03013101"
210,"NCT04294498","Durvalumab for Advanced Hepatocellular Carcinoma in Patients With Active Chronic Hepatitis B Virus Infection",,"Not yet recruiting","No Results Available","Advanced Hepatocellular Carcinoma","Drug: Durvalumab","The rate of HBV reactivation during durvalumab treatment|The rate of hepatitis flare during durvalumab treatment|To assess the rate of HBV-associated hepatitis during durvalumab treatment.|To assess the efficacy of durvalumab treatment|To assess the adverse events during durvalumab treatment.","National Taiwan University Hospital|Ministry of Science and Technology, Taiwan, ROC|AstraZeneca","All","20 Years and older   (Adult, Older Adult)","Phase 2","43","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","201910075MIPD","April 1, 2020","December 31, 2022","December 31, 2022","March 4, 2020",,"March 4, 2020","National Taiwan University Hospital, Taipei City, Taiwan",,"https://ClinicalTrials.gov/show/NCT04294498"
211,"NCT04414969","Anti-PD-1 Antibody Combined With Peg-Asparaginase and Chidamide for the Early Stage of NK/T Cell Lymphoma",,"Not yet recruiting","No Results Available","Immune Checkpoint Inhibitor|Chemotherapy Effect|Epigenetic Disorder|NK/T-cell Lymphoma of Nasal Cavity","Drug: Anti-PD-1 antibody+Peg-Asparaginase+Chidamide","Objective response rate (ORR)|Complete remission rate|Progression Free Survival (PFS)|Overall Survival (OS)|Safety issue","Hunan Cancer Hospital","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","35","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HNCH-NKT-2020","June 25, 2020","July 1, 2022","July 1, 2025","June 3, 2020",,"June 3, 2020",,,"https://ClinicalTrials.gov/show/NCT04414969"
212,"NCT03750071","VXM01 Plus Avelumab Combination Study in Progressive Glioblastoma",,"Recruiting","No Results Available","Recurrent Glioblastoma","Biological: VXM01|Biological: Avelumab","Treatment-emerging adverse events (safety and tolerability of VXM01 in combination with avelumab)|Clinical response as assessed by time to progression (TTP)|Clinical response as assessed by progression free survival (PFS)|Clinical response as assessed by recurrence-free survival after re-operation (RFS)|Clinical response as assessed by Overall Survival (OS)|Best overall response (OR) on MRI according to iRANO in subjects with or without surgery prior to trial entry (up to re-operation)|Duration of Response (DoR) on MRI according to iRANO in subjects with or without surgery prior to trial entry (up to re-operation)","Vaximm GmbH|Merck KGaA, Darmstadt, Germany|Pfizer","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","30","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","VXM01-AVE-04-INT","November 21, 2018","December 31, 2020","December 31, 2020","November 21, 2018",,"July 19, 2019","CHU La Timone, Marseille, France|Neurology Clinic and National Center for Tumor Diseases, Heidelberg, Germany|Neurology Clinic, Mannheim, Germany|UMC, Utrecht, Netherlands",,"https://ClinicalTrials.gov/show/NCT03750071"
213,"NCT03654833","Mesothelioma Stratified Therapy (MiST) : A Multi-drug Phase II Trial in Malignant Mesothelioma","MiST","Recruiting","No Results Available","Mesothelioma, Malignant","Drug: Rucaparib|Drug: Abemaciclib|Drug: pembrolizumab & bemcentinib|Drug: Atezolizumab & Bevacizumab","Disease control rate (DCR) at 12 weeks assessed by modified RECIST 1.1, in patients with relapsed mesothelioma.|Disease control rate (DCR) at 24 weeks assessed by modified RECIST 1.1, in patients with relapsed mesothelioma.|Objective response rate (ORR) assessed for 12 months|Safety assessed according to CTCAE criteria.|Toxicity assessed according to CTCAE criteria.","University of Leicester|British Lung Foundation|Clovis Oncology, Inc.|Eli Lilly and Company|Merck Sharp & Dohme Corp.|BerGenBio ASA|Roche Pharma AG|University Hospitals, Leicester|The Christie NHS Foundation Trust","All","18 Years and older   (Adult, Older Adult)","Phase 2","120","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","0627","January 28, 2019","July 30, 2021","November 30, 2021","August 31, 2018",,"January 30, 2020","University Hospitals of Leicester NHS Trust, Leicester, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03654833"
214,"NCT04417166","Pembrolizumab and Radiotherapy for Patients With NK/T Cell Lymphoma",,"Not yet recruiting","No Results Available","Lymphoma, Extranodal NK-T-Cell","Drug: Pembrolizumab|Radiation: Involved Field Radiation Therapy","Progression Free Survival (PFS) rate at 2 years - The proportion of patients without disease progression after 2 years from treatment start|Complete remission rate (CRR) - Proportion of patients with complete responses|2-year Event-free survival - Proportion of patient without disease related events after 2 years from treatment start|Treatment related mortality - Number of treatment related deaths|2-year Overall survival - Proportion of patients alive after 2 years from treatment start|Rate of adverse events - Analysis of incidence, severity and relationship of adverse events|Overall Response Rate (ORR) - calculated as the sum of the complete and partial remission rates","International Extranodal Lymphoma Study Group (IELSG)","All","18 Years and older   (Adult, Older Adult)","Phase 2","30","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IELSG50","June 2020","June 2024","June 2026","June 4, 2020",,"June 4, 2020","Shanghai Rui-Jin Hospital, Shanghai, China",,"https://ClinicalTrials.gov/show/NCT04417166"
215,"NCT03123276","Pembrolizumab and Gemcitabine Chemotherapy in Leiomyosarcoma and Undifferentiated Pleomorphic Sarcoma","GEMMK","Recruiting","No Results Available","Sarcoma","Drug: Pembrolizumab|Drug: Gemcitabine","Maximum tolerated dose of gemcitabine that can be safely combined with pembrolizumab in the absence of dose limiting toxicities.|Immunophenotyping of biopsies (FFPE samples, density and phenotype of tumour infiltrating lymphocytes; CD3+, CD8+, CD45, FoxP3 and PD1)|Location of tumour infiltrating lymphocytes (proximity to tumour cells and location relative to the microvasculature; Prototype analysis software at ICR)|Response stratification according to tumour PD-L1 expression|preliminary evaluation of response by using RECIST v1.1","Royal Marsden NHS Foundation Trust|Merck Sharp & Dohme Corp.","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 1|Phase 2","24","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","CCR 4541","November 29, 2017","December 2020","December 2020","April 21, 2017",,"May 19, 2020","Royal Marsden, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03123276"
216,"NCT04021420","Safety and Efficacy of Sonocloud Device Combined With Nivolumab in Brain Metastases From Patients With Melanoma","SONIMEL01","Not yet recruiting","No Results Available","Melanoma|Metastatic Melanoma","Device: SONOCLOUD|Drug: Nivolumab Injection","Most Successful Dose (MSD)|Best overall response rate, M3|Overall response rate, M3|Best intracranial overall response rate (BICORR), M3|Intracranial overall response rate (ICORR), M3|Best extracranial overall response rate (BECORR), M3|Extracranial overall response rate (BECORR), M3","Assistance Publique - Hôpitaux de Paris","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","21","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","P160950J","July 5, 2019","January 1, 2022","July 5, 2023","July 16, 2019",,"July 16, 2019","Saint-Louis Hospital, Paris, France",,"https://ClinicalTrials.gov/show/NCT04021420"
217,"NCT03178123","The Study of JS001 Compared to High-Dose Interferon In Patients With Mucosal Melanoma That Has Been Removed by Surgery",,"Recruiting","No Results Available","Mucosal Melanoma","Biological: humanized anti-PD-1 monoclonal antibody Toripalimab|Biological: high-dose recombinant interferon a-2B","Recurrence-free survival rate|Distant metastases-free survival|recurrence - free survival rate at 3 years|Overall survival (OS)|Number of participants with treatment-related adverse events","Shanghai Junshi Bioscience Co., Ltd.","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","220","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Junshi-JS001-010","May 31, 2017","April 30, 2022","April 30, 2025","June 6, 2017",,"March 11, 2019","Beijing Cancer Hospital, Beijing, Beijing, China",,"https://ClinicalTrials.gov/show/NCT03178123"
